Protocol I1F-MC-RHBW(d)
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study 
Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) 
in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
[STUDY_ID_REMOVED]   
Approval Date: 02-Jun-2017
I1F-MC-RHBW( d) Clinical Protocol Page 1
LY2439821Protocol I1F-MC-RHBW (d)
A Multicenter, Randomized, Double -Blind, 
Placebo- Controlled 16 -Week Study  Followed by  Long -Term 
Evaluation of Efficacy  and Safety  of Ixekizumab (LY2439821) 
in TNFi -Experienced Patients with Radiographic A xial 
Spondy loarthritis
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or i ts subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
ixekizumab (LY2439821 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  I n 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Ixekizumab (LY2439821)
Study I1F-MC-RHB Wis a Phase 3, multicenter, randomized, double -blind, 
placebo -controlled, parallel -group, outpatient study examining the efficacy and safety of 
ixekizumab (LY2439821) compared to placebo over 16 weeks in tumor necrosis factor 
(TNF) inhibitor -experienced patients with radiographic axial spondyloarthritis (rad -axSpA) .  
Patients will be randomized to subcutaneous (SC) placebo, or 1 of 2 treatment regimens of 
ixekizumab (80 mg every 2 wee ks [Q2 W] or every 4 weeks [Q4 W]).  This study will also 
evaluat e long -term efficacy and safety of ixekizumab during an Exten ded Treatment Period 
(36 weeks) .  All patients entering into the Extended Treatment Period from theplacebo 
treatment group will be re -randomized to ixekizumab 80 mg Q2 W or Q4W .
Eli Lilly and Com pany
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly : 23 November 2015
Amendm ent (a) Electronicall y Signed and Approved by Lilly:  19 September 2016
Amendm ent (b) Electronically Signed and Approved by Lilly:   14 January 2017
Amendm ent (c ) Electronically Signed and Approved by Lilly:   01 May 2017
Amendm ent (d) Electronically Signed and Approved by Lilly on approval date provided 
below.
Approval Date: 02-Jun-2017 GMT
I1F-MC-RHBW( d) Clinical Protocol Page 2
LY2439821Table of Contents
Section Page
1. Protocol  Synopsi s.............................................................................................................. 10
2. Introduction ...................................................................................................................... 13
2.1. Backgro und.................................................................................................................. 13
2.2. Study  Rati onale ............................................................................................................ 14
3. Object ives and Endpo ints.................................................................................................. 15
4. Study  Design ..................................................................................................................... 18
4.1. Overview of Study  Design ........................................................................................... 18
4.2. End of Trial Definit ion.................................................................................................20
4.3. Scientific Rationale for Study  Design ........................................................................... 20
4.4. Justification for Dose ................................................................................................... 21
4.5. Benefit/Risk Assessment .............................................................................................. 21
5. Study  Popul ation............................................................................................................... 22
5.1. Inclusio n Cri teria.......................................................................................................... 22
5.2. Exclusio n Cri teria........................................................................................................ 24
5.3. Screen Failures ............................................................................................................. 29
5.4. Lifest yle and/or Dietary Requirements ......................................................................... 30
6. Treatment .......................................................................................................................... 31
6.1. Treatments Administered ............................................................................................. 31
6.1.1. Administrati on of  Investi gational Product ............................................................ 34
6.2. Method of Treatment Assignment ................................................................................ 34
6.2.1. Selection and Timing o f Doses ............................................................................. 35
6.3. Blinding ....................................................................................................................... 35
6.4. Packaging and Labelling .............................................................................................. 36
6.5. Preparati on/Handling/Storage ....................................................................................... 36
6.6. Dose Modificat ion........................................................................................................ 36
6.6.1. Speci al Treatm ent Consi derat ions........................................................................ 37
6.7. Treatment Compliance .................................................................................................38
6.8. Concomitant Therapy ................................................................................................... 38
6.9. Treatment After Study  Com pletion............................................................................... 40
6.9.1. Study  Extensio ns.................................................................................................. 40
6.9.2. Continued Access .................................................................................................41
7. D iscontinuation Criteria .................................................................................................... 42
7.1. Discontinuati on from Study  Treatm ent......................................................................... 42
7.1.1. Discontinuati on from Study  Treatm ent.................................................................42
I1F-MC-RHBW( d) Clinical Protocol Page 3
LY24398217.1.1.1. Discontinuati on of  Study  Treatm ent Pri or to Week 16 .................................... 44
7.1.2. Discontinuati on of  Inadvertent ly Enrolled P atients ............................................... 44
7.1.3. Perm anent Discont inuat ion from the Study .......................................................... 44
7.1.4. Patients Lost to Follow -Up................................................................................... 44
8. Study  Assessments and Procedures ................................................................................... 46
8.1. Efficacy Assessments ................................................................................................... 46
8.1.1. Primary Efficacy  Assessments:  ASAS40 ............................................................. 46
8.1.2. Secondary  Efficacy  Assessments .......................................................................... 46
8.1.2.1. ASAS20, ASAS Individual Co mponents, ASAS Partial 
Remissio n, and ASAS 5/6 ............................................................................... 46
8.1.2.1.1. ASAS20 ................................................................................................... 46
8.1.2.1.2. ASAS Parti al Remissi on........................................................................... 47
8.1.2.1.3. ASAS 5/6 .................................................................................................47
8.1.2.2. Patient Gl obal (Assessment of Disease Activit y)............................................ 47
8.1.2.3. Spinal Pain ..................................................................................................... 47
8.1.2.4. Bath Ankylosing Spondylit is Disease Act ivity Index...................................... 47
8.1.2.5. Bath Ankylosing Spondylit is Funct ional Index ............................................... 47
8.1.2.6. Bath Ankylosing Spondylit is Metrol ogy Index —Spinal  
Mobilit y......................................................................................................... 47
8.1.2.7. Chest Expansion ............................................................................................. 48
8.1.2.8. Occiput to Wall Dista nce................................................................................ 48
8.1.2.9. Ankylosing Spondylit is Disease Act ivity Score .............................................. 48
8.1.2.10. Maastri cht Ankylo sing Spondylit is Enthesit is Score ....................................... 49
8.1.2.11. Spondyloarthrit is Research Con sortium of Canada –
Enthesit is Score .............................................................................................. 49
8.1.2.12. Peripheral  Arthritis......................................................................................... 49
8.1.2.12.1. Tender Joint Count ................................................................................... 49
8.1.2.12.2. Swollen Jo int Count .................................................................................. 50
8.1.2.13. Nonsteroidal Ant i-Infla mmatory  Drug Intake ................................................. 50
8.1.2.14. Assessment of Spondylo arthri tis Internat ional Society  
Health Index ................................................................................................... 50
8.1.2.15. Medical Outcomes Study  36-Item Short -Form  Heal th 
Survey ............................................................................................................ 50
8.1.2.16. Fatigue Severit y Numeri c Rat ing Scale ........................................................... 51
8.1.2.17. Work Productivit y and Act ivityImpairment 
Quest ionnaire –Spondyl oarthri tis..................................................................... 51
8.1.2.18. Jenkins Sleep Evaluat ion Quest ionnaire .......................................................... 51
8.1.2.19. Laboratory  Tests Used for Efficacy  Measures and 
Disease Diagnosis ........................................................................................... 51
I1F-MC-RHBW( d) Clinical Protocol Page 4
LY24398218.1.2.19.1. High Sensi tivity C-React ive Protein .......................................................... 51
8.1.2.20. Imaging Used for Efficacy Measures and Disease 
Diagnosis ........................................................................................................ 51
8.1.2.20.1. Imaging of Sacroiliac Jo ints and Spine ...................................................... 51
8.1.3. Other Assessments ............................................................................................... 52
8.1.3.1. European Qualit y of Life –5 Dimensi ons–5 Level ........................................... 52
8.1.3.2. Healthcare Resource Utilization ...................................................................... 52
8.2. Adverse Events ............................................................................................................ 53
8.2.1. Serious Adverse Events ........................................................................................ 54
8.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 54
8.2.2. Adverse Events of Special Interest ....................................................................... 54
8.2.3. Com plaint Handling ............................................................................................. 55
8.3. Treatment of Overdose .................................................................................................55
8.4. Safety Assessments ...................................................................................................... 56
8.4.1. Electrocardiograms .............................................................................................. 56
8.4.2. Vital Signs ........................................................................................................... 56
8.4.3. Laboratory  Tests .................................................................................................. 56
8.4.4. Physical Examinat ion........................................................................................... 56
8.4.5. Eye Symptom  Assessment ................................................................................... 56
8.4.6. Chest X -Ray and Tuberculosis Test ing................................................................
.57
8.4.7. Quick Inventory  of Depressive Symptom atology–Self-
Report (16 Items) ................................................................................................
.58
8.4.8. Columbia –Suicide Severi ty Rating Scale .............................................................. 58
8.4.9. Immunogenicit y................................................................................................... 59
8.4.10. Safety Moni toring ................................................................................................ 59
8.4.10.1. Neutropenia .................................................................................................... 59
8.4.10.1.1. During Treatm ent (Peri ods 2 and 3) .......................................................... 59
8.4.10.1.2. At Early  Terminat ion Visit ........................................................................ 60
8.4.10.1.3. Post-Treatment Follow -Up Peri od............................................................. 61
8.4.10.2. Hepati tis B Monitoring ................................................................................... 61
8.4.10.3. Hypertensio n.................................................................................................. 62
8.5. Pharmacokinet ics......................................................................................................... 62
8.6. Pharmacodynamics ...................................................................................................... 62
8.7. Genet ics....................................................................................................................... 62
8.8. Biomarkers ................................................................................................................... 63
8.8.1. Samples for Immunogenicit y Research .................................................................63
8.9. Heal th Economics ........................................................................................................ 64
9. Statistical Considerations and Data Analysis ..................................................................... 65
I1F-MC-RHBW( d) Clinical Protocol Page 5
LY24398219.1. Determinat ion of Sample Size ...................................................................................... 65
9.2. General Statist ical Considerat ions................................................................................ 65
9.2.1. General Considerations for Analyses during the Blinded 
Treatment Dosing Period (Period 2) ..................................................................... 65
9.2.2. General Con siderati ons f or Analyses during the Extended 
Treatment Period (Period 3) ................................................................................. 67
9.2.3. General Considerations for Analyses during the Post-
Treatment Follow -Up Peri od (Peri od 4) ............................................................... 67
9.2.4. Analysis Populat ions............................................................................................ 68
9.2.5. Missing Data Imputation ...................................................................................... 68
9.2.5.1. Nonresponder Imputati on............................................................................... 68
9.2.5.2. Modified Baseline Observat ion Carried Forward ............................................ 69
9.2.5.3. Last Observat ion Carried Forward .................................................................. 69
9.2.6. Adjustment for Mul tiple Com parisons .................................................................. 69
9.3. Treatment Group Comparabilit y................................................................................... 71
9.3.1. Patient Disposi tion............................................................................................... 71
9.3.2. Patient Characteri stics.......................................................................................... 72
9.3.3. Concomitant Therapy ........................................................................................... 72
9.3.4. Treatment Compliance ......................................................................................... 72
9.4. Primary and Secondary  Analyses ................................................................................. 72
9.4.1. Primary Analyses .................................................................................................72
9.4.2. Secondary  Analyses ............................................................................................. 73
9.4.2.1. Major Secondary  Analyses ............................................................................. 73
9.4.2.2. Other Secondary  Efficacy Analyses ................................................................ 74
9.4.2.2.1. Period 2 (Blinded Treatment Dosing Period) ............................................. 74
9.4.2.2.2. Period 3 (Extended Treatment Period) ...................................................... 75
9.4.3. Other Expl oratory  Analyses ................................................................................. 75
9.5. Safety Analyses ............................................................................................................ 75
9.5.1. Adverse Events .................................................................................................... 75
9.5.2. Clinical Laboratory  Tests ..................................................................................... 76
9.5.3. Vital Signs, Physical Findings, and Other Safet y Evaluat ions............................... 76
9.6. Pharmacokinet ic/Pharmacodynamic/Immunogenicit y Analyses ................................... 77
9.7. Other Analyses ............................................................................................................. 77
9.7.1. Health Economics ................................................................................................ 77
9.7.2. Subgroup Analyses .............................................................................................. 78
9.7.3. Immunogenicit y................................................................................................... 78
9.8. Interim Analyses .......................................................................................................... 79
10. Study Governance Considerat ions..................................................................................... 80
I1F-MC-RHBW( d) Clinical Protocol Page 6
LY243982110.1. Regulatory  and Ethi cal Considerat ions, Including the Informed 
Consent Process ........................................................................................................... 80
10.1.1. Inform ed Consent .................................................................................................80
10.1.2. Ethical Review ..................................................................................................... 80
10.1.3. Regulatory  Considerat ions................................................................................... 80
10.1.4. Invest igator Informat ion....................................................................................... 81
10.1.5. Protocol  Signatures .............................................................................................. 81
10.1.6. Final Report Signature ......................................................................................... 81
10.2. Data Qualit y Assurance ................................................................................................ 81
10.2.1. Data Capture System ............................................................................................ 82
10.3. Study  and Si te Cl osure .................................................................................................82
10.3.1. Discontinuati on of  Study  Sites............................................................................. 82
10.3.2. Discontinuati on of  the Study ................................................................................ 82
11. References ........................................................................................................................ 83
I1F-MC-RHBW( d) Clinical Protocol Page 7
LY2439821List of Tables
Table Page
Table RHBW.1. Object ives and Endpo ints............................................................................... 15
Table RHBW.2. Treatment Regimens fro m Weeks 0 to 14
Blinded Treatment Dosing Period (Period 2) .................................................. 32
Table RHBW.3. Treatment Regimens fro m Weeks 16 to 50
Extended Treatment Period (Period 3) ........................................................... 33
Table RHBW.4. Imaging Requirements for Sacroiliac Jo ints and Spine ................................... 52
Table RHBW.5. Primary and Major Secondary  Outcom e Analyses .......................................... 74
I1F-MC-RHBW( d) Clinical Protocol Page 8
LY2439821List of Figures
Figure Page
Figure RHBW.1. Illustrati on of  study  design for Clinical Protocol I1F -MC-RHBW. ................. 19
Figure RHBW.2. Illustrati on of  graphical mult iple testing procedure. ....................................... 71
I1F-MC-RHBW( d) Clinical Protocol Page 9
LY2439821List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 90
Appendix 2. Schedule of Act ivities.................................................................................... 94
Appendix 3. Clinical Laboratory  Tests ............................................................................. 104
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................. 106
Appendix 5. Spondyloarthrit is Features ........................................................................... 107
Appendix 6. Protocol  Amendment I1F -MC-RHBW(d) Summary:  A Mult icenter, 
Randomized, Double -Blind, Pl acebo -Controlled 16- Week Study  
Followed by Long -Term  Eval uation of  Efficacy and Safet y of 
Ixekizumab (LY2439821) in TNFi -Experienced Patients with 
Radiographic Axial Spondyloarthrit is.......................................................... 108
I1F-MC-RHBW( d) Clinical Protocol Page 10
LY24398211.Protocol Sy nopsis
Title of Study:
A Multicenter, Randomized, Double -Blind, Placebo -Controlled 16 -Week Study Followed by Long -Term Evaluation 
of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi -Experienced Patients with Radiographic Axial 
Spondyloarthr itis
Rationale: 
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that 
neutralizes the cytokine interleukin -17A (IL -17A, also known as IL -17).  Strong scientific evidence exists indicating 
an impo rtant role of the IL23/IL -17 pathway in axial spondyloarthritis (axSpA) pathogenesis (Baeten et al. 2010 , 
2014a ; Maksymowych 2010; Barkaliakos et al. 2011; Rev eille 2011; Yeremenko et al. 2014) .  Pivotal studies of 
secukinumab (Cosentyx ®), another IL -17A MAb, have r ecently demonstrated the efficacy of blocking IL -17A in 
the treatment of radiographic axial spondyloarthritis (rad -axSpA; anky losing spondy litis [ AS]) in biologic aldisease -
modifying antirheumatic drug (bDMARD) -naive as well as in tumor necrosis factor (TNF) inhibitor -experienced 
patients (Sanford and McKeage 2015) .
Objective(s)/Endpoints:
Objectives Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg every 2 weeks [Q2W] or 80 mg every 
4 weeks [Q4W]) v ersus placebo in patients with active 
radiographic axial spondyloarthritis ( rad-axSpA )at 
Week 16 .Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS 40) response .
Secondary
The major secondary objective is:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo at Week 16Proportio n of patients achieving an ASAS20 
response 
Change f rom baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) 
Proportio n of patients achieving Bath A nkylosing 
Spondylitis Disease Activity Index 50 (BASDAI50)
response
Change f rom baseline in Bath Ankylosing 
Spondylitis Functional Index (BASFI)
Proportio n of patients achieving ASDAS inactive 
disease
Change f rom baseline in Short Form 36 (SF -36) 
physical component score (PCS)
Change f rom baseline in ASAS Health Index 
(ASAS HI) 
Change f rom baseline in magnetic resonance 
imaging (MRI) of the spine (Spondyloarthritis 
Research Consortium of Canada [SPARCC] score).  
(This endpoint applies to MRI addendum only .)
I1F-MC-RHBW( d) Clinical Protocol Page 11
LY2439821Summary of Study Design:   
Study I1F -MC -RHBW (RHBW) is a Phase 3, multicenter, randomized, double -blind, placebo -controlled, parallel -
group, outpatient study examining the efficacy and safety of 2 treatment regimens of ixekizumab, 80 mg Q2W and 
80 mg Q4W subcutaneous (SC), as compared to placebo SC in patients with rad -axSpA, during a 16 -week Blinded 
Treatment Dosing Period.
Treatment Groups and Duration:  
Study RHBW has 3 treatment groups during the 16 -week Blinded Treatment Dosing Period: ixekizumab 80 mg 
Q4W, ixekizumab 80 mg Q2W, and placebo at 1:1:1 ratio.  All patients randomized to an ixekizumab treatment 
group will receive a starting dose of ixekizumab 80 mg or 160 mg (1:1 ratio) at Week 0 followed by ixekizumab 
80mg Q4W or Q2W there after. All administrations are SC.   Randomization will be stratified by country, baseline 
C-reactive protein (CRP) status ( nonelevated or elevated , elevated defined as >5.00 mg/L ), and number of prior TNF
inhibito rsused (1 or 2).  At Week 16, placebo pat ients will be rerandomized at a 1:1 ratio to ixekizumab 80 mg 
Q2W or Q4W. All patients will be on an ixekizumab regimen for the Extended Treatment Period (Week s16 to 52).  
The study  duration will be up to 1 year for ixekizumab administration, and up to 1 year and approximately 4 months 
for study participation over 4 periods ( [1]Screening Period:  up to 42 days; [2]Blinded Treatment Dosing Period:  
16 weeks; [3]Extended Treatment Period:  36 weeks; [4]Post-Treatment Follow -UpPeriod :  at least 12 weeks after 
the date of the patient’s early termination visit [ETV] or last regularly scheduled visit) .  Patients who complete 
Study RHBW may have the opportunity to continue into a long -term study instead of the Post -Treatment Follow -Up 
Period.
Study Population:
This study will include approximately 300 randomized patients. Patients are eligible to be included in the study if 
they have an established diagnosis of rad -axSpA with sacroiliitis defined radiographically according to the modifie d 
New York ( mNY) criteria, based on central reading, associated with ≥1 spondyloarthritis ( SpA)feature, and have 
active disease defined as BASDAI ≥4 and back pain ≥4 on a numeric rating scale (NRS).  Patients must have had an 
inadequate response, as determined by the investigator, to 2 or more nonsteroidal anti- inflammatory drugs 
(NSAIDs) at the th erapeutic dose range (for a total duration of at least 4 weeks) and a histo ry of prior rad-axSpA 
therapy  for at least 3 months .  Patients must also have a history  ofprior TNF inhibito rtherapy  use for at least 3 
months or intolerance to TNF inhibitor .  Only TNF inhibitor -experienced patients can be enrolled.  Prior use of 
maximum 2 TNF inhibito rswill be allowed.
Statistical Analysis:
Approximately 300 patients will be randomized at a 1:1:1 ratio in the Blinded Treatment Dosing Period to 
ixekizumab 80mg Q2W, ixekizumab 80 mg Q4W, and placebo.  With 100 patients per treatment group, this study 
will have approximately 96% power to test the superiority of ixekizumab Q2W to placebo for the ASAS 40 at 
Week 16.  The following assumptions were used for the power calculations for ASAS 40 response rates at Week 16
regardless of ixekizumab starting dose :  27% for ixekizumab Q2W treatment group and 7% for placebo group.   A 
2-sided Fisher’s exact test at the 0.05 level is assumed .  The efficacy analyses for the Blind edTreatment Dosing 
Period will be conducted on the intent -to-treat (ITT) population ,and safety analyses will be conducted on the safety 
populatio n.  
Comparisons between each ixekizumab treatment group(80mg Q2W or 80 mg Q4W) and placebo will be 
performed for all analyses in the Blinded Treatment Dosing Period.  Unless otherwise specified, ixekizumab 80 mg 
Q2W and Q4W groups will be analyzed without regard to starting dose .  The primary analysis method for treatment 
group comparisons of categorical efficacy and health outcome svariables will be a logistic regression analysis with 
treatment, geographic region, baseline CRP status ( nonelevated or elevated), and prior number of TNF inhibitor
used (1 or 2) as factors, using the nonresponder imputation (NRI)method .  Under NRI ,all nonresponders at Week 
I1F-MC-RHBW( d) Clinical Protocol Page 12
LY243982116 (Visit 8), as well as all patients who discontinue study treatment at any time prior to Week 16 for any reason, will 
be defined as nonresponders for the NRI analysis at Week 16.  Randomized patients with out any postbaseline 
observation will also be defined as nonresponders for the NRI analysis.  A graphic almultiple testing strategy for the 
primary  and major secondary objectives will be implemented to control the family -wise type I error rate at a 2 -sided
α level of 0.05 .  
The primary analyses for the continuous efficacy and health outcome svariables will be made using mixed-effects 
model of repeated measures (MMRM) analysis with treatment, geographic region, baseline CRP status, prior 
number of TNF inhibito rused, baseline value, visit, baseline value -by-visit, and treatment -by
-visit as fixed factors .
A secondary analysis for continuous efficacy and health outcome svariables will be made using analysis of 
covariance (ANCOVA) with treatment, geographic region, b aseline CRP status ,baseline value ,and number of prior 
TNF inhibitor sin the model .
Fisher’s exact test will be used for all adverse events (AEs), baseline, discontinuation, and other categorical safety 
data.  Continuous vital sign andlaboratory values will be analyzed by ANCOVA with treatment and baseline value s
in the model.
Efficacy, health outcomes, and safety variables during the Extended Treatment Period will also be summarized.
I1F-MC-RHBW( d) Clinical Protocol Page 13
LY24398212.Introduction
2.1. Background
Axial spondyloarthrit is (axSpA) is a chronic inflammatory  disease predominantly affect ing the 
axial skeleton (sacroiliac jo ints [SIJ] and spine) (Poddubnyy 2013).  AxSpA is now recognized 
as a single disease ent ity, with a subset defined by the presence of radiographically  defined 
structural  damage of the SIJ(rad-axSpA) and a subset without clear structural damage defined 
radiographically  (nonrad -axSpA) .  When comparing axSpA with rheumatoid arthrit is (RA) ,it 
can be noted that while RA can be divided into erosive and nonerosive or seroposit ive and 
seronegative subsets, it is well accepted that it is still one disease .  AxSpA, in a similar fashio n, 
also has subsets, and thus can be considered a single disease (Deodhar et al .2014).
Radiographic axSpA (rad -axSpA), formerly called ankylosing spondylit is (AS), represents a 
disease in which there is evidence of disease features on radiographic imaging.  It is achronic 
inflammatory  disease characterized by chronic inflammat ion of the axi al and SIJ and variable 
involvement of the peripheral jo ints (Braun and Sieper 2007).  As the disease progresses, it can 
lead to new bone formation in the form o f syndesmophytes and j oint ankylosis, primarily  in the 
axial skeleton .  Pati ents wi thrad-axSpA may also have extra -articular manifestations of the 
disease such as enthesit is, anteri or uveit is, psoriasis ,and inflammatory bowel disease (IBD) ,as 
well as c omorbidities of aortitis or cardi ac conductio n abnormalit ies.  Com pared wi th the general 
popul ation, pati ents wi th rad-axSpA have increased rates of work disabilit y, unempl oyment, and 
mortalit y (Boonen and van der Linden 2006).
AxSpA affects up to 1.4% of the adult populat ion worl dwide (Braun and Sieper 2007; Reveille et 
al. 2012 ;Strand et al. 2013 ).  Although the exact etio logy is unknown, i t has been indicated that 
genet ic factors and several loci are likely to be involved in suscept ibilit y to the di sease (Reveille 
2011).  There is a strong association wit h the m ajor hi stocom patibilit y complex, hum an 
leukocy te ant igen (HLA) -B27.  About 90% to 95% of patients with rad -axSpA are positive for 
HLA -B27, and the ri sk of this disease developing is as high as about 5% in HLA -B27-positive 
individuals and substant ially hi gher in HLA -B27-positive relatives of patients (Braun and Sieper 
2007).  Most of the other known genet ic suscept ibilit y comes from genes invo lved in cytokine 
producti on, specifically  including genes in the T hel per (Th) 17 pathway  (Maksymowych 2010; 
Reveille 2011).
Current standard of care for rad-axSpA includes regular exercise, physical therapy, nonsteroidal 
anti-inflammatory  drugs (NSAIDs), and tumor necrosi s factor (TNF) alpha inhibitors (Braun et 
al. 201 1; Ward et al. 2015).   Corticosteroi d inject ions may also be of so me benefit.  Though 
NSAIDs are the first line of drug treatment for axSpA, they  are not effect ive or well tolerated in 
all patients (Braun and Sieper 2009) .  In contrast to patients with RA, patients with axSpA do not 
respond well to convent ional disease -modifying antirheumatic drugs ( cDMARDs) including 
methotrexate (MTX) or systemic corticosteroi ds (Braun and Sieper 2009; Haibel and Specker 
2009).
Tumor necrosi s factor inhibitors are effect ive and frequent ly prescribed when NSAID treatm ent 
has failed or cannot be tolerated ( Zochling et al. 2006).  While TNF inhibitors have proven to be 
I1F-MC-RHBW( d) Clinical Protocol Page 14
LY2439821effect ive treatments for axSpA, an unmet need remains ,as not all patients respond well to or 
tolerate TNF inhibitor treatm ents (van der Heijde et al. 2006; Heiberg et al. 2008; Inman et al. 
2008; Glint borg et al . 2010) .  While TNF inhibitors have demo nstrated significant impact on 
signs and symptoms, funct ion,and quali ty of life, they have not been able to demonstrate 
significant effect on structural progression in prospective clinical studies. The use of these 
biologic therapi es in various diseases also i s associated wi th safet y concerns, such as
opportunist ic infect ions, demyelinat ing disorders, blood dyscrasias, reactivat ion of tuberculosis 
(TB), and exacerbat ion of congestive heart failure (M oreland 2005; Smit h et al . 2009).   There 
remains, therefore, a significant unmet need for safer, more effect ive treatments for patients with 
axSpA (Dougados and Baeten 2011).  Ixekizumab may offer an alternat ive treatm ent approach to 
TNF inhibitor therapy  in patients with axSpA.
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal 
antibody  (MAb) that neutralizes the cy tokine interleukin -17A (IL -17A, al so known as IL -17).  
Ixekizumab treatment is administered by subcut aneous ( SC)inject ions.  Com pelling scient ific 
inform ation exists to date suggesting an important role of the IL -23/IL -17 pathway  in the 
pathogenesis of axSpA (Baeten et al. 2010 , 2014a ; Maksymo wych 2010; Baraliakos et al. 2011; 
Reveille 2011 ;Yeremenko et al. 2014) .  The demonstration of increased IL -17 producing T h17 
lymphocy te numbers and serum IL -17 levels in rad -axSpA is consistent with a direct role of 
Th17 lymphocy tes in this di sease (Wendling et al. 2007; Jandus et al. 2008; Mei et al. 2011) .  
IL-17secreting cells have also been detected in sit u in the bone marrow of facet jo ints obtained 
from patients with rad-axSpA (Appel et al. 2008). 
Selectively targeting IL -17A wi th ixekizumab is hypothesized to provide therapeut ic benefit 
without unduly impac ting host defenses.  As such, ixekizumab may o ffer a therapeutic option for 
patients who are candidates for init ial systemic treatment as well as those patients who have lost 
response, failed to respond, or are intolerant to current lymarketed drugs ,and m ay also offer a 
more favorable safet y profile co mpared to currently marketed therapies.
2.2. Study Rationale
Eli Lilly and Company  (hereafter Lilly )is investigating ixekizumab as a treatment option for rad -
axSpA based on its mechanism o f action(MoA) , selectively bl ocking IL -17A (detailed in the 
Invest igator’s Brochure [IB]).  The fo llowing 2 SC ixekizumab treatment regimens will be 
studi ed in this trial: 80 m g every  4 weeks (Q4W) or 80 m g every 2 weeks (Q2W) .  Starting 
doses of 80 mg and 160 mg (at Week 0) will be evaluated for each ixekizumab regimen .  A wide 
range of dosing regimens were evaluated in Phase 2 psori asisand RA studi es and demo nstrated 
efficacy .  The 80 m g Q2W and Q4W treatm entregimens wit h a 160 mg starting dose were 
evaluate d in pivotal Phase 3 studies in psoriasis and psoriatic arthrit is (PsA) and demo nstrated 
efficacy , with a favorable benefit/risk profile (Gottlieb et al. 2015; Griffit hs et al. 2015; Mease et 
al. 2015) .Recent ly disclosed data fro m Phase 3 studies with se cukinumab (Cosent yx®), a drug 
with a similar MoA as ixekizumab, selectively  inhibi ting IL -17A, have demo nstrated the 
effect iveness of inhibit ing IL -17A in pat ients with rad-axSpA who were biologicaldisease -
modifying ant irheumatic drug ( bDMARD )-naive or had previ ously  received ant i-TNF agents 
(Sanford and McKeage 2015).
I1F-MC-RHBW( d) Clinical Protocol Page 15
LY24398213.Objectives and Endpoints
Table RHBW .1shows the objectives and endpo ints of t he study.
Table RHBW .1. Objectives and Endpoints
Objectives Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg Q2W or 80 mg Q4W) v ersus placebo 
in patients with active rad-axSpA at Week 16 .Proportio n of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS 40) response 
Secondary
The major secondary objective is:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo at Week 16Proportio n of patients achieving an ASAS20 
response 
Change f rom baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) 
Proportio n of patients achieving Bath Ankylosing 
Spondylitis Disease Activity Index 50 (BASDAI50) 
response
Change f rom basel ine in Bath Ankylosing 
Spondylitis Functional Index (BASFI)
Proportio n of patients achieving ASDAS inactive 
disease
Change f rom baseline in Short Form 36 (SF -36) 
physical component score (PCS)
Change f rom baseline in ASAS Health Index 
(ASAS HI)
Change f rom baseline in magnetic resonance 
imaging (MRI) of the spine (Spondyloarthritis 
Research Consortium of Canada [SPARCC] score).  
(This endpoint applies to MRI addendum only .)
I1F-MC-RHBW( d) Clinical Protocol Page 16
LY2439821Objectives Endpoints
Other secondary objectives are:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo during the 16 -
week placebo -controlled period (Period 2)Proportio n of patients who achieve ASAS20, 
ASAS40, ASAS 5/6, and partial remission by 
ASAS criteria
Change f rom baseline in the individual components 
of the ASAS criteria
Change f rom baseline in BASDAI
Proportio n of patients reaching BASDAI50
Change f rom baseline in ASDAS
Proportio n of patients who experience clinically -
important improvement (change of ASDAS from 
baseline ≥1.1), major improve ment (change of 
ASDAS from baseline ≥2.0), or inactive disease 
(ASDAS score <1.3)
Change f rom baseline in the measure of high 
sensitivity C -reactive protein (CRP )
Change f rom baseline in BASFI
Change f rom baseline in mobility
oBath Ankylosing Spondylitis Me trology 
Index (BASMI) (linear) and individual 
components
oChest expansion
oChange f rom baseline in occiput to wall 
distance
Change f rom baseline in Maastricht Ankylosing 
Spondylitis Enthesitis Score (MASES)
Change f rom baseline in SPARCC Enthesitis Score
Change f rom baseline in MRI of the spine 
(Anky losing Spo ndylitis Spin al Magnetic 
Resonance Imaging activity –Berlin Score 
[ASSpiMRI -Berlin]; this endpoint applies to MRI 
addendum only)   
Incidence and severity of peripheral arthritis by 
tender (TJC) and swollen joint count (SJC) scores of 
46/44 joints
Incidence rate of anterior uveitis or uveitis flares
Change f rom baseline in the following health 
outcome smeasures: Fatigue Numeric Rating Scale 
(NRS )score, ASAS HI score, Jenkins Sleep 
Evaluatio n Questio nnaire (JSEQ), Work 
Productivity Activity Impairment –Spondyloarthritis 
(WPAI -SpA) scores, SF -36 (both PCS and mental 
component scores [MCS] ),and Quick Inventory of 
Depressive Symptomatology –Self-R
eport (16 
Items )(QIDS -SR16) score
I1F - MC- RHBW (d)  C l in ica l  P ro toco l Page  17
LY2439821Ob j e c t i v e s Endp o in t s
 T o  d e t e rm i n e  i f  t h e  e f f e c to f  e i t h e r  i x e k i z um a b  
r e g im e n  i s  m a i n t a i n e d  t h r o u g h  W e e k  5 2A l l  e n d p o i n t s  a s s e s s e d  a t  W e e k  1 6  ( a b o v e )  a n d  d u r i n g  
th e  16 - w e e k  p l a c e b o- c o n t r o l l e d  p e r i o d  ( a b o v e )  w i l l  
c o n t i n u e  t o  b e  a s s e s s e d  t h r o u g h  W e e k  5 2  (w i t h  t h e  
e x c e p t i o n  o f  MR I - r e l a t e d  e n d p o i n t s ) .
I n  a d d i t i o n , t h e  f o l l ow i n g  e n d p o i n t  i s  a d d e d :
 NSA ID  i n t a k e  (ASAS- NSA ID  s c o r ea n d  %  o f  
p a t i e n t s  t a k i n g  NSA ID s )
 T o  ex p l o r e  e f f e c t  o f  s t a r t i n g  d o s e  ( 1 6 0  m g  
c om p a r e dt o  8 0  m g ) O n s e t  o f  a c t i o n  a n d  t r e a tm e n t  r e s p o n s e  (ASAS ,  
ASDAS,  CRP ,  BASF I)  d u r i n g  t h e  p l a c e b o -
c o n t r o l l e d  p e r i o d
 T o  ev a l u a t e  t h e  i n c i d e n c e  o f  a n t i - i x e k i z um a b  
a n t i b o d i e s  a n d  t h e i rr e l a t io n s h ip  to  t h e  e f f i c a cy  o f  
i x e k i z um a b   E f f i c a c y  r e s p o n s e  r a t e s  l i s t e db e l ow  a t  W e e k s  1 6  
a n d  5 2  b y  t r e a tm e n t - em e r g e n t  a n t i - d ru g  a n t i b o d y  
(TE - ADA )  s t a t u s  a n d  b y  n e u t r a l i z i n g  a n t i- d r u g  
a n t i b o d y  (NA b )  s t a t u s :
o P ropo r t ion  o f  p a t i e n t s  a c h i e v i n g  ASAS 4 0
o P ropo r t ion  o f  p a t i e n tsa c h i e v i n g  ASAS 2 0
o P ropo r t ion  o f  p a t i e n t s  a c h i e v i n g  ASDAS  
i n a c t i v e  d i s e a s e
 T o  m e a s u r e  i x e k i z um a b  e x p o s u r e  a n d  a s s e s s  t h e  
r e l a t io n s h i p  b e tw e e n  e x p o s u r e  a n d  e f f i c a c y ,  a n d  
e x p o s u r e  a n d  imm u n o g e n i c i t y S e r um  t r o u g h  c o n c e n t r a t i o n s  o f  i x e k i z um a b
 M o d e l  p a r am e t e r s  f o r  t h e  e x p o s u r e- r e s p o n s e  
r e l a t io n s h i p  b e tw e e n  i x e k i z um a b  s e r um  t r o u g h  
c o n c e n t r a t i o n s  a n d  e f f i c a c y  e n d p o i n t s  ( f o r  e x am p l e ,  
ASAS 2 0 ,  ASAS 4 0 )  a t  W e e ks1 6  a n d / o r  5 2
 I x e k i z um a bs e r um  t r o u g h  c o n c e n t r a t i o n s  a s s o c i a t e d  
w i t h  ADA  t i t e r  s u b  g r o u p s
CC I
I1F-MC-RHBW( d) Clinical Protocol Page 18
LY24398214.Study  Design
4.1. Overview of Study Design
Study  I1F-MC-RHBW (RHBW) is a Phase 3, mult icenter, randomized, double -blind, placebo -
controlled, parallel -group, outpati ent study  examining the efficacy  and safety  of 2 ixekizumab 
treatm entregimens (80 mg Q2W and 80 mg Q4W SC), as compared to plac ebo SC in pat ients 
with active rad -axSpA who are TNF inhibitor -experienced, during a double -blind, 16 -week 
treatment period (Peri od 2) .Starting doses of 80 mg and 160 mg (at Week 0) will be evaluated 
for each ixekizumab regimen . 
Study  RHBW will also evaluate long-term efficacy  and safet y of ixekizumab during the 
Extended Treatment Period (Peri od 3) for a total treatment duration of 1 year (52 weeks) .  
Patients that complete Study  RHBW may be eligible to enroll into a long -term study  (Study  I1F-
MC-RHBY [RHBY] ) for up to 2 addit ional years.  Patients that do not enroll into Study  RHBY 
will co mplete the Post -Treatment Follow -UpPeriod(Peri od 4) in Study RHBW.
Figure RHBW .1illustrates the study  design ;all treatment groups and administration of the 
investigat ional product are described in Section6.1;and the Study  Drug Administrati on Log is 
described in Secti on6.2.1 .
All procedures to be conducted during the study , including timing of all procedures, are indicated 
in the Schedule of Act ivities (Appendix 2 ).  Sel ected study  procedures are to be performed prior 
to administration of the invest igational product, as applicable.  
For each patient, x -rayswill be collected according to Section 8.1.2.20.1 and theSchedule of 
Activities 
(Appendix 2 ).  Appendix 3 lists the specific laboratory  tests that will be performed for 
this study. 
Patients di scont inuing fro m study treatm entwho have received at least 1 dose of investigational 
product will continue to the early terminat ion visit (ETV) prior to proceeding to the Post-
Treatment Follow -Up Peri od.  For the management of patient sa fety, all pat ients are to be 
monitored through the Post -Treatment Follow -Up Peri od at l east as frequently as indicated in the 
Schedule of Act ivities (Appendix 2 )
.
In addit ion to procedures specified in the protocol, a subset of patients (approximately 150) will 
participate in a nMRI addendum . (Sites will be selected by  the sponsor , and all pat ients at those 
sites will be requi red to parti cipate in the addendum, as l ong as they  satisfy MRI inclusio n 
criteria.
)
Excluded and conco mitant medicat ionsare detailed in Section6.8.
Pharmacokinet ic (PK) sampling is detailed in Section8.5.
Secti on9.8outlines the informat ion regarding the interim analyses including the primary 
database lock at Week 16.
I1F-MC-RHBW( d) Clinical Protocol Page 19
LY2439821Abbreviations:  LV = last visit; LY = ixekizumab; n = number of patients ; Q2W = ever y 2 weeks; Q4W = every 4 weeks; SC = subcutaneous; V = study visit; W 
= study week .
aAll patients will receive 2 injections at baseline, as detailed in Section 6.1.  Patients randomized to an ixekizumab regimen will be randomized to a 160 mg 
starting dose or 80 mg starting dose at a 1:1 ratio (within each ixekizumab regimen).
bAll patients will receive 2 injections at Week 16, as detailed in Section 6.1.  Patients randomized to placebo at Week 0 will begin ixekizumab 80 m g Q4W or 
ixekizumab 80 mg Q2W at Week 16 with a 160 mg starting dose (Section 6.1).
cPatients who discontinue from study treatment for any reason and who have received at least 1 dose of investigational product will continue to the early 
termination visit(ETV) before entering the Post -Treatment Follow -Up Period.  V801 and V802 are required for all patients; V803 may be needed depend ing 
on neutrophil counts (Section 8.4.10.1 ).
Figure RHBW .
1. Illustration of study design for Clinical Protocol I1F-MC-RHBW .

I1F-MC-RHBW( d) Clinical Protocol Page 20
LY24398214.2. End of Trial Definition
End of tri al is the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities(Appendix 2 ) for the l ast pati entin the trial .
4.3. Scientific Rationale for Study Design
Two treatm entregimens of ixekizumab 80 mg (Q2W and Q4W )will be studied as detailed in 
Secti on6.1, and the effect of a n80 m g and a 160 mg starting dose will  be evaluated for 
treatm ent outcom es.  Dose justificati on is outlined in Secti on4.4.  The study  blind i s maintained 
as described in Section6.3.
The placebo -controlled Blinded Treatment Dosing Period (Period 2) is designed to minimize bias 
in the evaluat ion of ixekizumab in pat ients with rad-axSpA for both efficacy and safet y.  All 
patients m ay still receive treatment in the form of the allowed conco mitant medications as 
described in the study  inclusio n and exclusio n criteria(Secti ons5.1and 5.2) and concomitant 
therapy  (Secti on 6.8).  Patients can be discont inued from study  treatm ent at any time by 
investigator or patient decisio n if they are considered to be receiving insufficient benefit fro m 
study  treatm ent (Se ction 7.1.1 ).
As of Week 16 (after completion o f Period2),investigators are allowed to adjust some 
concomitant medicat ions, if needed, as specified in Secti on 6.8,across all treatm ent groups.
Patients ori ginally assigned to pl acebo during Period 2 will be rerandomized at a 1:1 ratio to 
ixekizumab 80 m g Q2W or Q4W wi th a 160 m g starting dose at Week 16 .  
Ixekizumab 80 mg Q2W and 80 mg Q4W treatm ent regimens are continued beyo nd Week 16 to 
further assess safet y and efficacy during the Extended Treatment Period (Peri od 3) .
The effect iveness of ixekizumab in treating rad -axSpA will be assessed prim arily by  the 
AS
AS40 response rate at Week 16.  ASAS20 response will also be assessed at Week 16.  These 
measures and the Week 16 endpo int are in alignment with efficacy  endpoints for currently 
approved rad-axSpA therapies and with regulatory guidance (EMA 2009).  Steady state exposure 
of ixekizumab is expected to be reached by Week 16.  Based on previous studies wit h 
ixekizumab in pat ients with psoriasis , RA, and PsA ,it is ant icipated that maximum or near 
maximum clinical effect in rad -axSpA will be achieved wit hin this t imeframe for both 
ixekizumab treatm entregimens.  
Baseline CRP has been reported as a predictor of response in pat ients with rad-axSpA treated 
with TNF inhibito rs(Inm an et al . 2008; d
e Vri es et al . 2009; Si eper et al . 2011 ; Vastesaeger et al. 
2011); hence ,by including it as a stratificat ion factor, i t ensures balance in baseline CRP levels ,
resul ting in greater comparabilit y across treatment groups at baseline .  Similarly ,the number of 
prior TNF inhibitors used has been reported to potent ially impact response rates of subsequently 
used bio logics ( Lie et al. 2011; Glintborg et al. 2013); therefor e,patients will also be stratified 
based on the number of prior TNF inhibitors used (1 or 2).
The Extended Treatment Period (Peri od 3) will permit collection of data for the assessments of 
maintenance of efficacy and long -term safety with ixekizumab.
I1F - MC- RHBW (d)  C l in ica l  P ro toco l Page  21
LY2439821T h e  P o s t- T r e a tm e n t  F o l l ow- Up  P e r iod  (P e r i od  4 )  i sim p o r t a n tf o r  s a f e t y  a n d  e f f i c a c y  m on i to r i n g  
f o l l o w ing  adm in i s t r a t ion  o f  th e  l a s t  s tudy t r e a tm en t .
4 .4 .Jus t i f ica t ionfo r  Dose
L i l l y  c o n s i d e r s  i t  a p p r o p r i a t e  t o  e v a l u a t e  2  t r e a tm e n tr e g im e n s  i n  S tudy RHBW t o  e n a b l e  
a p p r o p r i a t e  e v a l u a t i o n  o f  t h e  r e l a t i v e  b e n e f i t / r i s k  a s s o c i a t ed  w i th  c o n t i n u o u s  i x e k i z um a bth e r apy
i n  a xS pA .  
A s  r e f e r r e d  t o  a b o v e ,  th e  c u r r e n t  i n t e r n a l  ( i x e k i z um a b )  a n d  e x t e r n a l  (TNFi nh ib i to r sa n d  
s e c u k i n um a b )  s c i e n t i f i c  d a t a  i n  t h i s  a r e a  s u p p o r t  t h e  r a t i o n a l e  f o r  s t u d y i n g  i x e k i z um a b  i n  p a ti e n ts  
w ith  r ad - a xS pA  w i t h  t h e  p r o p o s e d  t r e a tm e n tr e g im e n s .
4 .5 .Bene f i t /R isk  Assessmen tCC I
M o r e  i n f o rm a ti o n  a b o u t  t h e  k n ow n  a n d  e x p e c t e d  b e n e f i t s ,  r i s k s ,  s e r i o u s  a d v e r s e  ev en t s  (SAE s )  
a n d  r e a s o n a b l y  a n t i c i p a t e d  a d v e r s e  e v e n t s  (AE s )  o f  i x e k i z um a b  a r e  t o  b e  f o u n d  i n  t h e  IB .  
I1F-MC-RHBW( d) Clinical Protocol Page 22
LY24398215.Study  Population
The study  popul ation will include patients with active rad -axSp A(with sacroilii tis defined 
radiographically  according to the modified New York [ mNY ]criteria, based on central reading, 
associ ated wi th at least 1 SpA feature [Appendix 5 ]), who have given written informed consent.
Study  investigator(s) will review patient history and screening test results fro m Visit 1 (all  
criteria) and Visit 2 as per the Schedule of Act ivities (Appendix 2 ) to determine if the pat ient 
meets all inclusio n and none of the exclusio n criteria to qualify  for parti cipat ion in the study.  All
screening activit ies m ust be com pleted and reviewed before the patient is randomized.  Patients 
may be rescreened in the circumstances described in Section 5.3.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
In thi s protocol  section, the fo llowing definit ions apply:
Screening is defined as Visit 1, up to 42 day s prior to baseline randomizat ion.
Baseline rando mization visit is defined as Visit 2 (Week 0).
5.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening or as specified:
Type of Patient and Disease Characteristics
[1] Have an established diagnosis of rad-axSpA wit h sacroiliit is defined 
radiographically  according to the m NY cri teria (van der Linden et al. 1984) 
based on central reading: sacroiliit i
s grade ≥2 bilaterally  or grad es 3to 4 
unilaterally .
AND
At least 1 SpA feature, according to ASAS criteria ( Rudwaleit et al. 2009; 
Sieper et al . 2009), listed in
 Appendix 5 .
[2] Patients have a history  of backpain ≥3 m onths wi th age at onset <45 y ears.
[3] Have act ive rad -axSpA defined as BASDAI ≥4 and total back pain ≥4 (Si eper 
et al. 2009, Box 25 Spinal Pain) on a nNRS at screening and baseline.
[4] Have had prior treatment with at least 1 and not more than 2 TNF 
inhibitors. The patient must have discont inued at least 1 TNF inhibitor due to 
either intolerance or an inadequate response ( defined as:  In the opinio n of th e 
investigator, the pati ent hadan inadequate response to at least 12 weeks of 
treatm ent wi th a TNF inhibitor at an adequate dose ).
Note: The fo llowing washout periods prior to baseline rando mizat ion must be 
followed:  etanercept ≥28 day s; infliximab, ada limum ab,orcertolizumab 
pegol  ≥60 days; golimumab ≥90 days.
I1F-MC-RHBW( d) Clinical Protocol Page 23
LY2439821[5] Must have had an inadequate response, as determined by the invest igator, to 2 
or more NSAIDs at the therapeutic dose range for a total duration of at least 
4weeks OR have a history  ofintolerance to NSAIDs.  
[6] Patients m ust have a history  ofprior therapy  for axSpA of at least 12 weeks 
prior to screening.  Examples of prior therapy  may incl ude but are not limited 
to physical therapy ,NSAID ,and TNF inhibitor treatm ent.
[7] If taking NSAIDs o r cyclooxygenase -2 (COX -2) inhibitors, the dose must be 
stable for at least 2 weeks prior to baseline rando mizat ion.
Patient Characteristics
[8] Are ambulatory  male or female pat ients ≥18 years of age at tim e of screening.
[9] Must agree to use a reliable method o f birth control:
If a male patient, patient agrees to use a reliable method of birth control 
during the study  and f or at least 12 weeks fo llowing the l ast dose of 
investigat ional product, whichever is longer.  Methods of birth control 
include, but are not limited to, condoms with spermicide and male 
sterilizat ion.
OR
If a female pat ient is a woman of childbearing potent ial who tests negative 
for pregnancy  and agrees to use a reliable method of birth control or 
remain abst inent during the study and for at le ast 12 weeks following the 
last dose of invest igational product, whichever is longer .  Methods of 
contraception includ e,but are not limited to:   oral contraceptives, 
contraceptive patch, injectable or implantable contraceptives, intrauterine 
device, vaginal  ring, diaphragm  with contraceptive gel , or condom  with 
contraceptive foam.
OR
If a female pat ient is a wom an of nonchildbearing potential ,she is not 
requi red to use any  method of bi rth control . Nonchildbearing potential is 
defined as:  
Women who have had surgical sterilizat ion (hysterectomy or 
bilateral  oophorectomy or tubal ligat ion)  
-or -
Women who are ≥60 y ears of age  
-or -
Women ≥40 and <60 y ears of age who have had a cessat ion of 
menses for ≥12months and a fo llicle st imulat ing hormone (FSH) 
test confirming nonchildbearing potential ( ≥40 m IU/m Lor 
≥40IU/L ).
I1F-MC-RHBW( d) Clinical Protocol Page 24
LY2439821Informed Consent
[10] Have given written informed consent approved by Lilly, or its designee, and 
the Invest igational Review Board (IRB)/ Ethical Review Board ( ERB )
governing the site.
5.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at
screening or as specified:
Medical Conditions
[11] Have total ankylo sis of the spine, as assessed locally ,based on l ateral  
radiographs of the cervical and l umbar spine .
[12] Have a history  of other sy stemic inflammatory  diseases (such as but not 
limited to l upus, vasculit is,orRA) or other chronic pain condit ions (such as 
but not limited to fibro myalgia) that might confound the evaluations of benefit 
from ixekizumab therapy .  
Note:   Patients with psoriasis that have never received and do not requi re 
systemic treatment for psori asis, such as ,but not limited to ,oral agents or 
biologic therapi es, can be included provided these patients fulfill the entry  
criteria.
[13] Have act ive Crohn’s disease (CD) or active ulcerative co litis(UC) .  
Note :  Patients may be enro lled if they have had a history  ofIBD, including 
CDand UC, but have had no exacerbat ion for ≥6months prior to baseline 
rando mizat ion and, if current ly on treatm ent, m ust be on stable treatment for 
≥6 m onths pri or to baseline randomizat ion.
[14] Have evidence of active anteri oruveit is(an acute episode) within the last 4
weeks prior to baseline randomizat ion.
Note:   These patients may be rescreened only one time ≥4 weeks after 
resol ution of acute symptoms.
[15] Have current or a history  of lymphoproliferat ive disease, or signs or 
symptoms of lymphoproliferat ive disease ,within 5 years prior to baseline 
rando mizat ion; or have active or history  of malignant dise ase wi thin 5 y ears 
prior to baseline rando mizat ion. 
[16] Have a history  of fluid overload, myocardial  infarcti on (MI), uncompensated 
heart failure, or evidence of new -onset ischemic heart disease ,or in the 
opinio n of the invest igator ,other serious cardiac di sease, within 12 weeks 
prior to baseline rando mizat ion.  
I1F-MC-RHBW( d) Clinical Protocol Page 25
LY2439821[17] Presence of significant uncontrolled cerebrocardiovascular events (for 
example, unstable angina, unstable arterial hypertensio n, moderate -to-severe 
heart failure [New York Heart Associat ion class II I/IV], or cerebrovascular 
accident) at screening that, in the opinio n of the investigator, pose an 
unacceptable risk to the patient if participat ing in the study  or of  interfering 
with the interpretation of data. 
[18] Presence of any co morbid respiratory , hepa tic, renal , gastrointestinal, 
endocrine, hematologic disorders, at screening that, in the opinio n of the 
investigator, pose an unacceptable risk to the patient if participat ing in the 
study  or of  interfering with the interpretation of data.
[19] Presence of any neuro logic or neuropsy chiatric di sorders at screening that, in 
the opi nion of the invest igator, pose san unacceptable risk to the patient if 
participat ing in the study or of interfering wit h the interpretation of data.
[20] Presence of significant uncontrolled neuropsy chiatri c disorder; have recent 
history  (within 30 days prior to screening visit [Visit 1] and any t ime between 
screening visit [Visit 1] and baseline rando mizat ion [Visit 2]) of a suicide 
attem pt; or have a score of 3 on Item 12 (Thoughts of Death or Suici de) of  the 
Quick Inventory  of Depressive Symptom atology–Self-Report (16 Items) 
(QIDS -SR16 )at screening or baseline rando mizat ion;or are clinically judged 
by the investigator to be at risk for suicide. 
[21] Exclusio n criterion [21] has been deleted .
[22] Patients who have :
in the past 12 weeks prior to baseline rando mizat ion:
ohad a serious infect ion (for example, pneumonia, cellulit is), 
ohave been hospitalized for an infect ion,
oor have received intravenous ( IV)antibiot ics for an infect ion, 
or in the past 24 weeks prior to baseline rando mization had a serious bone 
or joint infect ion
or have ever had, 
oan infection o f an artificial jo int, 
oan infection that occurs wi th increased incidence in an 
immunocom promised host (including, but not limited to, 
Pneumocy stis jirovecii pneumo nia, symptom atic histoplasmosis, or 
coccidio idomycosis )
[23] Have a known immunodeficiency or are immunocompromised to an extent 
such that participat ion in the study  woul d pose an unacceptable risk to the 
patient.
I1F-MC-RHBW( d) Clinical Protocol Page 26
LY2439821[24] Have or had a herpes zos ter or any  other clinically apparent varicella -zoster 
virus infect ion within 12 weeks of baseline randomizat ion.
[25] Have any other active or recent infect ion within 4 weeks of baseline 
rando mizat ion that ,in the opinio n of the investigator, would pose an 
unac ceptable ri sk to the pati ent if parti cipat ing in the study .
Note:  These patients may be rescreened one time ≥4 weeks after resolution o f 
symptoms.
[26] Have a known allergy or hy persensi tivity to any  biologic therapy  that woul d 
pose an unacceptable risk to the patient if part icipating in this study .  
[27] Have had surgical treatment of a jo int that i s to be assessed in the study  within 
8 weeks prior to baseline rando mizat ion or will require surgical treatment of a 
joint that i s to be assessed in the study  during th e first 16 weeks of the trial.  
[28] Have had any  major surgery  within 8 weeks prior to baseline randomizat ion or 
will require major surgery  during the study  that,in the opinio n of the 
investigator and in consultat ion with Lilly or i ts desi gnee ,woul d pose an
unacceptable risk to the patient.
Prior/Concurrent Therapy or Clinical Trial Experience
[29] Have received cDMARDs and/or other therapies such as ,but not limited to :  
gold salts, cycl osporine, azathi oprine, dapsone, 6 -mercaptopurine, 
mycopheno late mofetil, o r any other immunosuppressive agents within
4weeks prior to baseline rando mizat ion.
Except ion:MTX (oral or parenteral up to 25 mg/week), sulfasalazine (up to 
3g/day ), or hy droxychl oroquine (up to 400 mg/day) may be allowed IF at 
stable dose for at least 4 weeks prior to baseline rando mizat ion
AND
if used, must not be in any co mbination wit h other cDMARDs.
Note: If MTX is used, local standard of care is to be followed for concomitant 
administration of fo licor folinic acid wi th MTX.
[30] Use of oral cort icosteroi ds >10 m g/day predniso ne or i ts equivalent .
Note: If patients are taking predniso ne or its equivalent and the dose is 
≤10mg/day, the dose must be stable for at least 4 weeks prior to baseline 
rando mizat ion.
[31] Have received any prior, or are curre ntly receiving, treatment with bio logic or 
other immuno modulatory  agents, including invest igational therapies (such as 
but not limited to Janus kinase ( JAK)inhibitors, IL-1, IL -6, IL -23, IL -17
[including ixekizumab ], IL-17R , T cell, or B cell targeted the rapies).
Note:  Previ ous TNF inhibitor therapy  is permitted.
I1F-MC-RHBW( d) Clinical Protocol Page 27
LY2439821[32] Are current ly enrolled in, have participated, or discontinued fro m a clinical
trial involving an invest igational product or nonapproved use of a drug or
device wit hin the last 30 days prior to screening or a peri od of  at least 5 half -
lives o f the lastadministration of the drug, whichever is longer .
Note :  Invest igational products that are bio logic or other immuno modulatory  
agents are not permitted ,regardless of washout period (describ ed in criterion
above).
[33] Are current ly enrolled in any other clinical trial invo lving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[34] Are current ly receiving or have r eceived treatment with denosumab within 
6months pri or to baseline rando mization .
[35] Have received any parenteral glucocortico id administered by intra -articular, 
intramuscular, or IV inject ion within 6 weeks prior to baseline rando mizat ion, 
or for whom a pare nteral injecti on of  glucocorti costeroi ds is anticipated 
during the Blinded Treatment Dosing Period (Peri od 2) of the study .  
[36] Use of any  opiate analgesic at average daily  doses >30 m g/day  of morphine or 
its equivalent ,or use of variable doses of any opiat e analgesic within 6 weeks 
prior to baseline rando mizat ion.
[37] Had a live vaccinat ion within 12 weeks prior to baseline rando mizat ion, or 
intend to have a live vaccinat ion during the course of the study  or wi thin 
12weeks of com pleting treatment in this stu dy, or have participated in a 
vaccine clinical study  within 12 weeks pri or to baseline rando mization.  
Invest igators are to review the vaccinat ion status of their patients and fo llow 
the local guidelines for adul t vaccinat ion with nonlive vaccines intended to 
prevent infect ious di sease pri or to therapy .  
Note:  Killed/ inactive or subunit vaccines are expected to be safe; however, 
their efficacy with conco mitant ixekizumab treatment is unknown.
[38] Had a vaccinat ion with Bacillus Calmette -Guérin (BCG) within 12 months 
prior to baseline rando mizat ion, or intend to have this vaccinat ion with BCG 
during the course of the study  or wi thin 12 m onths of co mpleting treatment in 
this study .
Diagnostics Assessments
[39] Have a body  temperature ≥38°C (100.5°F) at baseline rando mization.  
Note: These patients may be rescreened one time ≥4 weeks after documented 
resol ution of elevated temperature.
[40] Have evidence or suspicio n of act ive or latent TB (refer to Section 5.3for 
rescreening andSection8.4.6 for details on determining full TB exclusio n 
criterion).
I1F-MC-RHBW( d) Clinical Protocol Page 28
LY2439821[41] Are posi tive for hum an immunodeficiency virus serology  (HIV); that is, 
positive for human immunodeficiency  virus ant ibody  (HIVAb).  
[42] Have evidence of or test positive for hepatit is B virus (HBV) by  testing 
positive for: 1) HBV surface ant igen (HBs Ag+), OR 2) anti -hepat itis B core 
antibody  positive (HBcAb+) and are HBV DNA posit ive.
Note:  Patients who are HBcAb+ and HBV DNA negative may be enro lled in 
the study .  Pati ents who m eet these criteria at screening will be ident ified by 
the central  labora tory and m onitored during the study  as detailed in 
Secti on8.4.10.2 .
[43] Have evidence of or test positive for hepatit is C virus (HCV).  A posit ive tes t 
for HCV i s defined as:  1) posit ive for hepatit is C ant ibody  (anti–HCV Ab) 
and 2) posit ive via a confirmatory  test for HCV (for example, 
HCV -polymerase chain react ion).
[44] Have electrocardiogram (ECG) abnormalit ies that are considered clinically 
significant and woul d pose an unacceptable risk to the patient if part icipating 
in the study .  
Laboratory tests may not be repeated unless there is a technical error or clinical reason to 
believe a result may need to be retested within the screening period. Laboratory tests can be 
repeated a maximum of 1 time, and results must be received and reviewed prior to 
rando mizat ion. For eligibilit y, the most recent lab panel must not meet any  of the following 
criteria:
[45] At screening, have a neutrophil count <1500 cells/μL (<1.50x10 3/µL or 
<1.50 GI/L).  
[46] At screening, have a lymphocy te count <800 cells/μL (<0.80x10 3/µL or 
<0.80GI/L).  
[47] At screening, have a platelet count <100,000 cells/μL (<100x10 3/µL or 
<100 GI/L) .  
[48] At screening, have aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >2.5 times the upper limit  of normal ( >2.5x ULN).
[49] At screening, have a total white blood cell (WBC) count <3000 cells/μL 
(<3.00x10 3/µL or <3.00 GI/L).  
[50] At screening, have hemoglo bin <8.5 g/dL (85.0 g/L) for male patients and 
<8.0 g/dL (80 g/L) for female patients.  
[51] Have other clinical laboratory  test resul ts at screening that are outside the 
norm al reference range for the populat ion and are considered clinically 
significa nt, per invest igator assessment. 
I1F-MC-RHBW( d) Clinical Protocol Page 29
LY2439821Other Exclusions
[52] Have donated blood >450 m L within the last 4 weeks prior to screening , or 
intend to donate blood during the course of the study .
Note: Patients who have donated blood may be rescreened one time ≥4 weeks
have passed since init ial sc reening.
[53] Are women who are lactating or breastfeeding.
[54] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whe ther biological or legally adopted.
[55] Are Lilly  empl oyees or i ts desi gnee or are emplo yees of third -party  
organi zations involved in the study .
[56] Are unwilling or unable to comply wit h the use of a data collect ion device to 
directly record data from t he patient .
[57] Have any other condit ion that precludes the patient fro m following and 
completing the protocol, in the opinio n of the investigator.
[58] This criterion is applicable only to patients enrolled in the MRI subgroup and 
was assigned in a Protocol Addendum .
[59] Do not meet the enrollment requirements for the open cohort once the other 
cohorts have closed (Section 6.2).
5.3. Screen Failures
Individuals who do not meet the criteria for parti cipati on in this study  (screen failure) m ay be 
rescreened in the fo llowing ci rcumstances: Patients who test posi tive for latent TB at screening 
may be rescreened fo llowing appropri ate treatm ent as described in Sect ion8.4.6 ; patients who do 
not qualify at screening under Exclusio n Cri teria [14], [25], [39] , or [ 52]may be rescreened one 
time, ≥
4weeks after documented resolut ion of symptoms or from time of blood donation .
Patients who do not qualify  at screening for the elevated CRP cohort and therefore do not qualify 
for the study  under Exclusion Criterion [59] m ay be rescreened once at least 4 weeks after the 
initial screening.  If the CRP is elevated (>5.00 mg/L)during rescreening, pati ents m ay be 
enrolled via the elevated CRP cohort, provided all other entry criteria are met.
If a patient is unable to complete all screening procedures within the screening period, th e pati ent 
may be rescreened after consul tation wi thLilly  medical.
When rescreening is performed, the individual must sign a new informed consent form ( ICF) and 
will be assigned a new ident ificat ion number.  To ensure all eligibilit y criteria are m et, all  
screening procedures must be repeated unless previously conducted within t imeframes specified 
in the Schedule of Act ivities (Appendix 2 ).
I1F-MC-RHBW( d) Clinical Protocol Page 30
LY24398215.4. Lifestyle and/or Dietary Requirements
Not applicable.
I1F-MC-RHBW( d) Clinical Protocol Page 31
LY24398216.Treatment
6.1. Treatments Administered
The Blinded Treatment Dosing Period (Peri od 2) involves a com parison of 2 treatm entregimens
of ixekizumab , 80 m g Q2W and 80 m g Q4W ,to placebo.  Each ixekizumab treatm entregimen 
will include patients receiving a n80 m g or a 160 mg starting dose; pat ients will be rando mized 
to a starting dose at a 1:1 ratio .  All doses are administered via SC inject ion. Table RHBW. 2
shows the treatment regimens. 
At baseline (Week 0) ,all pat ients will receive 2 injections , and will be rando mized to atreatm ent 
regimen .  Patients assigned to an ixekizumab treatment regimen with a160 m g ixekizumab
starting dose will receive 160 mg of ixekizumab as 2SCinject ions.  Patients assigned to an 
ixekizumab treatment regimen with a n80 m g starting dose will receive 80 mg of ixekizumab as 
1 SC inject ion, and 1 SC inject ion of placebo .  Patients assigned to the placebo treatment group 
will receive 2 SC inject ions of pl acebo.  During the remainder of the Blinded Treatment Dosing 
Period (Peri od 2; Week 0 to Week 16) ,all pat ients will receive 1injection every 2 weeks.  
Details are provided in Table RHBW. 2.
During the Extended Treatment Period (Period 3 ; Week 16 to Week 52 ), pati ents ori ginally  
assigned to either ixekizumab treatm ent regimen will remain on the same treatm entregimen 
through Peri od 3.  At Week 16, patients originally assigned to placebo will be rerandomized at a 
1:1 rati o to ixekizumab 80 m g Q2W or Q4W wi th a 160 m g starting dose (as two 80 mg SC 
inject ions).  To m ainta in the blind, all pat ients, regardless of treatment group, will receive 2 SC 
inject ions at Week 16.   Treatment groups in this period are described in Table RHB W.3
.  
To m aintain blinding throughout the study , each pati ent will receive at least 1 SC injection Q2W 
regardl ess of his/her assigned treatm entregimen (that is, placebo will be administered every  
other week as necessary for the Q4W treatm ent group ).
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational product to the patient/patient caregiver
verifying that instructions are fo llowed properly
maintaining accurate records of inve stigational product di spensing, collect ion, and 
administration
returning all unused medication to Lilly  or its designee at the end of the study .
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or pro blem wit h the invest igational product so that the situation can be assessed.
Further instructions and special considerat ions for the administration o f the invest igational 
product are provided in Secti ons 6.1.1 , 6.2.1, and 6.6.1 .
I1F-MC-RHBW( d) Clinical Protocol Page 32
LY2439821Table RHBW. 2. Treatment Regimens from Week s0 to 14
Blinded Treatment Dosing Period (Period 2)
Initial RegimenDose
Week 0 (Day 1)Dose
Week 2 to Week 14 
(Remainder of Period 2)
Total injections per patient 2injections 1injection Q2W
ixekizumab 
80mg Q2W with 
160mg starting doseTreatment dose 2 ixekizumab 80 mg injections1 ixekizumab 80 mg Q2W
(Beginning at Week 2, Q2W) Injections to maintain blinding None
ixekizumab 
80mg Q2W with 
80mgstarting doseTreatment dose 1 ixekizumab 80 mg injection
None
Injections to maintain blinding 1 placebo for ixekizumab injection
ixekizumab 
80mg Q4W with 
160mg starting doseTreatment dose 2 ixekizumab 80 mg injection s1 ixekizumab 80 mg Q4W injection
(Beginning at Week 4, Q4W) Injections to maintain blinding None
ixekizumab
80mg Q4W with 
80mg starting doseTreatment dose 1 ixekizumab 80 mg injection1 placebo for ixekizumab injection 
(Beginning at Week 2, Q4W)
Injections to maintain blinding 1 placebo for ixekizumab injection
placebo Injections to maintain blinding 2 placebo for ixekizumab injections1 placebo for ixekizumab injection Q2W
(Beginning at Week 2, Q2W)
Abbreviations:  Q2W = ever y 2 weeks; Q4W = every 4 weeks.
Note: Shaded cells represent ixekizumab regimens with a starting dose ( ixekizumab 160 mg).
I1F-MC-RHBW( d) Clinical Protocol Page 33
LY2439821Table RHB W.3. Treatment Regimens from Week s16 to 50
Extended Treatment Period (Period 3)
Initial RegimenDose
Week 16 aDose
Week 18 to Week 50
(Remainder of Period 3)
Total injections per patients 2 injections 1 injection Q2W
ixekizumab 
80 mg Q2WTreatment dose 1 ixekizumab 80 mg injection 1 ixekizumab 80 mg injection Q2W
(Beginning at Week 18, Q2W)
Injections to maintain blinding 1 placebo for ixekizumab injection None
ixekizumab 
80 mg Q4WTreatment dose 1 ixekizumab 80 mg injection 1 ixekizumab 80 mg injection Q4W
(Beginning at Week 20, Q4W)
Injections to maintain blinding 1 placebo for ixekizumab injection 1 placebo for ixekizumab injection Q4W
(Beginning at Week 18, Q4W)
placebo Treatment dose 2 ixekizumab 80 mg injections 
(starting dose)ixekizumab 80 mg Q2W beginning at Week 18 
or
ixekizumab 80 mg Q4W beginning at Week 20
Injections to maintain blinding None None (ixekizumab 80 mg Q2W re gimen)
or
1 placebo for ixekizumab injection Q4W beginning at 
Week 18 (ixekizumab 80 mg Q4W regimen)
placebo 
rerandomizationrerandomized to ixekizumab 80 mg Q2W 
or
ixekizumab 80 mg Q4W
Abbreviations:  Q2W = ever y 2 weeks; Q4W = every 4 weeks.
aPatients on placebo will receive a starting dose of 160 mg ixekizumab (2 ixekizumab 80 mg injections) at Week 16.  All other patients will receive placebo 
injections as needed to maintain blinding.   
I1F-MC-RHBW( d) Clinical Protocol Page 34
LY24398216.1.1. Administration of Investigational Product
Inject ions will be administered subcutaneously by the pati ent or caregiver after training by  the 
clinical staff.
Training:   At Week 0 (baseline, Visit 2) ,each patient is scheduled to receive 2injections of 
blinded invest igational product.  For training purposes, the proper procedures for administration 
of the ini tial inject ion will be performed by clinical staff ,and the second inject ion of 
investigat ional product at that visit will be administered by  the patient or caregiver under the 
supervisio n of clinical staff.  If addit ional training is necessary , an inject ion may be administered 
by the patien tor caregiver under the supervisio n of clinical staff at Week 2 (Visit 4).  
Administration:   If the patient is unable to perform the inject ion, a caregiver, who will also be 
trained under supervisio n of site staff, may  administer the invest igational product.  All 
subsequent inject ions of invest igational product will be administered, unsupervised ,by the 
patient or caregiver.  It is reco mmended that these inject ions be administered away from the 
investigat ional site, except for Week s 0 and 16 when the inje ctions have to be done at the site for 
post-dose monitoring.  If the patient or caregiver is not able to administer the second injection o f 
the starting dose, or any  dose throughout the study , study  site staff may  administer that inject ion.
Refer to the ap propri ate Manual Syringe Directions for Use provided by the sponsor for the
investigat ional product.  Note that inject ions arenot to be given in the same arm fro m which 
patient bl ood sam ples, including PK/PD samples, are being drawn at relevant visits.
Study Drug Administration Logs will be dispensed to each patient as needed for recording 
pertinent data about each injection; details o f the use of these logs are provided in Secti on6.2.1 .
Possible inject ion sites are identified in the syringe Directions for Use .  The inject ion site is to be 
rotated to another area for subsequent doses.
Observation:  Patients are to remain under observation for at least 1 hour after dosing at Week 0 
(Visit 2) and Week 16 (Visit 8) to monitor for safety ,since some patients will be receiving 
ixekizumab for the first time at these visit s.  Therefore, at Week 16 (Visit 8) ,inject ions of the 
investigat ional product will be administered by  the pati ent or caregiver at the clinical site to 
allow for observat ion for any  AEs and co llection of post -inject ion blood pressure ( BP)and pulse 
measurements approximately 1 hour after administ ration of  the invest igational product 
(Secti on8.4.2 and Appendix 2 ).
6.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment at 
Week 0 (Visit 2).  Assignment to treatment groups will be determ ined by  a com puter -generated 
rando m sequence using an interactive web- response system  (IWRS).  The IWRS will be used to 
assign double -blind invest igational product to each patient.  Site personnel will confirm that they  
have located the correct assigned in vestigational product package by  entering a confirmation 
number found on the package into the IWRS.
To achieve between -group com parabilit y, the randomizat ion will be stratified by  country  and 
I1F-MC-RHBW( d) Clinical Protocol Page 35
LY2439821baseline CRP ( nonelevated or elevated ) and number of prior TNF inhibitors used (1 or 2) .  The 
study  willenroll approximately 60% of  patients with elevated baseline CRP (>5.00mg/L)and 
approximately 40% of  patients wi th nonelevated baseline CRP (≤5.00mg/L), and approximately  
60% of patients with 1 prior TNF inhibitor andapproximately 40% of  patients wi th2 prior TNF
inhibi tors.
Once a specific cohort is fully enrolled, the sponsor may stop further enrollment of patients 
fitting the cri teria of that cohort.  Once the nonelevated CRP cohortis fully enrolled, patients 
with nonelevated CRP may be rescreened once at least 4 weeks after the initial screening.  If the 
CRP i s elevated (>5 .00mg/L) during rescreening ,patients m ay be enro lled via the elevated CRP 
cohort , provided all other entry  criteria are m et.
6.2.1. Selection and Timing of Doses
Invest igational product is to be administered at approximately the same t ime each day, as much
as possible.  I f an inject ion is missed, the missed dose should be administered as soon as possible.  
Inject ion(s)for missed dose(s) should not be given within 5 days of the next scheduled dose; 
inject ionsshoul d be ≥5 days apart.   
Dates of subsequent study visits are not tobe modified 
according to this delay.
A paper Study  Drug Administration Log will be completed by rando mized patients for each 
inject ion throughout study  parti cipat ion.  The data fro m the Study  Drug Administration Log must 
be transcribed into the electronic case report form (eCRF) by site personnel.  
Patients will  be instructed to contact their study  site in the event of an inject ion probl em.  In 
addition, site personnel review all Study  Drug Administrati on Logs at each visit to ident ify any 
product complaint s,and they  will com plete a Product Com plaint Form  for each operati on failure 
reported on a Study  Drug Administration Log (see Secti on8.2.3 for addi tional instructi ons 
regarding complaint handling).
6.3. Blinding
This is a double -blind stu dy.  
Initial randomizat ion(study  treatm ent administered between Weeks 0 and 16) will remain 
blinded to study site personnel and patients until the final clinical trial database l ock has 
occurred. Thestudy  treatm ent in the Extended Treatment Period (Period 3) will remain blinded 
to study  site personnel  and pat ientsuntil final clinical trial database l ock or pati ents entering 
Study  RHBY, whichever comes first. 
Initial randomizat ionwill remain blinde d to the sponsor until the clinical trial database through 
Week 16 has been locked .  Subsequent randomizatio n at Week 16 for placebo patients ( to 
ixekizumab 80 m g Q2W or Q4W ) maybe blinded to sponsor until the clinical trial database 
through Week 52 has l ocked .
Emergency  unblinding for AEs m ay be perform ed through the IWRS , which m ay supplement or 
take the place of emergency  codes generated by  a com puter drug -labeling system.  This option 
I1F-MC-RHBW( d) Clinical Protocol Page 36
LY2439821may be used ONLY if the patient’s well -being requires knowledge of t he patient’s treatment 
assignment.  All actions resul ting in an unblinding event are recorded and reported by  the IWRS.
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient isto
be discont inued fro m the study treatm ent.  In cases where there are ethical reasons to have the 
patient rem ain on study  treatm ent, the invest igator must obtain specific approval fro m a Lilly 
clinical research physician or Lilly clinical research scient istfor the pati ent to continue onstudy  
treatm ent.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator is to make every effort to con tact the Lilly  clinical research 
physician /clinical  research scient ist prior to unblinding a patient’s treatment assignment.  If a 
patient’s treatment assignment is unblinded, the Lilly clinical  research physician/ clinical research 
scientist must be notified immediately .
6.4. Packaging and Labelling
The invest igational products will be supplied by  the sponsor or i ts desi gnee in accordance wit h 
current Good Ma nufacturing Practices (cGMP).  
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.  All 
investigat ional products will be stored, inventoried, reconciled, and destroy ed according to 
applicable regulat ions. 
Ixekizum ab and pl acebo to match will be supplied as injectable so lutionsin 1-mL, single -dose, 
prefilled, disposable manual syringes wit h study -specific labels.  Each sy ringe of ixekizumab is 
designed to deliver ixekizumab 80 m g.  The sy ringes (and contents) containing eit her 
ixekizumab or placebo will  be visibly  indist inguishable fro m each other .  Syringes will be 
supplied in cartons, with the appropriate quant ity of syringes specific to the planned dispensing 
schedule of the investigational product.
6.5. Preparation/Handling/Storage
Invest igational products will be supplied by Lilly or its representative, in accordance wit h 
cGMP ,and will be supplied with lot numbers, expiry  dates, and certificates of analysis, as 
applicable.
The invest igational product istobe stored at 2°C to 8°C (36°F to 46°F) in its original carton to 
protect from light.  Invest igational product must not be frozen.  Sites will be required to monitor 
temperature of the on -site storage condit ions of the inve stigational product.  
6.6. Dose Modification
No invest igational product dose modificat ions are permitted (refer to Section 8.4.10.1.1 for 
instances whe re drug may  be withheld) . 
I1F-MC-RHBW( d) Clinical Protocol Page 37
LY24398216.6.1. Special Treatment Considerations
Patients will  be screened for eligibilit y in the study as described in Sections5.1and 5.2and will 
be informed of the study -specific restrict ions and requirements of the study .  Pati ents who are not 
willing to comply wit h the stu dy restrictions and requirements of the study  will not be eli gible 
for enrollment.
All biological agents carry  the risk of systemic allergic/hypersensit ivity reacti ons.  Clinical  
manifestations of these reactions may include, but are not limit ed to:
skin r ash
pruri tus (i tching)
urticaria (hives)
angioedema (for example, swelling of the lips and/or tongue)
anaphylactic reaction.
Sometimes these react ions can be life threatening.  Proteins may also cause redness, itching, 
swelling, or pain locally at the inje ction site; therefore, all pat ients shoul dbe closely mo nitored 
for signs or symptoms that could result from such reactions, educated on the signs or symptoms 
of these ty pes of  react ions, and instructed to contact the study site immediately if any of the se
symptoms are experienced fo llowing an inject ion.  If a patient experiences an acute 
allergic/hypersensit ivity react ion after an inject ion of investigational product, he or she istobe 
managed appropriately and given instruction to receive relevant suppor tive care.  Addit ionally, 
for an event j udged by  the invest igator to be a potent ial systemic allergic/hypersensit ivity 
reacti on, a bl ood sam ple is to be drawn to test for anti-drug ant ibodies ( ADA )and PK as soon as 
possible ( see Secti on8.4.9 ).  
For pati ents who experience a potential allergic/hypersensit ivity react ion, consideration for any  
prem edicat ion for future inject ions wil l be agreed upon between the investigator and sponsor.  
Examples of potential allergic/hypersensit ivity reacti ons that might merit premedication include 
mild-to-moderate skin rashes, mild -to-moderate generalized pruritus and/or urticaria, and 
mild-to-moderate inject ion site react ions (for example, inject ion site ery thema, injecti on si te 
pruri tus, and so on ).  Pati ents who develop clinically  significant systemic allergic/
hypersensit ivity react ions following administrati on of invest igational product that do not respond 
to symptom atic m edicat ion or resul t in clinical sequelae (for example, hospitalizat ion) are to be 
discontinued fro m study  treatm ent and not receive further doses of invest igational product, with 
or wi thout prem edicati on (see Section7.1.1 ).  Medicat ions considered appropriate for 
prem edicat ion include, but are not restricted to, acetaminophen/paracetamo l up to 1000 m gand 
antihistamines (for example, oral diphenhydramine 50 mg) given after all efficacy assessments 
have been co mpleted for a given visit, and 30 to 60 minutes prior to invest igational product SC 
inject ionsfor visits where injections are administered at th e clinic.  For all other inject ions, 
patients m ay self -premedicate at hom e prior to administrati on of  invest igational product, as 
directed by  the invest igator.  All such premedicat ions will be recorded as concomitant 
medicat ions.  Corticosteroi ds are not p ermitted as agents for premedicat ion.
I1F-MC-RHBW( d) Clinical Protocol Page 38
LY24398216.7. Treatment Compliance
Patient com pliance wi th study  medicat ion will be assessed at each visit.  Compliance will be 
assessed by  review of the Study  Drug Administration Log, return of empt y or unused 
investigat ional produ ct packaging, and/or direct questioning.  Deviat ion(s) from the prescribed 
dosage regimen are to be recorded in the eCRF.
Com pliance i s defined in Sect ion 9.3.4 .
6.8. Concomitant Therapy
All conco mitant m edicat ion taken during the study must be recorded in the eCRF.  Patients will 
maintain their usual medicat ion regimen throughout the study  unless specifically  excl uded in the 
protocol .  Pati ents taking per mitted m edicat ions are to be on stable doses at the baseline visit 
(Week 0; Visit 2) through Week 16 as specified in the inclusio n/exclusio n criteria (Secti ons 5.1
and 5.2).  Up to Week 16, p atients shoul d not start new medicat ions or m akeany changes to 
concomitant medicat ionsunless changes need to be made for an AE or for safet y reasons.  
Beyond Week 16 ,some flexibilit y is allowed in conco mitant m edicat ion as outlined below.
Vaccines:
Live vaccines are not allowed during any  of the study  periods.  Use of nonlive seasonal 
vaccinations and/or emergency vaccinat ion (such as rabies or tetanus vaccinations) is allowed.
NSAIDs and Analgesics: 
Blinded Treatment Dosing Period (Period 2):
NSAIDs, including COX -2 inhibitors will be allowed up to the maximum reco mmended doses 
for pain .  Patients must be on a stable dose of NSAIDs/ COX -2 inhibitors for at least 2 weeks 
prior to baseline rando mizat ion. Introduction of a new NSAID or dose adjust ment to an exist ing 
NSAID is not permitted, unless required for safet yreasons.
Short -acting analgesics with no anti -inflammatory  action (such as paracetam ol) are permitted 
and may  be administered ad hoc as needed, and are to be withheld within the 24 -hour peri od 
prior to any  assessment.   Aspirin (dose not exceeding 350 mg/day) may be taken to manage 
cardi ovascular risk.
Opiate analgesic use is al lowed but not to exceed >30 mg/day  of morphine or i ts equivalent .  
Patients are to be on stable dose during Period 2. Introduction of a new opiate analgesic or dose 
adjustm ent to an exist ing opiate analgesic is not permitted, unless required for safet yreasons .
Extended Treatment and Post -Treatment Follow -Up Peri ods (Peri ods 3 and 4): 
After complet ion of the Week 16 assessments, alterations of NSAIDs, including COX -2 
inhibitors (dose change, introduction, or withdrawal) areallowed.  Doses are recommended to be 
stable in the 2 weeks prior to an arthrit is assessment.
Short -acting analgesics with no anti -inflammatory  action (such as paracetamol) are permitted 
and may  be administered ad hoc as needed but are to be withheld within the 24 -hour peri odprior 
I1F-MC-RHBW( d) Clinical Protocol Page 39
LY2439821to any  assessment.   Aspirin (dose not exceeding 350 mg/day) may be taken to manage 
cardi ovascular risk.
Use of variable doses of opiate analgesics is allowed, but not to exceed an average daily dose of 
30 m g morphine or i ts equivalent.
Conventional DMARDs: 
Blinded Treatment Dosing Period (Period 2):
Discontinuati on of  excluded oral  or injectable cDMARDs before study  enrollment m ust occur at 
least 4 weeks prior to baseline .  Methotrexate (oral or parenteral up to 25 mg/week), 
sulfasalazine (up to 3 g /day), or hy droxy chloroquine (up to 400 mg/day) may be allowed IF at 
stable dose for at least 4 weeks prior to baseline rando mizat ion.
During Peri od 2, al terati on of  cDMARD dose or route, and/or introduction of a new cDMARD ,
arenot permitted, unless requ ired for safet y reasons .  Co nvent ional DMARD scan only  be used 
as single agent sand not in co mbinat ion with other cDMARDs .  If, at any  time, the invest igator 
believes that side effects or laboratory  abnorm alities m ay be attributable to the cDMARD, the 
cDMA RD dose is to be lowered or the medicat ion stopped. 
Extended Treatment and Post -Treatment Follow -Up Peri ods (Peri ods 3 and 4): 
During Peri ods3 and 4, adj ustment of allowed cDMARDs ( for example , dose change, 
introducti on, wi thdrawal of cDMARDs ,or repl acement of a current cDMARD with the 
introducti on of  a new cDMARD) is allowed after all assessments at Week 16 are completed .  
Not m ore than 1 adj ustment of cDMARDs at 1 time within 12 weeks is reco mmended .  
Conventional DMARD scan only  be used as single age nts and not in combinat ion with other 
cDMARD s.  Any changes must be recorded in the eCRF.
For all study  periods, the m aximum  allowed dose sare25 m g/week MTX, 400 mg/day 
hydroxychloroquine ,and 3 g/day  sulfasalazine .  Local standard sof care are to be fo llowed for 
concomitant administration o f folic or fo linic acid if MTX is taken, and for administration of 
other cDMARDs. 
Corticosteroids :
Blinded Treatment Dosing Period (Period 2):
Oral corticosteroids : If on oral corticosteroids, the dose must no t exceed 10 m g/day  of 
prednisone or its equivalent and must be stable for at least 4 weeks prior to baseline 
rando mizat ion.  During Period2, treatment alterations in oral corticosteroid dose are strongly 
discouraged.
Parenteral corticosteroids ( IV, intram uscular, intra -articular) : Treatment with any parenteral 
corticosteroi ds is not permitted within 6 weeks prior to baseline or during Period 2. 
Inhaled and topical steroids :Regul ar use of inhaled or topi cal steroi ds will be permitted during 
any study  period.
I1F-MC-RHBW( d) Clinical Protocol Page 40
LY2439821Extended Treatment and Post -Treatment Follow -Up Peri ods (Peri ods 3 and 4): 
Oral corticosteroids : As of Week 16, adjustments of oral corticosteroids are allowed ;however ,
the maximum dose is not to exceed 10 mg/day of prednisone or its equivalent at any  time during 
these peri ods. 
Parenteral corticosteroids ( IV, intramuscular, intra -articular ): As of Week 16 ,intra-articular 
inject ion of corticosteroid may be allowed , as needed .  The j oint injected must be designated 
along wi th the medicat ion in the eCRF and must be recorded as unevaluable on the TJC/SJC 
assessment.
Inhaled and topical steroids :Regul ar use of inhaled or topi cal steroi ds will be permitted during 
any study  period.
Other Concomitant Medications (Periods 2, 3, and 4) :
Patients requi ring surgery  at any  time during the study  are to interrupt administration of the 
investigat ional product beginning 8 weeks prior to the surgery , or as early as possible wit hin 
8weeks of surgery , and resume administration of the invest igational product only  after com plete 
wound healing.
Addit ional drugs are to be avo ided during the study unless required to treat an AE or for the 
treatm ent of an ongoing medical problem.  If the need for concomitant medication arises, the 
investigator is to base decisio ns on the patient and on clinical factors.  Any addit ional 
medicat ion, whether prescription or over -the-counter, used at baseline (Week 0 ,Visit 2) and/or 
during the course of the study ,must be docum ented wi th the start and stop dates in the eCRF.
Addit ional systemic drugs are to be avo ided during the study, unless required to treat an AE.  
Other medications may be allowed, if approved by the sponsor or its designee.
Only f or pati ents who di scont inued study  treatment and have entered the Post -Treat ment Follow -
Up Peri od, axSpA therapy  with another agent previously excluded during the treatment period of 
the study  may be all owed, as determined appropriate by  the invest igator and approved by Lilly 
medical.  
Any changes in medicat ions not addressed above are to be discussed with the invest igator.  
Patients must be instructed to consult the invest igator or other appropriate study personnel at the 
site before taking any  new m edicat ions or suppl ements.
6.9. Treatment After Study Completion
6.9.1. Study Extensions
Patients who com plete thi s study  through Vi sit 15 (Week 52) may be eligible to participate in a 
long-term study  (RHBY) offering up to an addit ional 2 y ears of treatm ent, if enrollment criteria 
for Study  RHBY are m et.  For patients who have completed Study R HBW through Week 52 and 
meet exclusio n criteria at Week 44 and Week 52, patients will co mplete the Post -Treatment 
Follow-Up Peri od (Peri od 4) in Study  RHBW.
I1F-MC-RHBW( d) Clinical Protocol Page 41
LY24398216.9.2. Continued Access
Invest igational product will not be made available to patients after conclusio n ofthis study .  
However, patients who complete Study  RHBW and conti nue in the l ong-term study  (RHBY) will 
have access to invest igational product for up to an addit ional 2 years.
I1F-MC-RHBW( d) Clinical Protocol Page 42
LY24398217.Discontinuation Criteria
The reason for and date of discont inuat ion from study t reatment (invest igational product) and 
reason for and date of discont inuat ion from study participat ion will be collected for all 
rando mized patients. 
For any  patient permanent ly discont inuing from study treatment, the invest igational product will 
be wit hheld, and the patient will co mplete the ETV and the Post -Treatment Follow -Up Peri od 
(Peri od 4), as shown in the Schedule of Activit ies (Appendix 2 ).  For patients discont inuing prior 
to Week 16, the patient will co mplete addi tional assessments as described in Sect ion 7.1.1.1 and 
shown in the Schedule of Act ivities (Appendix 2 ).
7.1. Discontinuation from Study Treatment
7.1.1. Discontinuation from Study Treatment
Thefollowing cri teria m ust be fo llowed for discontinuat ion from study treatment .  Patients will 
enter into the Post -Treatment Follow -Up Peri od (Peri od 4) if they discont inue from study  
treatm ent.
[1] Discontinuati on of  the invest igational product for abnormal li ver tests shoul d 
be considered by  the invest igator when a patient meets one of the fo llowing 
condi tions, after consul tation wi th the Lilly designated medical mo nitor:
ALT or AST >8 xULN
ALT or AST >5 xULN for m ore than 2 weeks
ALT or AST >3 xULN and total bilirubin level >2 xULN or prothrombin 
time >1.5 xULN
ALT or AST >3 xULN wi th the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
alkaline phosphatase >2.5 xULN and total  bilirubin >2 xULN
alkaline phosphatase >2.5 xULN wi th the appearance of fat igue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
[2] Other laboratory  tests (Note :  Laboratory test(s) that may result in 
discontinuat ion based on a single result may be repeated only once if there is a 
technical error or clinical reason to believe a result may need to be retested .  
Laboratory  tests can only  be repeated after consultation with Lilly medical.  
Invest igational product should not be admi nistered in these cases unt il retest 
resul t is available.):
Neutrophil (segmented) counts (see safet y monitoring for neutropeni a in 
Secti on8.4.10.1 ):
I1F-MC-RHBW( d) Clinical Protocol Page 43
LY2439821o<500 cells/ L (<0.50x 103/µL or <0.50 GI/L)
o≥500 and <1000 cells/ L (≥0.50x10 3/µLand <1.00x10 3/µLor ≥0.50 
GI/L and <1.00 GI/L) (based on 2 test results; the second test 
perform ed wi thin 1week fro m knowl edge of  the ini tial resul t)  
o≥1000 and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 
GI/L and <1.50 GI/L) (based on 3 test results as specified in 
Secti on8.4.10.1 )
-AND -a concurrent infect ion
Total  WBC count <2000 cells/ L (<2.00x10 3/µL or <2.00 GI/L)
Lymphocy te count < 500 cells/μL (<0.50x10 3/µL or <0. 50 GI/L)
Platelet coun t <50,000 cells/μL (<50x10 3/µL or <50 GI/L) 
[3] The patient experiences a severe AE, an SAE, or a clinically significant 
change in a laboratory  value that, in the opinion o f the invest igator, merits the 
discontinuat ion of the invest igational product and appropriate measures being 
taken.  In this case, L illy or its designee is to be notified immediately.  Refer 
to Section 8.2.
[4] Clinically significant sy stemic hypersensit ivity reacti on following SC 
administrati on of  invest igational product that does not respond to 
symptom atic medicat ion or resul ts in clinical sequelae.  
[5] The patient beco mes pregnant.  
[6] The patient develops a malignancy. 
Note:  Patients may be allowed to continue if they develop no mo re than 
2nonmelano ma skin cancers during the study.
[7] Enrollment in any other clinical trial invo lving an investigational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study .
[8] The pati ent, at any  time during the study , scores a 3 for Item 12 (Thoughts of 
Death or Suicide) on the QIDS- SR16
-OR-
develops active suicidal ideat ion with som e intent to act with or without a 
specific plan (y es to questi on 4 or 5 on the “Suicidal  Ideati on”porti on of  the 
Columbia –Suicide Severi ty Rating Scale [ C-SSRS ])
-OR-
develops suicide -related behaviors as recorded on the C -SSRS .  
I1F-MC-RHBW( d) Clinical Protocol Page 44
LY2439821It is recommended that the subject be assessed by a psy chiatri st or 
appropriately  trained professio nal to assist in deciding whether the subject is 
to be discontinued from the study .  
[9] The invest igator or attending physician decides that the patient is to be 
withdrawn from  study  treatm ent.
[10] The patient requests to be withdrawn fro m study  treatm ent.
[11] Lilly or i ts desi gnee stops the pati ent’s parti cipat ion in the study  or Lilly  stops 
the study  for medical , safet y, regulatory , or other reasons consistent with 
applicable laws, regulat ions, and good clinical practice ( GCP ). 
[12] The patient beco mes HBV DNA pos itive, at whi ch time thepatient is to be 
referred to a specialist physician. Discussio n of the timing of discont inuat ion 
from the study and from study  treatm ent is provi ded in Sect ion8.4.10.2 .
7.1.1.1. Discontinuation of Study Treatment Prior to Week 16
Patients who discont inue prior to Week 16 will complete the ETV and the Post -Treatment 
Follow-Up Peri od (Peri od 4).  In addi tion, pati ents will co mplete sev eral addi tional assessments, 
as detailed in the Schedule of Act ivities (Appendix 2 ).
7.1.2. Discontinuation of Inadvertently Enrolled Patients
The cri teriafor enrollment must be fo llowed explici tly.If the sponsor or invest igator ident ifies a 
patient who di d not m eet enrollment criteria and was inadvertent ly enrolled, a di scussio n must 
occur between the sponsor clinical research physician /clinical research scient istand the 
investigator to determine if the pat ient may cont inue in the study .  If both agree ,it is medically 
appropriate to continue, the invest igator must obtain documented approval fro m the sponsor 
clinical research physician /clinical research scient istto allow the inadvertently enrolled pat ient to 
continue in the study  with or wi thout treatm ent wi th invest igational product.
7.1.3. Permanent Discontinuation from the Study
Some possible reasons that may  lead to perm anent di scontinuat ion include:
Enroll ment in any other clinical trial invo lving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
Parti cipation in the study  needs to be stopped for medical, sa fety, regul atory , or other 
reasons consistent with applicable laws, regulations, and GCP
Patientdecision:  The patient requests to be withdrawn fro m thestudy .
Patients who discont inue the study  early  will have end -of-study  procedures performed as shown 
in the Schedule of Act ivities(Appendix 2 ).
7.1.4. Patients Lost to Follow -Up
A pat ient will be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
I1F-MC-RHBW( d) Clinical Protocol Page 45
LY2439821diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I1F-MC-RHBW( d) Clinical Protocol Page 46
LY24398218.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limit s for timing).
Appendix 3 lists the laboratory tests that will be p erformed for this study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessment s
Below are bri ef descripti ons o fkey aspects of the scales used in the study .  Com plete 
assessments are included in site training materi als.
The fo llowing ASAS domains are used to determine ASAS20, ASAS40, ASAS partial 
remission, and ASAS 5/6 (Sieper et al. 2009, ASAS Handbook): 
1)Patient Gl obal (Secti on 8.1.2.2 )
2)Spinal Pain (Section 8.1.2.3 )
3)Funct ion (Section 8.1.2.5 ) 
4)Inflammat ion(mean of  BASDAI questions 5 and 6) (Section 8.1.2.4 )
5)CRP (Secti on8.1.2.19.1 ) and 
6)Spinal mo bility (lateral  spinal  flexi on) (Secti on 8.1.2.6 ).
8.1.1. Primary Efficacy Assessments :  ASAS40
The ASAS40 (Anderson et al. 2001; Brandt et al. 2004 ; Sieper et al . 2009) is derived fro m 
patient-reported assessments .  An ASAS40 response is defined as a ≥40% improvement and an 
absolute improvement from baseline o f ≥2 uni ts (range 0 to 10) in ≥3 of 4domains (Pati ent 
Global, Spinal Pain, Funct ion, and Inflammat ion) wi thout any  worsening in the remaining 
domain.
8.1.2. Secondary Efficacy Assessments 
8.1.2.1. ASAS20, ASAS Individual Components, ASAS Partial Remission ,and 
ASAS 5/6 
The ASAS20, ASAS individual co mponents, ASAS partial remissio n
,and ASAS 5/6 responses 
(Davis et al. 2003; Sieper et al. 2009) are secondary efficacy assessments that are calculated as 
improvements in respective response rates in mult iple di sease dom ains.
Com plete definit ions of each assessment are provided below.  
8.1.2.1.1. ASAS20
The ASAS20 is derived fro m patient -reported assessments.  An ASAS20 response is defined as a 
≥20% improvement and an abso lute improvement fro m baseline o f ≥1 uni ts (range 0 to 10) in 
I1F-MC-RHBW( d) Clinical Protocol Page 47
LY2439821≥3of 4domains (Pati ent Gl obal, Spinal Pain, Functi on, and Inflammat ion),and no worsening of 
≥20% and ≥1 unit (range 0 to 10) in the remaining domain .
8.1.2.1.2. ASAS Partial Remission
The ASAS partial remissio nis derived fro m patient-reported assessments .  An ASAS parti al 
remission response is defined as a value not above 2 units (range 0 to 10, NRS) in each of the 
following 4domains: Patient Gl obal, Spinal Pain, Funct ion, and Inflammat ion. 
8.1.2.1.3. ASAS 5/6
The ASAS 5/6 includes assessment of all 6individual ASAS domains listed inSection 8.1and 
represents improvement of ≥20% in at least 5domains .
8.1.2.2. Patient Global (Assessment of Disease Activity)
From  the ASAS Handbook (Si eper et al . 2009 ), the pati ent is asked to respond to the fo llowing 
question:   “How active was y our spondyli tis on average during the last week?”   The answer is 
recorded on a nNRS and is rated between “0” (not active) and “10” (very  active).
8.1.2.3. Spinal Pain
From  the ASAS Handbook (Si eper et al . 2009 ), the pati ent is aske d to respond to the fo llowing 
2questions (on average during the last week):
1.“How m uch pain o f your spine due to ankylo sing spondylit isdo you have?”
2.“How m uch pain o f your spine due to ankylo sing spondylit isdo you have at ni ght?”
The answers are recorded on a n NRS and are each rated between “0” (no pain) an d “10” (m ost 
severe pain) .  The first question is used to derive responses (that is,ASAS40, ASAS20, and so 
on).
8.1.2.4. Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI is a patient -reported assessment consist ing of 6 questions that relate to 5 major
symptoms relevant to rad -axSpA (Garrett et al. 1994; Sieper et al. 2009 ):  1) Fati gue, 2) Spinal 
pain, 3) Peripheral arthrit is, 4) Enthesit is, 5) Intensit y,and 6) Duration of morning st iffness .  
Patients need to score each item with a score from 0 to 10 (NRS).
BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
8.1.2.5. Bath Ankylosing Spondylitis Functional Index
The BASFI is a patient -reported assessment thatestablishes a patient’s functional baseline and 
subsequent response to treatment (Calin et al. 1995).  To complete the BASFI, a patient isasked 
to rate the difficult y associ ated wi th 10 individual basic funct ional activities.  Pati ents respond to 
each qu estion using an NRS scale ( range 0 to 10)with a higher score indicat ing worse funct ion.
The patient’s final BASFI score is the mean of the 10 item scores completed on a nNRS. 
8.1.2.6. Bath Ankylosing Spondylitis Metrology Index
—Spinal Mobility 
The BASMI is a co mbined index co mprising the following 5clinical measurements of spinal 
mobility in pat ients with rad-axSpA (Jenkinson et al. 1994) :
I1F-MC-RHBW( d) Clinical Protocol Page 48
LY2439821Lateral  spinal  flexion
Tragus -to-wall distance
Lumbar flexio n (modified Schrober)
Maximal intermalleo lar di stance
Cervical rotation .
The BASMI includes these 5 measurements thatare each scaled to a score of 0 to 10 depending 
on the result of the assessment (BASMI linear function) .  The average score of the 5 assessments 
gives the BASMI linear resul t (van der Heijde et al. 2008; Sieper et al. 2009 ). 
The BASMI must be assessed by a rheumatologist or health care provider who meets the 
qualificat ions for study  assessment .
8.1.2.7. Chest Expansion 
While pat ients have their hands rest ing on or behind the head, the assessor will measure the 
chest ’sencircled length by cent imeter at the fourth intercostal level anteriorly.  The difference 
between m aximal  inspiration and expi ration in centimeters will be recorded .  Two tries will be 
recorded .  The better measurement (larger difference ) of 2tries (in centimeters )will be used for 
analyses .
The m easurement of chest expansio n must be assessed by a rheumatologist or health care 
provi der who meets the qualificat ions for study  assessment .
8.1.2.8. Occiput to Wall Distance 
The patient is to make a maximum effort to touch the head against the wall when standing with 
heels and back against the wall (occi put).  Then the di stance fro m occiput to wall is measured .  
Two tri es will be recorded.   The better (smaller) measurement of 2tries (in centimeters )will be 
used for analyses .
The m easurement of occi put to wall distance must be assessed by  a rheumatol ogist or health care 
provi der who meets the qualificat ions for study  assessment .
8.1.2.9. Ankylosing Spondylitis Disease Activity Score
The ASDAS is a composite index to assess disease activit y in AS (Machado et al .2011a, 2011b; 
Zochling 2011) .  The parameters used for the ASDAS (with CRP as acute phase rea ctant) are the 
following :
1)Total  back pain (BASDAI quest ion 2)
2)Patient global (Secti on 8.1.2.2 )
3)Peripheral  pain/swelling (BASDAI question 3)
4)Durati on of  morning stiffness (BASDAI quest ion 6)
5)CRP in mg/L .
The ASDAS crpis calculated with the fo llowing equati on:  0.121 × total back pain + 0.110 × 
patient gl obal + 0.073 × peri pheral  pain/swelling + 0.0 58 × duration of morning st iffness + 0.579 
× Ln(CRP+1) (Machado et al. 2015).   (Note:  CRP is in mg/liter, the range of other variables is 
from 0 to 10; Ln represents the natural logarithm. )
I1F-MC-RHBW( d) Clinical Protocol Page 49
LY2439821Four di sease act ivity states have been defined by  ASAS consensus (Machado et al. 2011c):
ASDAS <1.3 defines inactive disease
1.3≤ ASDAS <2. 1 defin es moderate di sease act ivity
2.1≤ ASDAS ≤3. 5 defines high disease act ivity
ASDAS > 3. 5 defines very high disease act ivity. 
Clinically important improvement is defined as change ≥1.1 unit s,and major improvement is 
defined as change ≥2.0 units (Machado et al. 2011b).
8.1.2.10. Maastricht Ankylosing Spondylitis Enthesitis Score
The MASES is an index used to measure the severit y of enthesit is (Heuft- Dorenbosch et al. 
2003).  The MASES assesses 13 sites for enthesit is using a score of “0” for no activit y or “1” for 
activit y.  Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal 
iliaca anterior superior (right/left), crista iliaca (right/left), spina i liaca posterior (right/left), 
processus spinosus L5, and Achilles tendon proximal insertion (right/left).  The MASES is the 
sum of all site scores (range 0 to 13) ;higher scores indicate more severe enthesit is.
The MASES mustbe assessed by a rheumatologist or health care provi derwho meets the 
qualificat ions for study  assessments .
8.1.2.11. Spondyloarthritis Research Consortium of Canada –Enthesitis Score
The SPARCC enthesit is is an index used to measure the severit y of enthesi tis (Maksymowych et 
al.2009).  The SPARCC assesses 16 sites for enthesit is using a score of “0” for no activit y or 
“1” for activit y.  Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle 
(L/R), Supraspinatus insertion into greater t uberosity of humerus (L/R), Greater trochanter (L/R), 
Quadri ceps inserti on into superi or border of patella (L/R), Patellar ligament insertion into 
inferi or pol e of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R),
and Planta r fascia insert ion into cal caneum (L/R). The SPARCC is the sum of all site scores 
(range 0 to 16). Higher scores indicate more severe enthesit is.
The SPARCC mustbe assessed by a rheumatologist or health care provi derwho m eets the 
qualificat ions for study assessments .
8.1.2.12. Peripheral Arthritis
8.1.2.12.1. Tender Joint Count
The number of tender and painful jo ints will be determined by examinat ion of 46 jo ints (23 j oints 
on each side of the patient’s body ).  The 46 joints to be assessed and classified as tender or not 
tender are detailed in site training materi als.  Any  joints that requi re intra -articular injections 
during the study  (according to Section 6.8) are to be excluded fro m evaluat ion from the time of 
the inject ion to the conclusio n of the study .
Joint assessments must be assessed by a rheumatologist or health care provi derwho m eets the
qualificat ions for study  assessments .  To minimize interobserver variation, particularly during 
the Blinded Treatment Dosing Period (Peri od 2), it is recommended that the same assessor 
perform sthe TJC for a given patient.  Missing, replaced, ankylosed, o r arthrodesed jo ints will be 
I1F-MC-RHBW( d) Clinical Protocol Page 50
LY2439821ident ified by the investigator at the screening visit (Visit 1) and will be excluded from evaluat ion 
during the study .  
The TJC data will be co llected electronically.
8.1.2.12.2. Swollen Joint Count
The number of swo llen jo ints will be de termined by  examinat ion of 44 jo ints (22 jo ints on each 
side of  the pati ent’s body ).  The 44 j oints to be assessed and classified as swo llen or not swollen 
are detailed in site training materi als.  Any j oints that require intra- articular inject ions during the 
study  (according to Secti on6.8) are to be excluded fro m evaluation from the time of the inject ion 
to the conclusio n of the study .
Joint assess ments must be assessed by a rheumatologist or health care provi derwho m eets the 
qualificat ions for study  assessment s.  To minimize interobserver variation, particularly  during 
the Blinded Treatment Dosing Period (Peri od2), it is recommended that the same assessor 
perform sthe SJC for a given pat ient.  Mi ssing, replaced, ankylosed, or arthrodesed jo ints will be 
ident ified by the investigator at the screening visit (Visit 1) and will be excluded from evaluat ion 
during the study .
The SJC data will be collect ed el ectroni cally .
8.1.2.13. Nonsteroidal Anti -
Inflammatory DrugIntake 
Inform ation regarding NSAID intake will be collected in the eCRF ;the ASAS -NSAID score will 
be calculated at baseline and through Week 52 ( Dougados et al. 2011).
8.1.2.14. Assessment of Spondyloarthritis International Society Health Index
The ASAS HIis a disease -specific health -index instrum ent desi gned to assess the impact of 
intervent ions for SpA, including axSpA.  This broader concept of health is included in the 
International Classificat ion of Funct ioning,Disabilit y,and Heal th,which has been published by 
the World Healt h Organizat ion (WHO ).  The ASAS has applied this classificat ionas a basis to 
define a core set of items relevant for patients with rad -axSpA.  The 17
-item instrum ent has 
score s ranging fro m 0 (good health) to 17 (poor health)(Kiltz et al . 2013).  Each item consists of 
onequestion that the patient needs to respond to wit h either “I agree” (score of 1) or “I do not 
agree ”(score of0). A score of “1” is given where the item is affirmed, indicat ing adverse healt h.  
All item scores are summed to give a total score or index .
8.1.2.15. Medical Outcomes Study 36 -Item Short -Form Health Survey 
The SF -36 is a 36 -item patient -administered measure designed to be a short, mult ipurpose 
assessment of healt h in the areas of physical functioning, role –physical, role –emotional, 
bodily  pain, vi tality, social  functioning, mental healt h, and general healt h.  The 2 overarching 
domains o f mental well -being and physical well -being are captured by  the mental component 
summary (MCS) and physical component summary (PCS) scores.  The summary  scores range 
from 0 to 100; hi gher scores indicate better levels of funct ion and/or better health.  Items are 
answered on Likert scales of varying lengths.  The SF -36 ver sion 2 (acute versi on) will  be used, 
which utilizes a 1 -week recall period ( Ware 2000).
I1F-MC-RHBW( d) Clinical Protocol Page 51
LY24398218.1.2.16. Fatigue Severity Numeric Rating Scale
The Fatigue Severi ty NRS is a pati ent-administered ,single -item, 11-point horizontal scale 
anchored at 0 and 10, with 0 representing “no fat igue” and 10 represent ing “as bad as y ou can 
imagine” (Naegeli et al. 2013).  Patients rate their fatigue ( feeling tired or worn out ) by circling 
the onenumber that describes thei r worst l evel of fati gue during the previous 24 hours.  
8.1.2.17. Work Productivity and Activity Impairment Questionnaire –
Spondyloarthritis
The WPAI -SpA consists of 6 questions to determine emplo yment status, hours missed fro m 
work because o f SpA, hours missed fro mwork for other reasons, hours actually worked, the 
degree to which SpA affected work productivit y while at work, and the degree to which SpA
affected activit ies outsi de of work.  The WPAI -SpA has been validated in the rad- axSpA patient 
popul ation (Reilly et al. 2010).  Four scores are derived:  percentage of absenteeism, percentage 
of presenteei sm (reduced productivit y while at work), an overall work impairment score that 
combines absenteeism and presenteeism, and percentage of impairment in act ivities per formed 
outsi de of  work.  Greater scores indicate greater impairment ( Reilly Associates [ WWW ]).
8.1.2.18. Jenkins Sleep Evaluation Questionnaire
The JSEQ i s a 4-item scale designed to estimate sleep problems in clinical research.  The JSEQ 
assesses the frequency  of sleep disturbance in 4 categories:  1) trouble falling asleep, 2) waking 
up several times during the night, 3) having trouble staying asleep (including waking up far too 
early), and 4) waking up after the usual amount of sleep feeling tired and worn out.  P atients 
report the number of days they experience each of these problems in the past month on a 6 -point 
Likert scale ranging from 0 = “no days” to 5 = “22 -30 days.”  The total JSEQ score ranges fro m 
0 to 20, with higher scores indicat ing greater sleep dist urbance (Deodhar et al. 2010).
8.1.2.19. Laboratory Tests Used for Efficacy Measures and Disease Diagnosis
8.1.2.19.1.High Sensitivity C -Reactive Protein
High sensi tivity CRP will be the measure of acute phase reactant .  It will be measured with a 
high sensit ivity assay  at the central laboratory to help assess the effect of ixekizumab on disease 
activit y.  
The results will not be shared with the investigative sites after baseline randomizat ion
to maintain the study  blind.
8.1.2.20. Imaging Used for Efficacy Measures and Disease Diagnosis
8.1.2.20.1. Imaging of Sacroiliac Joints and Spine
For each patient, x -ray image swill be collected according to the Schedule o f Activities 
(Appendix 2 )andTable RHBW. 4, and will follow the study -specific recommendations included 
in site training materialsfor this study .  The SIJ x-ray will be used to confirm pat ients have 
radiographic sacroil iitis as defined by the mNY criteria .  The screening x-ray of the spine will 
also serve as baseline for later evaluat ion of change fro m baseline in structural progression in the 
long-term study  (RHBY) .  
The s ite will read the screening x
-ray of the spine (cervical+lumbar) for presence or absence of 
total ankylo sisto determine study  eligibilit y.  The site will then send the x -ray to the central  
I1F-MC-RHBW( d) Clinical Protocol Page 52
LY2439821reader to be maintained as a baseline for later structure assessments. All otherimages (x-ray of 
the SIJ) are centrally read for eligibilit y and/or for assessment of treatment effect.
Table RHBW. 4. Imaging Requirements for Sacroiliac Joints and Spine
Time Point a Type of Image b Purpose Reading Requirements
Screening X-ray  of the SIJ Eligibility to determine 
rad-axSpA (per mNY 
criteria)Centrally readc Send to central reader ; 
results must be received 
from central reader prior to 
baseline randomization
Screening X-ray  of the spine 
(cervical and 
lumbar)Eligibility to determine 
total anky losisLocally read (by 
investigator) dSend to central reader 
(as baseline for later 
structure assessments)
Abbreviations:  mNY = modified New York; rad-axSpA = radiographic axial spondyloarthritis; SI J= sacroiliac
joints.
aScreening procedures must be conducted within timeframes specified in the Schedule of Activities ( Appendix 2 ).
bImaging to be reviewed and approved for quality; imaging that does not pass the quality assessment must be 
repeated prior to baseline randomization.
cPatient cannot be randomized until centrally read results are received by site.
dPatient can be enrolled by investigator for this inclusion/exclusion criterion of ankylosis.
8.1.3. Other Assessments
8.1.3.1. European Quality of Life –5 Dimensions –5Level
The European Qualit y of Life –5 Dimensi ons–5 Level ( EQ-5D-5L )is a standardized measure of 
healt h status used to provide a simp le, generic measure of healt h for clinical and econo mic 
apprai sal.  The EQ -5D
-5Lconsists of 2 components:  a descript ive system o f the respondent’s 
healt h and a rating of his/her current health state using a 0- to 100 -mm visual analog scale 
(VAS).  The de scriptive system co mprises the fo llowing 5 dimensio ns:  m obility, self -care, usual 
activit ies, pain/disco mfort, and anxiet y/depressi on.  Each dimensio n has 5 levels:  no problems, 
slight problems, moderate problems, severe problems, and extreme problems.  The respondent is 
asked to indicate his/her healt h state by  ticking (or pl acing a cross) in the box associated with the 
most appropri ate statement in each of the 5 dimensio ns.  It should be noted that the numerals 1 to 
5 have no arithmetic properties and are not to be used as ordinal score s.  The VAS records the 
respondent’s self -rated heal th on a vert ical VAS in which the endpo ints are labeled “best 
imaginable healt h state” and “worst imaginable health state.”  This informat ion can be used as a 
quant itative measure of healt h outcome s.  The EQ -5D-5L healt h states, defined by the EQ -5D-
5Ldescript ive system, may be converted into a single summary index by applying a formula that 
essent ially attaches values (also called weights) to each of the levels in each d imensio n (EuroQol 
Group 2011).
8.1.3.2. Healthcare Resource Utilization
Healthcare resource utilization data regarding the number of visits to medical care providers, 
such as general pract itioners, specialists, physical, or occupational therapists, and other 
nonphy sical care provi ders f or servi ces outsi de of the clinical trial; emergency room admissio ns; 
hospi tal admissi ons; and concomitant medicat ions will be recorded by the invest igator in the 
study’s CRF .  These data will be collected to support economic evaluat ions of  treatm ent.
I1F-MC-RHBW( d) Clinical Protocol Page 53
LY24398218.2. Adverse Events
An AE is defined as:   Any untoward medical occurrence in a pat ient or clinical investigation 
subject administered a pharmaceut ical product that does not necessarily have a causal 
relationship with this treatment.  An AEcan therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (invest igational) product, whether or not related to the medicinal 
(invest igational) pro duct.
Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of pat ients during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate healt h care opt ion, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue the invest igational product before 
completing the study.  The patient is to be fo llowed un til the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, be cause the purpose of the clinical study  is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via CRF the occurrence and nature of 
each patient’s preexist ing condit ions, including clinically significant signs and sympt oms of the 
disease under treatment in the study .  In addi tion, si te personnel  will record vi a CRF any change 
in the condit ion(s) and any new condit ions as AEs. Invest igators must record their assessment of 
the potenti al relatedness of each AE to protocol procedure, invest igational product, via CRF .
The invest igator decides whether he or she interprets each AE as reasonably possibly  related to 
the study  product, study  procedure, di sease under study , or other concomitant medications,or 
pathol ogies.To asse ss the rel ationship of the AEs, the fo llowing is defined:
Reasonably Possibly Related :Reasonable possibilit y that there i s a cause and effect 
relationship between the study  product and/or study  procedure and the AE.
The invest igator answers yes/no when m aking this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient’s investigational product is discontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via electronic data entry , clarifying if possible, the 
circumstances leading to any  dosage m odificat ions, or di scontinuati ons of  treatm ent. 
I1F-MC-RHBW( d) Clinical Protocol Page 54
LY2439821Accurate start and stop dates (and times, whe re requi red) are to be reported via electronic data 
entry  for all  AEs.  Only AEs that are ongoing at the last study visit and/or communicat ionare to 
be docum ented as “ongo ing”.
8.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the following outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization bu tmay jeopardi ze the pati ent or may  requi re intervent ion to prevent 
one of the other outcomes listed in the definit ion above .
If an SAE occurs after signing the ICF, but prior to receiving investigat ional product, i t needs to 
be reported ONLY if it is considered reasonably possibly related to study procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 24 -
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up SAE 
information.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy (during m aternal  
or paternal exposure to invest igational product) mustbe reported following the SAE process and 
data are to be collected on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientsumm ary CRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  participation, the invest igator m ust prom ptly notify Lilly .
8.2.1.1. Suspected Unexpected Serious Adverse Reactions
Lilly has procedures that will be fo llowed for the recording and expedited reporting of suspected 
unexpected serious adverse reactions ( SUSARs )that are consistent with global regulat ions and 
the associ ated detailed guidances.
8.2.2. Adverse Events of Special Interest
The fo llowing adverse events of special interest (AESIs) will be used to determine the safet y and 
tolerabilit y of ixekizumab over the range of dose s selected for this clinical study .
The AESIs for ixekizumab are:
I1F-MC-RHBW( d) Clinical Protocol Page 55
LY2439821cytopeni as (leukopenia, neutropenia, and thrombocy topeni a)
clinically significant hepatic events and/or significant el evations in liver funct ion test 
changes/enzyme elevat ions (ALT, AST, bilirubin, and alkaline phosphatase)
infect ions
inject ionsite reacti ons
allergic reactions/hypersensit ivities
cerebrocardiovascular events 
malignancies
IBD
depressio n.
Sites will provide details on so me of these AEs as instructed on the CRF.  Invest igato rs will also 
educate patients and/or caregivers about the symptoms of allergic/hypersensit ivity react ions and 
will provide instructions on dealing with these reactions (see also Secti on6.6.1 ).  A blood 
sample is to be collected as soon as possible for any patient who experiences an AE of a potential 
systemic allergic/hypersensit ivity react ion during the study  as judged by the invest igator.
Data on preferred terms associated with cerebrocardiovascular events (defined as death, cardiac 
ischemic events including MI and hospitalization for unstable angina, hospitalizat ion for heart 
failure, serious arrhy thmia, resuscitated sudden death, cardioge nic shock, coronary  
revascularization procedure, stroke/transient ischemic attack, peripheral revascularization 
procedure, and peripheral arterial event and hospitalizat ion for hypertensi on)will be co llected, 
and these events and any  deaths will be adjudicated by  an external  Clinical  Events Committee 
(CEC) m ade up of a chairman, 2 cardio logists, and a neurologist .  
Data on suspected IBD, as identified by  events possibly indicat ive of ulcerative colit is and 
Crohn’s disease ,will be co llected and the events will be adjudicated by an external CEC with 
expert ise in IBD.  
The rol e of external  CECs is to adj udicate defined clinical events in a blinded, consistent, and 
unbiased manner throughout the course of a study .The purpose of the CEC for adjudicat ion of  
cerebrocardiovascular events and the CEC for adjudicat ion of suspected IBD events is to ensure 
that all reported events are evaluated uniformly by a single group.
8.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and dr ug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
8.3. Treatment of Overdose
Refer to the IB.
I1F-MC-RHBW( d) Clinical Protocol Page 56
LY24398218.4. Safety Assessments
8.4.1. Electrocardiograms
For each patient, 12 -lead ECGs must be collected locally at screening ( Appendix 2 ).  Pati ents are 
to be resting for 5 minutes prior to the ECG.  It is recommended that patients be in a supine 
position.  
Any clinically  significant findings from ECGs that resul t in a di agnosis and that occur after the 
patient receives the first dose o f the invest igational treatment are to be reported to Lilly or its 
designee as AE svia CRF.  Any clinically significant ECG f indings prior to receiving drug are to
be reported as a preexist ing condit ion.
8.4.2. Vital Signs
For each patient, vital sign measurements are to be conducted according to the Schedule of 
Activities (Appendix 2 ).  Vi tal signs include BPand pulse .  Patients are to be resting for a 
minimum o f 5 minutes prior to vital sign co llection. 
Any clinically  significant findings from vital sign measurement sthat resul t in a diagnosi s and 
that occur after the patient receives the first dose of study treatment are to be reported to Lilly or 
its designee as AE svia CRF .
8.4.3. Laboratory Tests
For each patient, laboratory  tests (detailed in Appendix 3 ) will be sent to a central laboratory for 
processing and must be conducted according to the Schedule of Activit ies (Appendix 2 ).  Pl ease 
reference the central laboratory  manual  for specific instructi ons.
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of invest igatio nal product areto be reported to Lilly or its 
designee as AE svia CRF .
8.4.4. Physical Examination
For each patient, a complete physical examinat ion must be conducted according to the Schedule 
of Activities (Appendix 2 ).  
Any clinically  significant findings from a complete physical examinat ion that result in a 
diagnosis and that occur after the pati ent receives the first dose of study  treatm ent are to be 
reported to Lilly  or its designee as AE svia CRF .
8.4.5. Eye Symptom Assessment
At each study  visit, study  heal thcare provi ders will  evaluate the patient for any  symptoms of 
anteri or uveit is as specified in the Schedule of Act ivities(Appendix 2 ).  If the pati ent has no 
prior opht halmo logist-diagnosed anteri or uveit is and develops eye pain or disco mfort, ey e 
redness, blurring of visio n
,or any  other symptom s suggest ive of anteri or uveit is, the patient must 
be evaluated by  an op hthalmologist .  If a patient has prior history  of opht halmo logist-diagnosed 
I1F-MC-RHBW( d) Clinical Protocol Page 57
LY2439821anteri or uveit is, then she/he must be evaluated b y a physician for recurrence of anteri or uveit is 
(whenever possible ,diagnosis is to be confirmed by an opht halmo logist).
8.4.6. Chest X -Ray and Tuberculosis Testing
For each patient, a posterior anterior chest x -ray and TB testing must be conducted according to 
the Schedule of Act ivities (Appendix 2 ).  
The posteri or anteri or chest x -ray or resul ts will be reviewed by the invest igator or designee prior 
to baseline randomization to exclude patients with active TB infect ion.
Any clinically  significant findings from a posteri or anteri orchest x -ray or TB testing that resul t 
in a new diagnosis and that occur after the patient receives the first dose of study  treatment are to 
be reported to Lilly or its designee as AEsvia CRF .
Patients with no TB test (purified protein derivative [PPD ]and/or Interferon -Gamma 
Release Assay) results on file:   These patients will be tested at screening as indicated on the 
Schedule of Act ivities (Appendix 2 ) for evi dence of active or latent TB indicated by a posit ive 
PPD skin test response ,defined as ≥5 mm diameter of indurat ion, between approximately  2 and 
3 day s after test applicat ion, regardless o f BCG vaccinat ion history .  In countries where the 
Interferon -Gamma Release Assay ( Quant iFERON ®-TB Gold te st, or T -SPOT ®)is available 
and,in the judgment of the investigator ,preferred as an alternat ive to the PPD skin test for the 
evaluat ion of TB infect ion, itmay be used instead of the PPD test (posit ive tests excluded) .  The 
Quant iFERON ®-TB Gol d test maybe read locally or centrally , while the T-SPOT ®must be 
read locally .  If the QuantiFERON® -TB Gol d test is indeterminate, or the T -SPOT® is invalid or 
borderline , one retest i s allowed.  If the retest for the Quant iFERON® -TB Gol d test i s 
indeterminate, or the retest for the T -SPOT® is invalid or borderline, then the patient is excluded 
from enrolling in the study .
However, patients with a PPD skin test ≥5 mm indurati on or a posit ive Quant iFERON® -TB 
Gold or posi tive T-SPOT® test at screening, but no other e vidence of act ive TB ,may be 
rescreened onetime and may be enro lled without repeating a PPD or QuantiFERON®- TB Gol d 
test or T -SPOT® (TB test) if the fo llowing condi tions are met:
after receiving at least 4 weeks of appropriate latent TB infection (LTBI) t herapy .
with no evidence o f hepatotoxicit y (ALT/AST must remain ≤2xULN) upon retesting of 
serum  ALT/AST pri or to randomization .  Such patients must complete appropriate LTBI 
therapy  during the course of the study  in order to remain eligible .
meet all other inclusio n/exclusio n criteria for partici pation.
If rescreening occurs within 6 months of the initial screening posteri or anteri or chest x -ray, there 
is no necessit y for repeat of the chest x -ray for consi dering enrollment. 
Patients with negative TB test results on file:   Pati ents wi th documentati on of  a negat ive test 
resul t within 3 m onths pri or to baseline (Week 0, Visit 2) do not need a TB screen at Visit 1 .  
Docum entati on of  a PPD test result must include a record of the size of the induration response
docum enting no indurat ion or indurat ion measuring <5 mm in diameter . A PPD test recorded as 
I1F-MC-RHBW( d) Clinical Protocol Page 58
LY2439821negat ive wit hout document ing the size of indurat ion will result in a required test at screening to 
determine patient eligibilit y.
Patients with positive TB test results on file :  Patients with prior history  of a posi tive TB test 
are not to have a TB test at Visit 1.  Documentation of this history  and of at l east 4 weeks of 
appropriate LTBI prior to baseline (Week 0, Visit 2) i s requi red f or study eligibilit y.  Patients 
who have a documented history  of com pleting an appropriate TB treatment regimen wit h no 
history  of re-exposure to TB since their treatment was completed ,and no evidence of act ive TB ,
are eligible to participate in the study .  Patients who have had h ousehol d contact wi th a person 
with active TB are excluded, unless appropriate and documented prophylaxis for TB was 
completed .
8.4.7. Quick Inventory of Depressive Symptomatology –Self-Report 
(16Items)
For each patient, a QIDS -SR16 assessment will be collected a ccording to the Schedule of 
Activities (Appendix 2 ).
Any clinically  significant findings from the QIDS -SR16 assessment that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment are to be reported to Lilly or 
its designee as AE sviaCRF .
The QIDS -SR16 is a self-administered, 16-item instrum ent intended to assess the existence and 
severit y of symptom s of depressio n as listed in the American Psychiatric Associat ion’s 
Diagnostic and Statistical Manual of Mental Disorders , 4th Edi tion (APA 1994).  A patient is 
asked to consider e ach statem ent as i t relates to the way  they  have fel t for the past 7 days.  There 
is a 4 -point scale for each item ranging from 0 to 3.  The 16 items corresponding to 9 depression 
domains are summed to give a single score ranging from 0 to 27, with higher scores denoting 
greater symptom severit y.  The dom ains assessed by  the instrum ent are (1) sad mood, 
(2)concentration, (3) self -criticism, (4) sui cidal  ideati on, (5) interest, (6) energy/fatigue, 
(7)sleep disturbance (init ial, middle, and late insomnia or hyperso mnia), (8) decrease/increase in 
appeti te/wei ght, and (9) psy chomotor agi tation/retardati on.  Addi tional informat ion and the 
QIDS -SR16 questions may be found at the Universit y of Pittsburgh IDS/QIDS internet page 
(http://www.ids -qids.org/ ).
8.4.8. Columbia –Suicide Severity Rating Scale
The C-SSRS (Posner et al. 2007 ;Columbia Universit y Medical  Center [WWW]) is a scale that 
captures the occurrence, severit y, and frequency  of sui cide-related i deati ons and behaviors 
during the assessment period.  The C -SSRS m ust be administered by  appropri ately trained site 
personnel.  The tool was developed by  the Nat ional Inst itute of Mental Healt h (NIMH) 
Treatment of Ado lescent Suicide Attempters (TASA) trial group for the purpose of being a 
counterpart to the Columbia Classificat ion Algori thm of Suicide Assessment (C -CASA) 
categori zation of suicidal events .  Pati ents will  be assessed according to the Schedule of 
Activities (Appendix 2 ).
I1F-MC-RHBW( d) Clinical Protocol Page 59
LY2439821The Self -Harm  Supplement Form is a one -quest ion form that is completed, at any  visit, including 
baseline visits, that asksfor the number of suicidal or nonsuicidal self -injuri ous behavi orsthe 
patient has experienced since the last assessment. For each unique event ident ified, a 
questionnaire (Self -Harm  Follow-up Form ) which collects supplemental informat ion on the self -
injuri ous behavi or is to be completed. This informati on is then docum ented in the eCRF . 
8.4.9. Immunogenicity
For each patient, an immunogenicit y sample will  be collected according to the Schedule of 
Activities (Appendix 2 ).  
Addit ionally , a bl ood sam ple is to be collected, as soon as possible, for any  patient who 
experiences a potential systemic allergic/hypersensit ivity react ion during the study  as judged by
the invest igator .  These samples will be tested for immunogenicit y and PK, while other 
laboratory  tests m ay be perform ed as needed to elucidate the cause of the allergic/
hypersensit ivity react ion.
8.4.10. Safety Monitoring 
Lilly will periodically  review evolvin g aggregate safet y data wi thin the study  by appropri ate 
methods.
If a study  patient experiences elevated ALT ≥3xULN, alkaline phosphatase ≥2xULN, or el evated 
total bilirubin ≥2xULN, clinical and laboratory  monitoring is to be initiated by the investigator .  
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.  For other AESIs or abnormal lab results, please refer to the appropriate 
protocol  section that addresses these topics .  To ensure patient safet y and co mply with regulatory  
guidance, the investigator is to consult with the Lilly  clinical research physician /clinical  research 
scientist regarding collect ion of specific reco mmended clinical information and fo llow-up 
laboratory  tests(see Appendix 4 ).
8.4.10.1. Neutropenia
8.4.10.1.1. During Treatment (Periods 2 and 3)
During treatment with invest igational product , patients with neutrophil counts <1500 cells/ L 
(<1.50x 103/µL or <1.50 GI/L) are to be managed for neutropenia as fo llows:
<500 cells/ L (<0.50x 103/µL or <0.50 GI/L) , see Discontinuation Criteria (Section 7.1)
≥500 cells/ L and <1000 cells/ L (≥0.50x10 3/µLand <1.00x10 3/µLor ≥0.50 GI/L and 
<1.00 GI/L), see Discont inuat ion Cri teria (Secti on7.1)
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and 
<1.50 GI/L), and the patient has a concurrent infection that requires systemic ant i
-
infect ive therapy (for example, a ntibiotic, antifungal agent, antiviral agent):  
oThe dose of invest igational product is to be withheld, the patient is to receive 
appropriate medical care, and a repeat test for neutrophil count is to be performed 
within 4 weeks from knowledge of the initial report.  If the repeat neutrophil 
count has returned to ≥1500 cells/ L (≥1.50x10 3/µLor ≥1.50x10 3/µL)and the 
I1F-MC-RHBW( d) Clinical Protocol Page 60
LY2439821infect ion has resolved or is resolving, the patient may resume dosing of 
investigat ional product and evaluat ion at scheduled visits.  If t he neutrophil count 
remains ≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor 
≥1.00 GI/L and <1.50 GI/L), invest igational product is to continue to be withheld 
and a repeat neutrophil count is to again be performed within another 4 weeks.   If, 
after 2 repeat tests, the neutrophil count still remains ≥1000 cells/ L and 
<1500 cells/L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L), 
and:
the infect ion has not fully  resolved, the pati ent will be discontinued from 
the study treatm ent.
the infect ion has reso lved, the patient may resume dosing and evaluat ion 
at scheduled visit s.  However, if resumpt ion of dosing is not deemed 
appropriate by  the investi gator, the pati ent will be discontinued fro m the 
study treatm ent.
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and 
<1.50 GI/L), and the patient has no concurrent infection that requires systemic ant i-
infect ive therapy (for example, ant ibiotic, antifungal agent, antiviral agent):  
oDosing may continue, and a repeat neutrophil count is to be performed 4 to 
8weeks from knowledge of the init ial report.  Testing may be at a regularly 
scheduled visit or at an unscheduled visit, as necessary .
Repeat testing is to be performed at 4- to 8-week intervals unt il the neutrophil 
count has returned to ≥1500 cells/L (≥1.50x10 3/µL or ≥1.50 GI/L) .  If the 
patient has 3 or m ore postbaseline neutrophil counts of ≥1000 cells/L 
(≥1.00x10 3/µL or ≥1.00 GI/L) and <1500 cells/L (<1.50x10 3/µL or 
<1.50 GI/L), no value of <1000 cells/L (<1.00 x10 3/µL or <1.00 GI/L), and no 
postbaseline infection requiring systemic ant i-infective therapy, the patient may 
continue or resume further evaluation at scheduled visits, as deemed appropriate 
by the investigator.
If a patient wi thout ini tial concurrent infecti on devel ops an infecti on that requi res systemic ant i-
infect ive therapy, then the patient istobe managed as indicated above for patients with 
concurrent infect ion.  
8.4.10.1.2. At Early Termination Visit
For patients not enrolling in Study RHBY :  If, at the last scheduled study  visit, the pati ent’s 
neutrophil count is <1500 cells/ L (<1.50x10 3/µL or <1.50 GI/L) and less than the patient’s 
baseline neutrophil count, the following measures are to be taken :
Patients with Concurrent Infection:   If there is a concurrent infect ion that requires 
systemic anti -infect ive therapy, the patient is to receive appropriate medical care and a 
repeat test for neutrophil count is to be performed at least Q4W (or sooner as 
appropriate) un til reso lution of infect ion.  Upon resolut ion of infection, the neutrophil 
count is to be monitored using the required study visit s in Post -Treatment Follow -Up 
Period (Peri od 4) :  Visit 801 (4 weeks post -resolut ion of infection), Visit 802 (8 weeks 
I1F-MC-RHBW( d) Clinical Protocol Page 61
LY2439821after V isit 801 unless otherwise specified ), and Visit 803 (if necessary; 12 weeks after 
Visit802); addit ional visits may be requi red depending on the degree of neutropenia .  
For pati ents wi th a neutrophil count below the abovement ioned thresho ld at Week 52 
who have already enroll edin Study  RHBY, requi rements f or repeat test for neutrophil 
count will be specified in the Study  RHBY protocol .
Patients without Concurrent Infection:   If there is no concurrent infection that requires 
systemic anti -infect ive therapy, the neutrophil count is to be monitored using the 
requi red study  visits in the Post -Treatment Follow -Up Peri od (Peri od 4) :Visit 801 
(4weeks post -ETV or last regularly s cheduled visit), Visit 802, and Visit 803 (if 
necessary ); addi tional visi ts may  be requi red depending on the degree of neutropenia.
8.4.10.1.3. Post -Treatment Follow- UpPeriod
For pati ents not enrolling in Study  RHBY, at Visit 801 and subsequent visits, the following 
monitoring applies:
As long as a pati ent’s neutrophil count is <1000 cells/ L (<1.00x10 3/µL or <1.00 GI/L)
at any  follow-up visit, the patient is to return for visits at least Q4W (may require 
unscheduled visits).  
As long as a pati ent’s neutrophil count is ≥1000 cells/ L and <1500 cells/ L 
(≥1.00x10 3/µLand <1.50x10 3/µLor ≥1.00 GI/L and <1.50 GI/L) at any fo llow-up visit, 
the pati ent is to return for addit ional visit(s) at l east every  4to 8 weeks (may require 
unscheduled visits).  
If, at Vi sit 802 or V isit 803, the patient’s neutrophil count is ≥1500 cells/ L 
(≥1.50x10 3/L or ≥1.50 GI/L) or greater than or equal to the patient’s baseline neutrophil 
count (whichever is lower), the patient’s participat ion in the study  will be considered 
complete unless the invest igator deems addit ional follow-up m ay be necessary .  
If, at Vi sit 803, the pati ent’s neutrophil count remains <1500 cells/ L (<1.50x10 3/µL or 
<1.50 GI/L) and less than the patient’s baseline neutrophil count, or if the invest igator deems 
additional follow-up m ay be necessary , the invest igator ,in consultation wit h Lilly, or qualified 
designee, will determine the appropriate management of the patient and the appropriate timing of 
additional contact(s) or vi sit(s).
8.4.10.2. Hepatitis B Monitoring
Patients that are HBcAb+ at screening, regardless of other hepat itis B testing resu lts, will have a 
serum  HBV DNA specimen obtained to be analyzed by the central laboratory.  Such p atients that 
aredetermined to be HBV DNA negat ive (undetectable) may be enrolled into the study with 
requi red HBV DNA mo nitoring every  3to 4 months during t reatm ent and 12 weeks after the last 
dose of ixekizumab .  Pati ents that are found to be HBV DNA posit ive (detectable) at screening 
will be excluded fro m the trial.  
If the result of any subsequent HBV DNA testing is posit ive, the patient is to be discont inued 
from the study  treatm ent, is to continue safet y follow up, and is to receive appropriate fo llow-up 
medical care, including considerat ion for antiviral therapy .A specialist physician in the care of 
patients wi th hepat itis (for example, infect ious di sease or hepatol ogist subspecialists) is to be 
I1F-MC-RHBW( d) Clinical Protocol Page 62
LY2439821consulted and potentially  start antivi ral therapy  prior to di scont inuat ion of any  
immunosuppressant or immuno modulatory  therapy (including invest igational drug). Timing of 
discontinuat ion from the study  and of any immunosuppressant /immuno modulatory therapy  
(including investigat ional product) needs to be based on the recommendat ions of the consult ing 
specialist physician in conjunct ion with the invest igator and medical guidelines/standard of care.
8.4.10.3. Hypertension
Patients who experience changes in BP (sy stolic BP at ≥160 mm Hg plus ≥20 mm Hg increase 
from baseline [Week 0 ,Visit 2]; and/or di astolic BP at ≥100 mm Hg plus ≥10 mm Hg increase 
from baseline) on 2 consecutive visit s are to receive intervent ion for the m anagement of 
hypertensio n.  Intervent ion coul d include the maximal intervent ion of wit hholding the dose of 
investigat ional product and/or the introduction of ant i-hypertensive agent(s) as medically 
appropriate. 
8.5. Pharmacokinet ics
At the visit s and t imes specified in the Schedule of Act ivities(Appendix 2 ),blood samples of 
approximately  4mL each will be co llected to determine the serum concentrations of ixekizumab .  
These blood samples for PK analysis are matched to the timing of samples for the assessment of 
immunogenicit y.  It is expected that these PK samples will allow sufficient description of 
ixekizumab PK profiles at steady  state throughout the study .  Instructions for the collection and 
handling of blood samples will be provided by  the sponsor .  The actual date and time (24 -hour 
clock time) of each sampling will be recorded.
Samples co llected for PK analysis will be tested at a laboratory approved by Lilly or its designee.  
Concentrations of immunoreactive ixekizumab in human serum wil l be determined by  a 
validated m ethod.
Bioanaly tical samples collected to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study .
8.6. Pharmacodynamics
Refer to Section 9.6.
8.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule o f 
Activities (Appendix 2 )where l ocal regulati ons and ERBs allow. These samples are not being 
collected to create a biobank for conducting unspecified disease or populat ion genet ic research 
either now or in the future. Samples may be used to invest igate variable response to ixekizumab 
and to investigate genetic variants though t to pl ay a rol e in axSp Aand/or associ ated 
autoimmune /inflammatory condi tions. Assessment of variable response may include evaluat ion 
of AEs or differences in e fficacy .These studies may  include but are not limited to axSp Aand/or 
associ ated autoimmune /inflammatory condi tionsto evaluate their associat ion with observed 
response to ixekizumab.
I1F-MC-RHBW( d) Clinical Protocol Page 63
LY2439821All pharmacogenet ic samples will be coded with the pat ient number. These samples and any 
data generated can be linked back to the patient only by the invest igator site personnel. Samples 
will be destroy ed according to a process consistent with local regulat ions.
Samples will  be retained for a m aximum  of 15 y ears after th e last pati ent visi t for the study , or 
for a shorter peri od if local regulations and/or ERBs impose shorter time limits, at a facilit y 
selected by  the sponsor. This retent ion peri od enables use of new techno logies, response to 
regul atory  questi ons, and in vestigation of variable response that may not be observed unt il later 
in drug development or when the drug is co mmercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  name d.However, exist ing approaches include who le geno me or exome 
sequencing, geno me wide association studies, candidate gene studies, and epigenetic 
analyses. Regardless of techno logy utilized, genotyping data generated will be used only  for the 
specific re search scope described here.
8.8. Biomarkers
Urine, serum, plasma, RNA, and who le blood for epigenet ics samples will be co llected for non -
genet ic biomarker research at the times specified in the Schedule of Act ivities(Appendix 2 ) 
where local regulat ions and ERBs allow .  Samples will be used for research on the drug target, 
disease process, pathways associated with axSp Aand/or associ ated autoimmune /inflammatory
condi tions, MoA of ixekizumab, and/or research method, or in validat ing diagnostic tools or 
assay(s) related to axSp A and/or associated autoimmune /inflammatory condi tions.
All biomarker samples will be coded with the patient number. These samples and any  data 
generated can be linked back to the patient only by the investigator site personnel. Samples will 
be destroy ed according to a process consistent with local regulat ions.
Samples will  be retained for a m aximum  15 years after the l ast pati ent vi sit for the study , or f or a 
shorter period if local regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor. This retent ion peri od enables use o f new techno logies, response to regulatory  
questions, and invest igation of varia ble response that may  not be observed unt il later in drug 
development or when the drug is commercially available.
8.8.1. Samples for Immunogenicity Research
Blood sam ples f or immunogenicit y testing will  be collected to determine ant ibody  producti on 
against the in vestigational product(s) as specifie d in the Schedule of Act ivities
(Appendix 2 ).Immunogenicit y will be assessed using a validated assay  designed to detect ADA
in the presence of the investigational product(s).  Ant ibodies may be further characterized and/or 
evaluated for their abilit y to neutralize the activit y of the invest igational product(s). 
Samples will  be retained for a maximum o f 15 years after the last patient visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  The duration allows the sponsor to respond to future regulatory  requests related to 
the ixek izumab.
I1F-MC-RHBW( d) Clinical Protocol Page 64
LY24398218.9. Health Economics
Refer to Section 8.1.2 .
I1F - MC- RHBW (d)  C l in ica l  P ro toco l Page  65
LY24398219 .S ta t is t ica l  Cons ide ra t ions  and  Da ta  Ana lys is
9 .1 .De te rm ina t ion  o f  Samp le  S ize
A p p r o x im a t e l y 3 0 0  p a ti e n ts  w i l l  b e  r a n d o m i z e d  a t  a  1 : 1 : 1r a t i o  i n  t h e  B l i n d e d  T r e a tm e n t  D o s i n g
P e r iod  (P e r i od  2 )  to  i x e k i z um a b8 0m g  Q 2W ,  i x e k i z um a b80  m g  Q4W ,a n d  p l a c e b o .   W i t h  
1 0 0p a t i en t s  p e r  t r e a tm en t  g roup ,   
 
a s s um p t i o n s  a r e  
b a s e d  o n  t h e  r e v i ew  of  h i s to r i c a l  c l i n i c a l  s t u d i e s  i n  r ad - a xS pA( e t a n e r c e p t ,  a d a l im um a b ,  
i n f l i x im a b ,  c e r t o l i z um a b ,a n d  g o l im um a b  [D a v i se t  a l .  2 0 0 3 ;  v a n  d e r  H e i j d e  e t  a l .  2 0 0 5 ,2 0 0 6 ;  
I nm a n  e t  a l .  2 0 0 8 ,  L a n d ew ée t  a l .  2014 ] )  a n d  r e c e n t  s e c u k i n um a b  d a t a  i n  p a t i e n ts  w h o  a r e  TNF
i nh ib i to re x p e r i e n c e d  (B a e t en  e t  a l .2 0 1 4 b ; S iep e r  e t  a l .2014 ) .   
9 .2 .Gene ra l  S ta t is t ica l  Cons ide ra t ions
S t a t is t i c a l  a n a l y s i s  o f  th i s  s tudy  w i l l  b e  t h e  r e s p o n s i b i l i t y  o f  L i l l y .
C o n t i n u o u s  d a t a  w i l l  b e  s umm a r i z e d  i n  t e rm s  o f  t h e  m e a n ,  s t a n d a r d  d e v i a ti o n ,  m i n im um ,  
m a x im um ,  m e d i a n ,  a n d  n um b e r  o f  o b s e r v a ti o n s .   C a t e g o r i c a l  d a t a  w i l l  b e  s umm a r i z e d  a s  
f r e q u e n c y  coun t s  and  p e r c e n t a g e s .
A n y  c h a n g e  t o  t h e  d a t a  a n a l y s i s  m e t h o d s  d e s c r i b e d  i n  t h e  p r o t o c o l  w i l l  r e q u i r e  a n  am e n dm e n t  
ONLY  i f  i t  c h a n g e s  a  p r i n c i p a l  f e a t u r e  o f  t h e  p r o t o c o l .   A n y  o t h e r  c h a n g e  t o  t h e  d a t a  a n a l y s i s  
m e t h o d s  d e s c r i b e d  i n  t h e  p r o t o c o l ,  a n d  t h e  j u s ti f i c a t i o n  f o rm a ki n g  t h e  c h a n g e ,  w i l l  b e  d e s c r i b e d  
in  th e  c l in i c a l  s tudy  r epo r t(CSR ) .   A d d i t i o n a l  e x p l o r a t o r y  a n a l y s e s  o f  t h e  d a t a  w i l l  b e  c o n d u c t e d  
a sd e em e d  a p p r o p r i a t e .   
Comp l e t e  d e t a i l s  o f  t h e  p l a n n e d  a n a l y s e s  w i l l  b e  d o c um e n t e d  i n  t h e  SAP .
9 .2 .1 .Gene ra l  Cons ide ra t ionsfo r  Ana lyses  du r ing  the  B l inded  
T rea tmen t  Dos ingPe r iod( Pe r iod  2)CC I
Comp a r i s o n s  b e tw e e n  e a c h  i x e k i z um a br e g im e n  ( 8 0  m g  Q 2W  o r  8 0  m g  Q 4W )  a n d  p l a c e b ow i l l  
b e  p e r fo rm e d  f o r  a l l  a n a l y s e s  i n  P e r i o d  2 .   
P e r io d  2  s t a r t s  a t  t h e  f i r s t  i n j e c ti o n  o f  s tudy  t r e a tm e n ta t  W e e k  0  (V i s i t  2 )  a n d  e n d s  p r i o r  t o  t h e  
f i r s t  in j e c t i o n  o f  s tudy  t r e a tm e n t  a t  W e e k  1 6  (V i s i t  8 )  o r  t h e  ETV  ( b e tw e e n  W e e k s0  a n d  1 6 ) .
B a s e l i n e  w i l l  b e  d e f i n e d  a s  t h e  l a s t  a v a i l a b l e  v a l u e  b e f o r e  t h e  f i r s t  i n j e c ti o n  f o r  e f f i c a c y ,  h e a l t h  
ou t com e s ,a n d  s a f e t y  a n a l y s e s .   I n  m o s t  c a s e s ,  t h i s  w i l l  b e  t h e  m e a s u r e  r e c o r d e d  a t  W e e k  0  
(V i s i t2 ) .   F o r  e f f i c a c y  m e a s u r e s ,  i f  t h e  p a t i e n t  d o e s  n o t  t a k e  a n y  i n j e c ti o n ,  t h e  l a s t  a v a i l a b l e  
v a l u e  o n  o r  p r i o r  t o  r a n d om i z a ti o n  d a t e  w i l l  b e  u s e d .   C h a n g e  f r om  b a s e l i n e  w i l l  b e  c a l c u l a t e d  a s  
th e  v i s i t  v a l u e  o f  i n t e r e s t  m i n u s  t h e  b a s e l i n e  v a l u e .  F o r  s a f e ty  an a ly s e s  u s ing  a  b a s e l in e  p e r iod ,  
th e  b a s e l i n e  p e r i o d  i s  d e f i n e d  a s  t h e  t im e  f r o m  V i s i t  1  t o  t h e  d a t e / t im e  o f  t h e  f i r s t  i n j e c ti o n .
I1F-MC-RHBW( d) Clinical Protocol Page 66
LY2439821The rando mizat ion to treatm ent groups is stratified by country , baseline CRP status (nonelevated
or elevated) ,and number of prior TNF inhibitor sused (1 or 2) as described in Sect ion 6.2. The 
countri es will  be categori zed into geographic regions for analysis .  Geographic regio ns will be 
defined in the SAP upon country  finalizat ion.Unless otherwise specified, the statist ical analysis 
models will adjust for geographi c regi on,baseline CRP status ,and number of prior TNF
inhibi torsused.  
Unless otherwise specified, treatment groups of ixekizumab 80 mg Q2W and Q4W will be 
analyzed without regard to starting dose.
The primary  analysis method for treatment comparisons of categorical effic acyandhealth 
outcom esvariables at specific time point swill be made using a logistic regression analysis with 
treatm ent, geographi c regi on, baseline CRP status ,and number of prior TNF inhibitors used in 
the model.  The odds rati o and 95% confidence int ervals (CIs) will be reported ;treatm ent 
difference and 95% CIswill also bereported .  Secondary analysis will be conducted using a 
Fisher’s exact test.
As a secondary  analysis for the primary and major secondary categori cal efficacy  measures, a 
categori cal mixed -effects m odel of repeated measures ( categori cal MMRM) estimat ing the 
percentage of patients achieving response across postbaseline visits may be used.  The model 
will include treatment, geographic region , baseline CRP status, number of prior TNF inhibitors
used, visit, and treatm ent-by-visit as fixed factors , as well as the continuous, fixed covariate of 
baseline value and baseline value -
by-visit interaction (when appropriate) .  The bino mial 
distribut ion and the logit link will be used.  An unstruc tured covariance matrix will be used to 
model the wi thin-patient vari ance-covariance errors.  The Kenward -Roger approximat ion will  be 
used to estimate the deno minator degrees of freedom.  The Newton- Raphson with ridging 
optimizat ion technique will be used to aid with convergence.  The probabilit y of response, the 
corresponding 2- sided 95% CI, and the p -value for treatment comparisons at Week 16 (Visit 8) 
and all other postbaseline visit s will be reported.  
If the unstructured covariance matrix results in a lack of convergence, the heterogeneous 
Toeplitz covariance structure, followed by the heterogeneous autoregressive covariance 
structure, followed by the compound symmetry ,will be used.  This order is specified according 
to a decreasing number of covarian ce parameters in the structure.  The sandwich estimator 
(Diggle et al . 1994) for the covariance est imation will be used by specifying the EMPIRICAL 
option in SAS PROC MIXED.  When sandwich estimat ion is used, the Kenward- Roger 
approximat ion for denominator degrees of freedom cannot be used.  Instead, the DDFM= 
BETWITHIN option will be used to estimate denominator degrees of freedo m.
The primary  analyses for continuous efficacy and healt h outcom esvariables will be made using 
MMRM.  A secondary  analysis for continuous efficacy  and heal th outcome svariables will be 
made using analysis o f covari ance ( ANCOVA ).
When the MMRM is used, the model will include treatment, geographic region, baseline CRP 
status, number of prior TNF inhibitors used, baseline value, baseline value -by-visit, visit, and 
treatm ent-by-visit interaction as fixed factors.  The covariance structure to model the 
I1F-MC-RHBW( d) Clinical Protocol Page 67
LY2439821within-patient errors will be unstructured.  If the unstructured covariance matrix results in a lack 
of convergence, the similar approac h specified above for categorical MMRM will be used.  The 
Kenward -Roger m ethod will be used to estimate the deno minator degrees of freedo m.  Type III 
tests for the least -squares (LS) means will be used for the statist ical co mpar ison; the 95% CI will 
also b e reported .  Treatment group comparisons with placebo at Week 16 (Visit 8) and all other 
visits will be tested.
When the ANCOVA is used, the model will include treatment, geographic region, baseline CRP 
status , number of prior TNF inhibitors used,and base line value.  Ty pe III sum s of squares for the 
LS m eans will be used for the statist ical co mpar ison; the 95% CI will also be reported.
The impact of ixekizumab starting dose of 160 mg versus 80 mg on time -to-onset (focus on 
Week 4) and treatment response during the Period 2 (focus on Week 16) will be summarized and 
evaluated; details will be specified in the SAP.
For vari ables that are not collected at each postbaseline visit, data may  exist at visi ts where the 
variable was not sche duled to be collected, due to early  discontinuat ion visit s.  In these 
situations, data from  the early  discontinuati on visi t that do not correspond to the planned 
collect ion schedule will be excluded fro m the MMRM and categori cal MMRM analyses.  
However, th e data will st ill be used in other analyses, including shift analyses, change fro m 
baseline to last observat ion carri ed forward (LOCF) or modified baseline observat ion carri ed 
forward (mBOCF) endpo int analyses and other categorical analyses.
Fisher ’s exact test will be used for all AE, baseline, discontinuat ion, and other categorical safet y 
data.  Continuous vital sign and laboratory values will be analyzed by an ANCOVA with 
treatm ent and baseline value in the model.
9.2.2. General Considerations for Analyses duri ng the Extended 
Treatment Period (Period 3 ) 
Unless otherwise specified, Period 3 starts at the first injection o f study  treatm ent at Week 16 
(Visit 8) and ends on the date of Week 52 (Visit 15) or the ETV (between Weeks 16 and 52).
For the efficacy and he alth outcom esanalyses, baseline is defined as the last available value 
before the first inject ion in Period 2 and, in most cases, will be the value recorded at Week 0 
(Visit 2).
Unless otherwise specified, for the safet y analyses during Period 3, baseline is defined as the last 
available value before first inject ion of ixekizumab in Period 3.  In most cases, this will be the 
measure recorded at Week 16 (Visit 8).
All efficacy and safet y data collected will be summarized using descriptive statist ics.
9.2.3. Genera l Considerations for Analyses during the Post -
Treatment Follow -Up Period (Period 4 )
For the safet y analyses during Period 4, baseline is defined as the last nonmissing assessment on 
or pri or to entering Period 4, that is, on or prior to Week 52 (Visit 15), or ETV.  
I1F-MC-RHBW( d) Clinical Protocol Page 68
LY2439821Safety data collected will be summarized using descript ive statist ics.
9.2.4. Analysis Populations 
The fo llowing analysis populat ions will be used:
Intent -to-Treat Population (ITT) :  Unless otherwise specified, efficacy and healt h outcomes 
analyses for Period 2 will be conducted on the ITT population, defined as all rando mized 
patients, even if the pat ient does not take the assigned treatment, does not receive the correct 
treatm ent, or otherwi se does not fo llow the protocol .  Patients will be analyzed according to the 
treatm ent to whi ch they  were assi gned.
Per-Protocol Set (PPS): In addition, the primary  efficacy  analysis will be repeated using the 
PPS, which is defined as all rando mized patients who are compliant with therapy , who do not 
have significant protocol deviat ions, and whose investigator site does not have significant GCP 
issues that require a report to the regulatory  agencies pri or to Week 16 (Visit 8).  Compliance 
with therapy is defined to be missing no more than 20% o f expected doses, not missing 
2consecutive doses (all inject ions at a visit are counted as 1 dose), and not have any occurrence 
of doubl e-dosing (that i s, took m ore inject ions at the same t imepoint than spec ified in the 
protocol ) during Period 2.
Significant protocol  deviat ionswill be described in the SAP.  Patients will be analyzed according 
to the treatment to which they  were assi gned.
Safety Population: Safety analyses for Period 2 will be conducted on t he Safety Population, 
defined as all rando mized patients who received at least 1 dose of study treatment.  Patients will 
be analyzed according to the treatment to which they  were assigned in that period.
Extended Treatment Period Population: Efficacy , hea lth outcom es, and safety  analyses for 
Period 3 will be conducted on the Extended Treatment Period Population, defined as all pat ients 
who received at least 1 dose of ixekizumab treatment during Period 3.
Follow -Up Population: Safet y analyses for Period 4 will be conducted on the Follow-Up 
Population, defined as all rando mized patients who received at least 1 dose of study treatment 
and have entered Period 4.  Patients will be analyzed according to the treatment they received 
before entering Period 4.
9.2.5. Missing Data Imputation 
In accordance with precedent set with other Phase 3 axSpA trials (van der Heijde et al. 2006; 
Inman et al. 2008), the fo llowing methods for imputation of missing data will be used .
9.2.5.1. Nonresponder Imputation 
Analysis of categorical e fficacy and healt h outcome svariables will be assessed using a 
nonresponder imputation ( NRI)method .  Patients will be considered nonresponder sfor the NRI 
analysis if they  do not m eet the clinical response criteria or have missing clinical response data a t 
the primary analysis t ime point.  All nonresponders at Week 16 (Visit 8), as well as all patients 
who discont inue study  treatm ent at any  time pri or to Week 16 for any  reason, will be defined as 
I1F-MC-RHBW( d) Clinical Protocol Page 69
LY2439821nonresponders for the NRI analysis at Week 16.  Rando mized p atients without at l east 
1postbaseline observation will also be defined as nonresponders for the NRI analysis.
The NRI m ay be applied at any  time point specified for analysis.
9.2.5.2. Modified Baseline Observation Carried Forward
AnmBOCF analysis will be perform ed on efficacy and health outcomes variables in the major 
and other secondary  objectives.  For patients discont inuing study drug due to an AE, the baseline 
observat ion will  be carri ed forward to the corresponding time point for evaluat ion.  For pati ents 
discontinuing study drug for any  other reason, the last nonmissing observation before 
discontinuat ion will  be carri ed forward to the corresponding timepoint for evaluation.  
Randomized patients without at least 1 postbaseline observat ion will not be include d for 
evaluat ion with the except ion of pat ients discont inuing study  treatm ent because of an AE.
9.2.5.3. Last Observation Carried Forward
AnLOCF analysis will be performed on continuous efficacy  and healt h outcom es variables in 
the major secondary  object ives.  This approach is ident ical to the mBOCF approach, with one 
exception:  For pati ents di scontinuing study  drug because of an AE, the last nonmissing 
postbaseline observat ion before discont inuat ion will be carried forward to the corresponding 
endpo int for eva luation.  Rando mized patients without any postbaseline observat ion will not be 
included for evaluat ion.
9.2.6. Adjustment for Multiple Comparisons 
A multiple testing strategy  for the primary  and major secondary  objectives will be implemented 
to con trol theovera llfamily -wise t ype I error rate at a 2 -sided α level o f 0.05.  A graphical 
multiple testi ng procedure (Bretz et al. 2011) will be used ( Figure RHB W.2). The graphical 
approach i s a cl osed testing procedure ;hence ,it strongly controls the family -wise error rate 
(Alosh et al . 2014).  The following is a list of primary  and m ajor secondary  outcom es to be tested 
for both ixekizumab 80 mg Q2W and Q4W regime nsat Week 16:
Primary : proporti on of  patients achi eving an ASAS 40 response [ASAS 40]
Secondary  1:proporti on of  patients achieving an ASAS 20 response [ASAS 20]
Secondary  2:change from baseline (CFB) in ASDAS score [ASDAS CFB]
Secondary  3:proporti on of  patients achieving BASDAI50 [BASDAI50]
Secondary  4:change from baseline in BASFI [BASFI CFB]
Secondary  5:proporti on of  patients achieving ASDAS inact ive disease [ASDAS 
inact ive]
Secondary  6:change from baseline in SF -36 PCS score [SF -36 PCS CFB]
Seconda ry 7:change from baseline in ASAS HI[ASAS HI CFB]
Secondary  8:change from baseline in MRI of the spine
[MRI spine SPARCC score
CFB] .
The 8 secondary  outcom es are grouped into 2 tiers ( Figure RHB W.2
) based on the clinical 
importance as well as statist ical significance observed in historical axSpA studies. 
Figure RHB W.2 shows a general form of the graphical testing scheme.  
I1F-MC-RHBW( d) Clinical Protocol Page 70
LY2439821The primary  outcom e of ASAS40 will  be tested for ixekizumab 80 mg Q2W v ersus placebo at a 
2-sided α=0.05.  If the null hypothesis is no t rejected, no further testing is conducted ,as the α for 
that test is considered “spent ”and cannot be passed to other endpoints.  If the null hypothesis is 
rejected, the α will be distributed to the Tier 1 set of secondary outcomes for ixekizumab 80mg 
Q2W and ASAS 40 for ixekizumab 80 m g Q4W .  The testing process continues for the remaining 
outcom es by all ocating the remaining αto the next set of outcomes as lo ng as at least one 
hypothesis can be rejected.  Each time a hypothesis is rejected, the graph is updated to reflect the 
reallocat ion of α, which is considered “recycled” (Alosh et al. 2014).  This iterative process of 
updating the graph and reallocat ing α is repeated unt il all major secondary hypotheses have been 
tested or when no remaining hypothe ses can be rejected at their corresponding α levels.  The 
weights along the edges for α allocat ion between ixekizumab 80 mg Q2W and ixekizumab 
80mgQ4W outcom es,as well as within each of the tiers,will be prespecified in the SAP prior 
to the first patie nt randomizat ion of the study .
I1F-MC-RHBW( d) Clinical Protocol Page 71
LY2439821Abbreviations:  ASAS = Assessment of Spondyloarthritis International Society; ASAS HI = ASAS Health Index; 
ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease 
Activity  Index; BASFI = Bath Ankylosing Spondylitis Functional Index; CFB = change from baseline; SF-36 
PCS = Short Form 36 physical component score ;SPARCC = Spondyloarthritis Research Consortium of Canada ; 
Q2W = every 2 weeks; Q4W = ever y 4 weeks .
Figure RHB W.2. Illustration of graphical multiple testing procedure.
There will be no adjust ment for multiple com parisons for any  other analyses.  
9.3. Treatment Group Comparability
9.3.1. Patient Disposition
All patients who prematurely discontinue fro m the study treatment and /or from the study  will be 
ident ified, and the extent of their participation in the study will be reported. Tier 1 Q2W
ASAS20
ASDAS CFB
BASDAI50
BASFI CFB
ASDAS -InactiveASAS40
Q2Wα = 0.05
ASAS40
Q4W
Tier 2 Q2W
SF-36 PCS CFB
ASAS -HI CFB
MRI spine SPARCC CFBTier 1 Q4W
ASAS20
ASDAS CFB
BASDAI50
BASFI CFB
ASDAS -Inactive
Tier 2 Q4W
SF-36 PCS CFB
ASAS- HI CFB
MRI spine SPARCC CFB
I1F-MC-RHBW( d) Clinical Protocol Page 72
LY2439821Patient disposi tion will be summarized for each treatment period with reasons for 
discontinuat ion.  The reasons for discontin uation during Peri od 2 will be co mpared between 
treatm ent groups using Fisher’s exact test.
9.3.2. Patient Characteristics
Patient characterist ics and baseline clinical measures will be summarized for each treatment 
period.  Baseline characterist ics will include sex, age, age category , wei ght, body  mass index 
(BMI), race, geographic region, country , baseline disease act ivity (BASDAI), duration of 
disease, HLA -B27 posi tivity, baseline CRP (% of nonelevated or elevated), baseline MRI status, 
number of prior TNF inhibitors used, and history of extra -axial disease manifestations.  Baseline 
clinical measurements may include ASDAS, CRP , BASFI, BASMI, chest expansion, Fatigue 
NRS, Patient Global NRS, total back pain, spinal pain at ni ght due to AS, spinal pain due to AS, 
inflammat ion (mean of quest ions 5 and 6 of BASDAI), MASES, SPARCC Enthesit is, TJC, and 
SJC.
Treatment group compari sons in Period 2 will  be conducted using Fisher’s exact test for 
categori cal data and an analysis o f variance ( ANOVA )with treatm ent as a factor for continuous 
data.
9.3.3. Concomitant Therapy
Previous and concomitant medicat ions will be summarized for patients w ho enter each treatment 
period and will be presented by  WHO Anatomic Therapeut ic Class Level 4 and WHO preferred 
term.  Conco mitant DMARDs, conco mitant oral  corti costeroi ds, and conco mitant NSAIDs will 
also be summarized.  Treatment group comparisons in Pe riod 2 will  be conducted using Fisher’s 
exact test.
9.3.4. Treatment Compliance 
Treatment compliance wit h investigational product will be summarized for patients who enter 
each treatment period.  A patient will be considered overall co mpliant for each study  period if 
he/she is missing no more than 20% of the expected doses, does not miss 2 consecut ive doses ,
and does not over -dose (that is, take more inject ions at the same time po int than specified in the 
protocol ).
Proporti ons of pat ients com pliant by  visit and overall will be compared between treatment 
groups during Period 2 using Fisher’s exact test.
9.4. Primary  and Secondar y Anal yses
9.4.1. Primary Analyses
The primary  analysis, the proporti on of  patients with ASAS 40 at Week 16 com pared wi th 
placebo, will be based on theITT Population.  In addi tion, an analysis o f the PPS Population will 
be used to support the primary  efficacy  analysis.
I1F-MC-RHBW( d) Clinical Protocol Page 73
LY2439821Treatment comparisons between each ixekizumab treatm ent group and placebo in the proportion 
of patients achieving an ASAS 40 response at Week 16 (Vi sit 8) will be analyzed using the 
logistic regressio n model defined in Section 9.2.1 .  Missing data will be imputed using the NRI 
method described in Section 9.2.5 .
Secondary analyses for ASAS 40 at Week 16 will be conducted using c ategori cal MMRM and 
Fisher’s exact test as described in Sect ion 9.2.1 .
9.4.2. Secondary Analyses 
9.4.2.1. Major Secondary Analyses 
The m ajor secondary  analyses a t Week 16 will be based on the ITT population for Peri od 2.  The 
major secondary  com parisons will be based on the multiple testi ng procedure detailed in 
Secti on9.2.6 .
 Treatment comparisons in the proportion of patients achieving a categori cal 
response at Week 16 (Visit 8) will be analyzed using the logistic regressio n model defined in 
Secti on 9.2.1 . For categorical responses, missing data will be imputed using the NRI method 
described in Section
 9.2.5 .  Treatment comparisons in the continuous measures will be analyzed 
using the MMRM model defined in Sect ion 9.2.1 .
Table RHB W.
5summarizes the primary  and maj or secondary  outcom es and analysis methods .  
All analys es listed will be performed based on theITT Population unless otherwise specified.
I1F-MC-RHBW( d) Clinical Protocol Page 74
LY2439821Table RHB W.5. Primary and Major Secondary Outcome A nalyses
Outcome Measure Primary Analysis Method Secondary Analysis Method 
ASAS40 (primary  efficacy 
outcome)Logistic regression analysis 
with NRI Categorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on PPS 
ASAS20 (major secondary 
outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NR I
Logistic regression analysis with NRI on PPS
Change f rom baseline in ASDAS 
(major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
BASDAI50 (major secondary 
outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
Change f rom baseline in BASFI 
(major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
ASDAS inactive disease (major 
secondary outcome)Logistic regression analysis 
with NRICategorical MMRM
Fisher’s exact test with NRI
Change f rom baseline in SF -36 PCS 
(major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in the ASAS 
HI(major secondary outcome)MMRM ANCOVA with mBOCF/LOCF
Change f rom baseline in MRI of the 
spine [ SPARCC score] (major
secondary outcome)ANCOVA with observed 
case analysis aSecondary analysis maybe specified in SAP
Abbreviations:  ANCOVA = analy sis of covariance; ASAS = Assessment of Spondyloarthritis International Society; 
ASAS HI = Assessment of Spondyloarthritis International Society Health Index; ASDAS = Ankylosing 
Spondylitis Disease Activity Score; BASDAI50 = Bath Ankylosing Spondylitis Disease Activity Index 50; 
BASFI = Bath Ankylosing Spondylitis Functional Index; LOC F = last observation carried forward; mBOCF = 
modified baseline observation carried forward; MMRM = mixed -effects model of repeated measures; MRI = 
magnetic resonance imaging; NRI = nonresponder imputation; PPS = per -protocol set; SAP = statistical analysi s 
plan; SF -36 PCS = Short Form -36 physical component scores ; SPARCC = Spondyloarthritis Research 
Consortium of Canada . 
aOnly patients with both baseline and Week 16 MRI scores will be included in the observed case analysis. 
9.4.2.2. Other Secondary Efficacy Anal yses 
There will be no adjust ment for multiple com parisons.  Analyses will be conducted for the other 
secondary  efficacy object ives defined in Section 3.  Specific details o f analyses will be specified 
in the SAP.
9.4.2.2.1. Period 2 (Blinded Treatment Dosing Period)
Unless otherwise specified, the other secondary  analyses during Period 2 will be based on the 
ITT Population.
Treatment comparisons in the proportion of pat ients achieving a categori cal response at specified 
time point swill be analyzed using the logistic regressio n model defined in Sect ion9.2.1 . 
Missing data will be imputed using the NRI method described in Section
 9.2.5 .
For all continuous efficacy variables that are collected at repeated visit s, treatment group 
comparisons will be analyzed using the MMRM model  defined in Section 9.2.1 .  No imputation 
I1F-MC-RHBW( d) Clinical Protocol Page 75
LY2439821methods are applied to MMRM analysis.  Addit ional analys es will be conducted using the 
ANCOVA model defined in Sect ion 9.2.1 ;missing data will be imputed by the mBOCF method 
as described in Section 9.2.5.  For continuous efficacy variables that are collected only once 
within Peri od 2, analyses will be m ade using the ANCOVA model wit h the mBOCF method.
9.4.2.2.2. Period 3 (Extended Treatment Period) 
Data collected in this study period will be summarized for the Extended Treatment Period 
Popul ation.  The within -treatm ent group comparisons may be conducted as appropriate.  
9.4.3. Other Exploratory Analyses
Details about exploratory analyses will be included in t he SAP or appropri ate bi omarker analysis 
plan.  
9.5. Safety Analyses
Safety will be assessed by summarizing and analyzing AEs including adjudicated 
cerebrocardiovas cular events, laboratory  analy tes including neutrophil counts, QIDS -SR16 , 
C-SSRS , and vital signs .  The duration of treatment exposure will also be summarized .
For Peri od 2 (Blinded Treatment Dosing Period), safet y data will be summarized for the Safety 
Population.  Treatment group comparisons will be performed on categori cal safety data using 
Fisher’s exact test as described in Section9.2.1 ;continuous safet y data will be analyzed by an 
ANCOVA model .
For Peri od 3 (Extended Treatment Period), the safety  data will be summarized and no treatment 
group comparisons will be performed .  
For Period 4 ( Post-Treatment Follow -Up Peri od), safety data will be summarized according to 
the treatment patients were on prior to entering Period 4. 
Thecategori cal safety measures will be summarized with incidence rates.  The mean change of 
the continuous safet y measures will be summarized by  visits.
Further details will be described in the SAP.
9.5.1. Adverse Events
Adverse events are classified based upon the Medical Dict ionary for Regul atory  Activities 
(MedDRA ).  A treatm ent-emergent adverse event (TEAE) is defined as an event that first 
occurred or worsened in severit y after baseline and on or prior to the date of the last vi sit within 
the treatment period.   Both the date/time of the event onset and the date/time of the first study  
drug inject ion are considered when determining TEAEs.  Treatment -emergent adverse events
will be assigned to the treatment period in whi ch they first occurred or worsened.  A follow
-up 
emergent adverse event (FEAE) is defined as an event that first occurred or worsened in severit y 
after the date of Week 52 (Visit 15) or the ETV.  For events that are gender -specific, the 
deno minator and com putati on of  the percentage will include only  patients from the given gender.
I1F-MC-RHBW( d) Clinical Protocol Page 76
LY2439821An overall summary o f AEs will be provided for each o f the treatment periods, including the 
number and percentage of patients who experienced TEAEs , TEAE sby maximum severit y, 
deaths, SAE s, TEAE srelated to study drug, discontinuat ions from the treatm ent due to an AE, 
and treatment -emergent AESI s.  Treatm ent-emergent adverse events (all, by  maximum  severi ty, 
and TEAEs possibly related to study  drug by  the investi gator), SAEs including deaths, and AEs 
that lead to treatment discont inuat ion will be summarized and analyzed by MedDRA system 
organ clas s (SOC) and preferred term . 
In addit ion to general safet y param eters, safet y inform ation on specific topi cs of  AESIs will also 
be presented.  Poten tial AESIswill be ident ified by a standardized MedDRA query (SMQ) or a 
Lilly -defined MedDRA preferred term listing.
Follow-up em ergent adverse events, SAEs including deaths, and AEs that lead to study  
discontinuat ion will  be summarized for Peri od 4.  
9.5.2. Clinical Laboratory Tests
Laboratory  assessments will be presented as mean changes from baseline, and as incid ence of 
treatm ent-emergent abnormal, high, or low laboratory  values (see bel ow).  Shift tables will be 
presented for selected parameters.  
For categorical lab tests: 
oTreatment -emergent abnormal value = a change from  norm al at all  baseline visi ts 
to abnor mal at any  time postbaseline.
For continuous lab tests: 
oTreatment -emergent high value = a change fro m a value less than or equal to the 
high limit at all baseline visits to a value greater than the high limit at any  time 
postbaseline.  
oTreatment -emergent lowvalue = a change from a value greater than or equal to 
the low limi t at all  baseline visi ts to a value l ess than the l ow limi t at any  time 
postbaseline.
9.5.3. Vital Signs, Physical Findings, and Other Safety Evaluations
Vital signs will  be presented as m eanchanges from baseline and as incidence of treatment -
emergent hi gh or l ow values (see below ) and will be summarized both pre -and postdose a t 
Week 0 (Visit 2), Week 16 (Visit 8) ,and Week 20 ( Visit 9)as applicable.
For treatm ent-emergent high and low:
oA treatment -emergent high resul t is defined as a change fro m a value less than or 
equal  to the high limit at baseline to a value greater than the high limit at any  time 
that meets the specified change criteria during the treatment period.
oA treatment -emergent lowresul t is defined as a change from a value greater than 
or equal to the low limit at baseline to a value less than the low limit at any t ime 
that meets the specified change criteria during the treatment period.
I1F-MC-RHBW( d) Clinical Protocol Page 77
LY2439821The m aximum  postbaseline QIDS -SR16 to tal score will be summarized by treatment group, and 
a shift table will be produced for the change fro m baseline in QIDS -SR16 total  score category .
Suicide-related thoughts and behaviors and self- injuri ous behavior with no suicidal intent, based 
on the C -SSRS, will be listed by  patient.
9.6. Pharmacokinetic/Pharmacodynamic /Immunogenicity Analyses
Observed ixekizumab serum concentrations will be summarized by  treatm entregimen, visit,and 
corresponding time when sampling occurred.
As appropri ate, the PK and the exposure -response relat ionship between ixekizumab exposure 
and clinically  important effic acy measures (for example, ASAS40 or ASAS2 0) may be expl ored 
using graphical methods and/or a modeling approach.  Pharmacokinetic and/or 
exposure -response data from this study  may be combined wi th exist ing PK and/or exposure -
response data from other studies, if considered appropriate.   
If a trend or statistically  significant difference between the ixekizumab dose cohorts and/or the 
placebo cohort i s noted i n any safe ty endpoint, the exposure relat ionship for this endpo int may  be 
explored graphically.
In addit ion, the potential impact of immunogenicit y on ixekizumab exposure and/or efficacy  
responses may be evaluated by  graphical  assessments, as appropriate, to compare drug exposure 
or efficacy responses between ADA negative and ADA posit ive pat ients at corresponding visits, 
or before and after ADA development for patients who develop ADA .  Both treatment -emergent 
only and all ADA posi tive/negat ive patients may be explo red.  A similar approach may be taken 
if pat ients beco me N Ab posi tive.  The effect of immunogenicit y may be evaluated as a covariate 
in the populat ion PK and exposure -response analyses, if applicable . 
9.7. Other Analyses
9.7.1. Health Economics 
There will be no adj ustment for multiple com parisons.  Analyses will be conducted for the other 
secondary  health outcom esobject ives as defined in Secti on 3.  
Period 2 (Blinded Treatment Dosing Period):   
Unless otherwise specified, the other secondary  analyses during Period 2 will be based on the 
ITT Population.  
Treatment comparisons in the proportion of pat ients achieving a categori cal response at specified 
time point swill be analyzed using the logistic regressio n model defined in Sect ion9.2.1 . 
Missing data will be imputed using the NRI method descr ibed in Section 9.2.5 .
For all continuous health outcome svariables that are collected at repeated visits, treatment group 
comparisons will be analyzed using the MMRM model  defined in Section 9.2.1 .
  No imputation 
methods are applied to MMRM analysis.  Addit ional analys es will be conducted using the 
ANCOVA model defined in Sect ion 9.2.1 ;missing data will be imputed by the mBOCF method 
I1F-MC-RHBW( d) Clinical Protocol Page 78
LY2439821as described in Section9.2.5 .  For continuous health outcom esvariables that are collected only 
once wi thin the Peri od 2, analyses will be made using the ANCOVA model wit h the mBOCF
method.
Period 3 (Extended Treatment P eriod):   
Data collected in Period 3 will be summarized for the Extended Treatment Period Popul ation.  
The wi thin-treatment group comparisons may be conducted as appropriate.  
Addit ional analyses of health outcome smeasures will be specified in the SAP.
9.7.2. S ubgroup Analyses
Subgroup analys es will  be conducted for ASAS 40 and selective m ajor secondary  outcom es 
(defined in the SAP) at Week 16 (Visit 8) using the ITT Population. 
Subgroup analyses may  be conducted based on gender, age category , race, baseline disease 
severit y, country , geographi c regi on, baseline CRP status, baseline MRI status, number of prior 
TNF inhibitors used, and presence of HLA -B27.
For ASAS 40, a l ogistic re gressio n model with treatm ent, subgroup, and the interaction of 
subgroup-by- treatm ent included as factors will be used.  The subgroup-by
-treatm ent interacti on 
will be tested at the significance level o f 0.10.  Treatment group differences will be evaluated 
within each category  of the subgroup using Fisher’s exact test, regardless of whether the 
interact ion is statist ically significant.  Missing data will be imputed using NRI as described in 
Secti on 9.2.5 .  If any group within the subgroup is <10% of the total populat ion, only summaries 
of the efficacy  data will  be provi ded (that is, no inferent ial testing).
For continuous efficacy  outcom e (for example, mean change fro m baseline in ASDAS), an 
ANCOVA model wit h treatment, baseline value, subgroup, and the interaction of subgroup-by-
treatm ent will be used.  The subgroup-by- treatm ent interacti on will be tested at the significance 
level of 0.10.  Treatment g roup differences will be evaluated within each category o f the 
subgroup using an ANCOVA model wit h treatment and baseline value as a covariate, regardless 
of whether the interaction is statist ically significant.  Missing data will be imputed using the
mBOCF method as described in Section9.2.5 .
Detailed descript ion of the subgroup variables will be provided in the SAP.  Addit ional subgroup 
analyses on efficacy or subgroup analyses on safety  may be perform ed as deemed appropriate 
and necessary .
9.7.3. Immunogenicity
The analyses of ADA effects will be conducted on all evaluable patients within the defined 
safet y popul ation.  Evaluable pat ients will be defined as either a) patients with an evaluable 
baseline sample and at least 1 evaluable postbaseline sample (that is, sample after administration 
of study  drug); or b) pati ents wi th no evaluable baseline sample whose evaluable postbaseline 
samples were all ADA negat ive.
I1F-MC-RHBW( d) Clinical Protocol Page 79
LY2439821A TE -ADA positivepatient will be defined as any occurrence of a ≥4-fold or 2 dilution increase 
in immunogenicit y titer over the baseline t iter.  This is equivalent to an increase in t iter to ≥1:10, 
in the case of a negative result at baseline.  The frequency and percentage (incidence) of patients 
with posi tive, negat ive, or in conclusive ADA at baseline and postbaseline (and NAb at baseline 
and postbaseline) will be summarized by  treatm ent group.  Pati ents who are TE -ADA posit ive, 
TE-ADA persistent posit ive, and TE -ADA transient positive will also be summarized.
The potential im pact of  immunogenicit y on ixekizumab exposure and/or efficacy responses will 
be evaluated, as appropriate. 
Assessment of immunogenicit y with respect to safety  will include com parison of patients who 
experience TEAEs of systemic allergy/hypersensit ivity and of inject ionsite reacti ons,and who 
also develop treatment -emergent ant i-ixekizumab ant ibody  posi tivity with patients who 
experience the same t ypes of TEAEs but who remain treatment -emergent anti -ixekizumab 
antibody  negat ive.  Ant i-ixekizumab antibody  titers will also be evaluated in anti -ixekizumab 
antibody  posi tive patients who experience these events.
9.8. Interim Analyses
Aninterim database lock and unblinding will occur, and interim analyses will be performed at 
the time (that is, a cutoff date) the las t pati ent com pletes Visi t 8 (Blinded Dosing Treatment 
Period [Period 2], Week 16) or ETV.  This interim database lock will include all data collected 
by the cutoff date, including the data from the Extended Treatment Period (Period 3) and fo llow-
up data from pat ients that have begun thePost-Treatment Follow -Up Peri od (Peri od 4).  The 
analyses fro m the Week 16 l ock will be treated as a primary  analysis because all primary  and 
major secondary  study  objectives will be assessed at this time.
Addit ional analy ses and snapshot sof study  data may  be performed during Period 3 or after 
completion of Period 4 to fulfill the need for regulatory  interacti ons or publicat ion purposes. 
Unblinding details are specified in the blinding/unblinding plan .
I1F-MC-RHBW( d) Clinical Protocol Page 80
LY243982110.Study  Governance C onsiderations
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process
10.1.1. Informed Consent
The invest igator is responsible for ensuring:
that the patient understands the potential risks and benefits of part icipating in the study
that info rmed consent is given by  each patient or l egal representative.  This includes 
obtaining the appropriate signatures and dates on the ICF prior to the performance of any 
protocol  procedures and prior to the administration of invest igational product.
answerin g any quest ions the pati ent m ay have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the patient’s willingness to 
continue his or her participat ion in the trial.
10.1.2. Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and t he ICF must be provided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be complian t with the ICH guideline on GCP.
The study  site’s ERB(s) will be provided wit h the following:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae.
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations .
Some of the obligat ions of the sponsor will be assigned to a third party .
I1F-MC-RHBW( d) Clinical Protocol Page 81
LY243982110.1.4. Investigator Information
Licensed physicians with a specialt y in rheumatology  will partici pate as invest igators in this 
clinical trial.
10.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.1.6. Final Report Signature
The CSR coordinat ing invest igator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowl edge, the report accurately describes the conduct and results 
of the study .
The CSR coordinat ing invest igator will be selected by the sponsor. If this investigator is unable 
to fulfill this funct ion, another invest igator will be chosen by Lilly to serve a s the CSR 
coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate .
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the CRFs, and study  
procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail,
telephone, and/or fax .
review and evaluate CRF data and use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient da ta 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives, and/or regulatory  agencies ,at any  time.  Investigators will be given notice before 
an audit occurs.
I1F-MC-RHBW( d) Clinical Protocol Page 82
LY2439821The invest igator will keep records of all original  source data.  Thi s might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
10.2.1. Data Capture System
An electronic data capture sy stem  and an electronic source system will be used in this 
study .The site maintains a separate source for the data entered by the site into the sponsor -
provi ded el ectroni c data capture sy stem .Some or al l of a pati ent’s data will be directly entered 
into the eCRF at the time that the informat ion is obtained. In instances where direct data entry  is 
not used, the site will maintain source documentation in the trial files, and the patient’s data will 
be tra nscribed into the eCRF. Paper documentation provided by the patient will serve as the 
source document, including a study  drug administrati on log and an event -medication diary , that 
will be ident ified and documented by each site in that site’s study file.
In thi s study , pati ent-rated scales/quest ionnaires will be co llected at office visits (or even at 
home) direct ly via an electroni c pati ent-reported outcome (ePRO) tablet device as part of an 
ePRO/Clinical Outcome Assessment (COA) system. Data entered in to the ePRO/COA system 
will serve as the source data .  Electroni c PRO records are stored at a third party  site.  Invest igator 
sites will have continuous access to the source data during the study  and will receive an archival 
copy  at the end of the study  for retenti on.  Any data collected within the ePRO instrument will 
serve as the source data and will be ident ified and documented by each site in that site’s study 
file.
Data m anaged by  a central  vendor, such as laboratory  test data or ECG data, will be stor ed 
electroni cally in the central vendor’s database syst em.Data will subsequent ly be transferred 
from the central  vendor to the Lilly generic labs system.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem .
10.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
10.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regu lations, and GCP.
I1F-MC-RHBW( d) Clinical Protocol Page 83
LY243982111.References
Alosh M, Bretz F, Huque M. Advanced mult iplicit y adjust ment methods in clinical tri als. Stat 
Med. 2014;33(4):693 -713.
Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylo sing spondylit is 
assessment group preliminary definit ion of short -term improvement in ankylosing spondylit is. 
Arthritis Rheum. 2001;44(8):1876 -1886.
[APA] American Psychiatric Associat ion. Diagnosti c and stati stical manual  of mental  disorders. 
4thed. Washington, DC: American Psychiatric Association; 1994.
Appel H, Hey drich R, Loddenkemper C, Hempfing A, Sieper J. In situ detection of IL -17 
secreting cells in the bone marrow of facet jo ints obtained fro m patients wi th ankyl osing 
spondylitis. Arthritis Rheum. 2008;58(suppl S ):S351.
Baeten D, Sieper J, Emery  P, Braun J, Heijde D, McInnes I, van Laar JM, Landewe R, 
Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Berolino AP, Wright AM, Hu eber W. 
The ant i-IL-17A m onocl onal ant ibody  secukinumab (AIN457) showed good safet y and 
efficacy  in the treatm ent of  active ankylosing spondylit is[poster] . Poster presented at: Annual 
Meet ing of the American Co llege of Rheumatology; 10 November 2010; At lanta, GA. 
Available at:
http://www.abstracts2view.co m/acr/view.php?nu=4350&t ype=abstract&sesId=541&num=AP
S&trk =). Accessed February 21, 2011.
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, 
Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, 
Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Ant i-
interleukin -17A m onoclonal antibody  secukinumab in treatm ent of ankylo sing spondylit is: a 
rando mised, double -blind, pl acebo -controlled trial. Lancet. 2013;382(9906):1705 -1713. 
Erratum  in: Lancet. 2014a ;383(9928):1548.
Baeten D, Braun J, Baraliakos X, Sieper J, Dougados M, EmeryP, Deodhar A,Porter B, Martin
R, Mpofu S, Richards H. Secukinumab, a m onocl onal ant ibody to interl eukin- 17A, 
significant ly improves signs and symptoms o f active ankylosing spondylit is: results of a 52
-
week phase 3 rando mized placebo -controlled tri al wi th intravenous loading and subcutaneous 
maintenance dosing [abstract] . In: ACR/ARHP Annual Meet ing Abstract Supplement. 14-19 
Nov 2014; Boston, MA. Arthritis Rheum. 2014b;66(S10):S360 .Abstract 819.
Baraliakos X, Braun J, Laurent DD, Baeten D, van der Heijde D, Sieper J, Emery P, McInnes I, 
van Laar J, Landewe R, Wordsworth P, Wo llenhaupt J, Kellner H, Wright AM, Gsteiger S, 
Hueber W. Interleukin- 17A blockade with secukinumab reduces spinal inflammat ion in 
patients wi th ankylo sing spondylit is as early as week 6, as detected by  magnetic resonance 
imaging. Arthritis Rheum. 2011; 63(suppl 10):2486D .
Boonen A, van der Linden SM. The burden of ankylosing spondylit is. J Rheumatol Suppl .
2006;78:4 -11.
Brandt J, List ing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and 
preselect ion of criteria for short term improvement a fter ant i-TNF al pha treatm ent in 
ankylo sing spondylit is. Ann Rheum Dis. 2004;63(11):1438 -1444.
I1F-MC-RHBW( d) Clinical Protocol Page 84
LY2439821Braun J, Sieper J. Ankylosing spondylit is. Lancet. 2007;369(9570):1379-1390.
Braun J, Sieper J. Treatment of rheumatoid arthrit is and ankylosing spondylit is. Clin Exp 
Rheumatol . 2009;27(4 suppl 55):S146 -S147.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos -Vargas R, Collantes -Estevez E, 
Dagfinrud H, Dijkmans B, Dougados M, Emery  P, Geher P, Hammoudeh M, Inman RD, 
Jongkees M, Khan MA, Kilt z U, Kvien T, Leiri salo-Repo M, Maksymowych WP, Olivieri I, 
Pavelka K, Sieper J, Stanislawska -Biernat E, Wendling D, Ozgocmen S, van Drogen C, van 
Royen B, van der Heijde D. 2010 update of the ASAS/EULAR reco mmendat ions for the 
management of ankylo sing spondylit is. Ann Rheum Dis. 2011;70(6):896 -904.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. 
Biom J. 2011;53(6):894 -913.
Calin A, Jones SD, Garret t SL, Kennedy LG. Bath Ankylosing Spondylit is Funct ional Index. 
BrJ Rheumatol . 1995;34(8):793 -794.
Cimzia [package insert]. Smyrna, Georgi a: UCB; 201 5. Available at: 
http://medlibrary .org/lib/rx/meds/cimzia/ . Accessed October 19, 2015.
Columbia Universit yMedical Center. Columbia –Suicide Severi ty Rating Scale (C -SSRS) web 
site. Available at: http://www.cssrs.columbia.edu. Accessed April 21, 2011.
Cosent yx [package insert]. East Hanover, New Jersey: Novartis; 2015. Available at: 
http://www.pharma.us.novarti s.com /product/pi /pdf/cosent yx.pdf. Accessed October 19, 2015.
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, 
Fleischmann R, Inman R, Tsuji W ;Enbrel  Ankyl osing Spondylit is Study  Group. Recombinant 
human tumor necrosis facto r receptor (etanercept) for treating ankylosing spondylit is: a 
rando mized, controlled trial. Arthritis Rheum . 2003;48(11):3230-3236.
Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van 
der Heijde D. Golimumab reduces slee p disturbance in patients with act ive ankylo sing 
spondylit is: results fro m a rando mized, placebo -controlled trial. Arthritis Care Res (Hoboken) .
2010;62(9):1266 -1271.
Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos -Vargas R, Caplan L, Clegg DO, 
Colbert RA, Gensler LS, van der Heijde D, van der Horst -Bruinsma IE, Inman RD, 
Maksymowych WP, Mease PJ, Raychaudhuri S, Reimo ld A, Rudwaleit M, Sieper J, Weisman 
MH, Landewé RB. The concept of axial spondyloarthrit is: joint statement of the 
spondylo arthri tis research and treatment network and the Assessment of Spondylo Arthri tis 
internat ional Societ y in response to the US Food and Drug Administration ’s comments and 
concerns. Arthritis Rheumatol. 2014;66(10):2649 -
2656.
de Vries MK, van Eijk IC, van der Horst -Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans 
BA, Hazenberg BP, Wo lbink GJ. Erythrocyte sedimentati on rate, C -reactive protein level, and 
serum  amyl oid A protein for patient select ion and mo nitoring of ant i-tumor necrosi s factor 
treatm ent in ankylosing spondylit is. Arthritis Rheum . 2009;61(11):1484- 1490.
Diggle PJ, Heagerty  P, Li ang K -Y, Zeger SL. Analysis o f longitudinal data. Oxford: Oxford 
Universit y Press; 1994.
I1F-MC-RHBW( d) Clinical Protocol Page 85
LY2439821Dougados M, Baeten D. Spondyloarthrit is. Lancet . 2011;377(9783):2127-2137.
Dougados M, Simo n P, Braun J, Burgos -Vargas R, Maksymo wych WP, Si eper J, van der Heijde 
D. ASAS recommendations for collect ing, analysing and reporting NSAID intake in clinical 
trials/epidemio logical  studi es in axial spondyloarthritis. Ann Rheum Dis . 2011; 70(2):249 -251.
[EMA] European Medicines Agency, Committee for Medicinal Products for Human Use 
(CHMP). Guideline on clinical invest igation of medi cinal products for the treatment of 
ankylo sing spondylit is. 2009. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scient ific_guideline/2009/09/WC50
0003424.pdf. Accessed October 26, 2015 . 
Enbrel  [package insert]. Thousand Oaks, California: Amgen Inc; 2015. Available at: 
http://pi.amgen.co m/united_states/enbrel/derm/enbrel_pi.pdf. Accessed Octobe r 19, 2015.
EuroQol  Group. EQ -5D- 5L user guide. Versio n 1.0. April 2011. Available at: 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Fo lders_Flyers/UserGuide_
EQ-5D- 5L.Accessed September 14, 2012.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylit is: the Bath Ankylosing Spondylit is Disease 
Activity Index. J Rheumatol . 1994;21(12):2286- 2291.
Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benicho u O, Xi e L, 
Braun D, Berclaz PY, Banerjee S. A phase II randomized study  of subcutaneous ixekizumab, 
an ant i-interleukin- 17 m onocl onal antibody , in rheum atoid arthri tis pati ents who were naive to 
biologic agents or had an inadequate response to tumor necro sis factor inhibitors. Arthritis 
Rheumatol. 2014;66(7):1693 -1704.
Glint borg B, Ostergaard M, Krogh NS, Drey er L, Kristensen HL, Hetland ML. Predictors of 
treatm ent response and drug continuation in 842 patients with ankylo sing spondylit is treated 
with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide 
DANBIO regi stry. Ann Rheum Dis . 2010;69(11):2002-2008.
Glint borg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A,
Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen 
PM,Hetl and ML. Clinical response, drug survival and predictors thereof in 432 ankylo sing 
spondylit is pat ients after switching tumour necrosis factor α inhibitor therapy : resul ts from the 
Danish nat ionwide DANBIO registry . Ann Rheum Dis. 2013;72(7):1149 -
1155.
Gottlieb AB, Mease PJ, Cuchacovich RS, Shuler CL, Lin CY, Burge RT, Samanta S, Lee CH, 
Gladman DD. Ixekizumab improves physical functio n, qualit y of life, and work productivit y in 
biologic disease -modifying ant irheumat ic drug -naive pat ients with active pso riatic arthrit is 
[abstract]. Arthritis Rheumatol . 2015;67(suppl 10).
Griffit hs CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson 
J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nicko loff BJ, Papp 
K, UNCO VER -2 and UNCOVER -3 invest igators. Comparison o fixekizumab with etanercept 
or placebo in m oderate -to-severe psoriasis (UNCOVER -2 and UNCOVER -3): results from 
two phase 3 rando mised trials. Lancet. 2015;6736(15 ):60125 -8.
I1F-MC-RHBW( d) Clinical Protocol Page 86
LY2439821Haibel H, Specker C. Disease -modifying ant i-rheumat ic drugs in rheumatoid arthrit is and 
ankylo sing spondylit is. Clin Exp Rheumatol . 2009:27(4 suppl 55):S159 -S163.
Heiberg MS, Ko ldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK. 
The comparat ive one -year performance of a nti-tumor necrosis factor alpha drugs in patients 
with rheumatoi d arthri tis, psori atic arthrit is, and ankylosing spondylit is: results fro m a 
longitudinal, observat ional, mult icenter study . Arthritis Rheum. 2008;59(2):234 -240.
Heuft -Dorenbosch L, Spoorenber g A, van Tubergen A, Landewé R, van ver Tempel H, Mielants 
H, Dougados M, van der Heijde D. Assessment of enthesit is in ankylosing spondylit is. Ann 
Rheum Dis. 2003;62(2):127 -132.
Humira [package insert]. North Chicago, IL: AbbVie Inc; 2015. Available at: 
http://www.rxabbvie.com/pdf/humira.pdf. Accessed October 19, 2015.
Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, 
Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safet y of golimumab in pat ients 
with ankylo sing spondylit is: resul ts of a rando mized, double -blind, placebo -controlled, phase 
III tri al. Arthritis Rheum. 2008;58(11):3402 -3412.
Jandus C, Bio ley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulat ing 
polyfunctional Th17 memory  cells in pat ients with seronegative spondylarthrit ides. Arthritis 
Rheum . 2008;58(8):2307 -2317.
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy  LG, Garrett SL, Calin A. Defining spinal 
mobility in ankylo sing spondylit is (AS). The Bath AS Metrology  Index. J Rheumatol.
1994;21(9):1694 -1698.
Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, 
Marzo -Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a healt h index in 
patients wi th ankylo sing spondylit is (ASAS HI): f inal result of a global init iative based on the 
ICF gui ded by  ASAS. Ann Rheum Dis. 2013;74(5):830 -835.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, 
Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G , de Longueville 
M, Si eper J. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthrit is 
including ankylo sing spondylit is: 24 -week results of a double -blind rando mised placebo -
controlled Phase 3 study . Ann Rheum Dis. 2014;73(1):39 -47.
Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rødevand E, Koldingsnes W, Kaufmann C, 
Kvien TK. Effectiveness of switching between TNF inhibitors in ankylosing spondylit is: data 
from the NOR -DMARD regi ster. Ann Rheum Dis. 2011;70(1):157 -163.
Machado P, Cas trejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva -Fernández L, 
Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, van der Heijde 
D, Bijlsma JW, By kerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb 
BF,Losada B, Martín -Mola EM, Martinez -Osuna P, Montecucco C, Müller -Ladner U, 
Østergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Mult inational 
evidence -based reco mmendat ions on how to investigate and fo llow-up undifferent iated 
peripheral  inflammato ry arthri tis: integrating systemat ic literature research and expert opinio n 
of a broad internat ional panel o f rheumatol ogists in the 3E Ini tiative. Ann Rheum Dis . 
2011a;70(1):15-24.
I1F-MC-RHBW( d) Clinical Protocol Page 87
LY2439821Machado PM, Landewé RB, van der Heijde DM. Endorsem ent of definit ions of disease act ivity 
states and improvements scores for the Ankylosing Spondylit is Disease Act ivity Score: resul ts 
from OMERACT 10. J Rheumatol. 2011b;38(7):1502 -1506.
Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D, Assessment of 
Spondylo Arthri tis Internat ional Society . Ankyl osing Spondyli tis Disease Act ivity Score 
(ASDAS): defining cut -off values for disease activit y states and improvement scores. Ann 
Rheum Dis . 2011c;70(1):47 -53.
Machado P, Navarro -Compán V, Landewé R, van Gaalen FA, Roux C, van der Heijde D. 
Calculating the ankylosing spondylit is disease activit y score if the convent ional C-react ive 
protein level is below the limit of detection or if high- sensi tivity C-react ive protein is used: an 
analy sis in the DESIR cohort. Arthritis Rheumatol. 2015;67(2):408 -413.
Maksymowych WP, Mallo n C, Morrow S, Shojania K, Olszynski WP, Wong RL, Sampalis J, 
Conner -Spady  B. Development and validat ion of the Spondylo arthri tis Research Consortium 
of Canada (SPARCC) Enthesit is Index. Ann Rheum Dis. 2009;68(6):948 -953.
Maksymowych WP. Disease modificat ion in ankylosing spondylit is. Nat Rev Rheumatol. 
2010:6(2):75 -81.
Mease PJ, van der Heijde D, Ritchlin CT, Cuchacovich R, Shuler CL, Lee CH, Samanta S, Lin 
C-Y, Gl adman DD, Vangerow H. A randomized, double -blind, act ive-and placebo -controlled 
phase 3 study  of efficacy  and safet y of ixekizumab, adalimumab, and placebo therapy  in 
patients naive to bi ologic disease m odifying ant i-rheumat ic drugs with act ive psoriatic arthri tis 
[abstract]. Arthritis Rheumatol . 2015;67(suppl 10).
Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye 
D. Increased serum IL -17 and IL -23 in the patient with ankylo sing spondylit is. Clin 
Rheumatol. 2011;30(2):269 -273.
Morel and L. Unmet needs in rheumatoid arthrit is. Arthritis Res Ther . 2005 ;7(suppl  3):S2 -S8.
Naegeli AN, Flood E, Tucker J, Devlen J, Edson -Heredi a E. The pati ent experi ence wi th fatigue 
and content validit y of a measure to assess fat igue severit y: quali tative research in patients 
with ankylo sing spondylit is (AS). Health Qual Life Outcomes. 2013;1 1(11):192.
Poddubnyy  D. Axial spondyloarthrit is: is there a treatment of cho ice? Ther Adv Musculoskelet 
Dis. 2013;5(1):45 -54.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA): classificat ion of  suicidal events in the FDA’s pediatric 
suicidal risk analysis of ant idepressants. Am J Pyschiatry. 2007;164(7):1035 -1043.
Reilly Associates .Health Outcomes Research web site. 2002. Available at: 
http://www.reillyassociates.net/. Accessed September 14, 2012 .
Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validit y, reliabilit y and 
responsiveness of the Work Productivit y and Act ivity Impairment Questi onnai re in ankylo sing 
spondylitis. Rheumatology (Oxford). 2010;49(4):812 -819.
Reveille JD. The genet ic basis o f spondyloarthrit is. Ann Rheum Dis . 2011;70(suppl 1):i44- i50.
I1F-MC-RHBW( d) Clinical Protocol Page 88
LY2439821Reveille JD, Wittier JP, Weisman MH. Prevalence of axial spondylarthri tis in the United States: 
estimates from a cross-sectional survey . Arthritis Care Res (Hoboken) . 2012;64(6):905 -910.
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, 
Collantes -Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, 
Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Val le-Oñate R, Weber U, Wei J, Sieper J. 
The development of Assessment of Spondylo Arthrit is Internat ional Society classificat ion 
criteria for axi al spondyl oarthri tis (part II): validat ion and final select ion. Ann Rheum Dis . 
2009;68(6):777 -783.
Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329 -338.
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos -Vargas R, Dougados M, 
Herm ann KG, Landewé R, Maksymowych W, van der Heijde D. The Assessment of 
Spondylo Arthri tis Inter national Society  (ASAS) handbook: a guide to assess spondyloarthrit is. 
Ann Rheum Dis . 2009;68(suppl 2):ii1- ii44.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymo wych WP, Brown MA, Arora V, 
Pangan AL. Efficacy  and safet y of adalimumab in pati ents w ith non -radiographic axial 
spondylo arthri tis: resul ts from a phase 3 study . Presented at: Annual Meet ing of the American 
College o f Rheumatol ogy; 4-9November 2011; Chicago, IL. Presentation number 2486A.
Sieper J, Braun J, Baraliakos X, Baeten D, Dougados M, Emery P, Deodhar A, Porter B, 
Andersson M, Mpofu S, Richards H . Secukinumab, a monoclonal ant ibody  to interl eukin -17A, 
significant ly improves signs and symptoms o f active ankylosing spondylit is: results of a phase 
3, randomized, placebo -controlled tria l with subcutaneous l oading and maintenance dosing
[poster] .Poster presented at: American College of Rheumatology 2014 Annual  Scient ific 
Meet ing; 14-19 November 2014; Boston , MA . Poster 536.
Simponi [package insert]. Horsham, PA: Janssen Biotech Inc; 201
5. Available at: 
http://medlibrary
.org/lib/rx/meds/simponi/ . Accessed October 19, 2015.
Smith CH, Anstey  AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffit hs 
CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. Brit ish Associat ion of 
Derm atologists’ gui delines for bi ologic interventi ons for psori asis 2009. Br J D ermatol . 
2009;161(5):987 -1019.
Strand V, Rao S A, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM. Prevalence of axial 
spondylo arthri tis in United States rheumatology p
ractices: Assessment of Spondylo Arthri tis 
International Societ y criteria versus rheuma tology expert clinical diagnosis. Arthritis Care Res
(Hoboken) . 2013 ;65(8):1299 -1306.
van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody  K, Williamso n P, Braun J;
Ankylosing Spondylit is Study  for the Eval uation of Reco mbinant Infliximab Therapy Stu dy 
Group. Efficacy and safet y of infliximab in patients with ankylo sing spondylit is: resul ts of a 
rando mized, placebo -controlled trial (ASSERT). Arthritis Rheum . 2005;52(2):582 -591.
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dou gados M, Reveille 
JD, Wong RL, Kupper H, Davis JC Jr ;ATLAS Study  Group. Efficacy  and safet y of 
adalimumab in pat ients with ankylo sing spondylit is: resul ts of a multicenter, randomized, 
doubl e-blind, placebo -controlled trial. Arthritis Rheum . 2006;54(7):21 36-2146.
I1F-MC-RHBW( d) Clinical Protocol Page 89
LY2439821van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definit ion of the Bath 
Ankylosing Spondylit is Metrol ogy Index (BASMI) and comparison with the 2- step and 
10-step definit ions. Ann Rheum Dis. 2008;67(4):489 -493.
van der Linden S, Val kenburg HA, Cats A. Evaluation of diagnost ic criteria for ankylo sing 
spondylit is. a proposal for modificat ion of the New York criteria. Arthritis Rheum.
1984;27(4):361 -368.
Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, 
Dijkmans B, Geusens P, Vander Cruy ssen B, Collantes E, Sieper J, Braun J. Predict ing the 
outcom e of ankyl osing spondyli tis therapy . Ann Rheum Dis. 2011;70(6):973 -981.
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smit h JA, Borenstein D, Hiratzka 
J,Weiss PF, Inman RD, Majit hia V, Haroon N, Maksymowych WP, Jo yce J, Clark BM, 
Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, 
Yu DT, Miller AS, Reveille JD, Caplan L. American Co llege of Rheumatology/Spondylit is 
Association of America/Spondylo arthri tis Research and Treatment Network 2015 
Reco mmendat ions for the Treatment of Ankylosing Spondylit is and Nonradiographic Axial 
Spondyloarthrit is. Arthritis Rheumatol. 2015. doi: 10.1002/art.39298 [Epub ahead of print].
Ware JE Jr. SF -36 health 
survey  update. Spine. 2000;25(24):3130 -3139..
Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL -17, BMP -7, and bone turnover 
markers in pat ients with ankylo sing spondylit is. Joint Bone Spine. 2007;74(3):304 -305.
Yerem enko N, Paramarta JE, Baeten D. The interleukin -23/interl eukin- 17 immune axis as a 
promising new target in the treatment of spondyloarthrit is. Curr Opin Rheumatol.
2014;26(4):361 -370.
Zochling J, van der Heijde D, Burgos -Vargas R, Collantes E, Davis JC Jr, Dijkman s B, 
Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo -Repo M, Olivieri I, 
Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van 
Royen BJ, Braun J, ASsessment in AS internat ional working group, European League Agai nst 
Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylit is. 
Ann Rheum Dis. 2006;65(4):442 -452.
Zochling J. Measures of symptom s and disease status in ankylo sing spondylit is: Ankylosing 
Spondylit is Disease Activit y Score (ASDAS) , Ankylosing Spondylit is Qualit y of Life Scale 
(ASQoL), Bath Ankylosing Spondylit is Disease Activit y Index (BASDAI), Bath Ankylosing 
Spondylit is Funct ional Index (BASFI), Bath Ankylosing Spondylit is Glo bal Score (BAS- G), 
Bath Ankylosing Spondylit is Metrol ogy Index (BASMI), Dougados Funct ional Index (DFI), 
and Healt h Assessment Questionnaire for the Spondylarthropathies (HAQ -S). Arthritis Care 
Res (Hoboken) . 2011;63(suppl 11):S47 -S58.
I1F-MC-RHBW( d) Clinical Protocol Page 90
LY2439821Appendix 1. Abbreviations and Definitions
Term Definition
ADA anti-drug antibodies
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavor able and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALT alanine aminotransferase
ANCOVA analy sis of covariance
AS anky losing spondy litis:  currently referred to as radiographic axial spondyloarthritis 
(rad-axSpA)
ASAS Assessment of Spondyloarthritis International Society
ASAS HI Assessment of Spondyloarthritis International Society Health Index
ASDAS Anky losing Spondylitis Disease Activity Score.  In this study, it refers to the ASDAS crp
score which includes high sensitivity C -reactive protein (CRP).
ASSpiMRI -Berlin Anky losing Spondylitis Spinal Magnetic Resonance Imaging Activity –Berlin Score
AST aspartate aminotransferase
axSpA axial spondyloarthritis:  a single disease entity with a subset defined by the presence of 
clear structural damage (rad -axSpA) and a subset with no clear structural damage as 
defined by conventional x-rays (nonrad -axSpA)
BASDAI50 Bath Ankylosing Spondylit is Disease Activity Index 50
BASFI Bath Ankylosing Spondylitis Functional Index
BASM I Bath Ankylosing Spondylitis Metrology Index
blinding A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the t reatment or clinical evaluation of the subjects are 
aware of the treatment received.
bDMARD biological disease -modifying antirheumatic drug
I1F-MC-RHBW( d) Clinical Protocol Page 91
LY2439821Term Definition
cDM ARD conventional disease -modifying antirheumatic drug
CEC Clinical Events Committee
complaint A complaint is any written, electro nic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRP C-reactive protein
C-SSRS Columbia –Suicide Severity Rating Scale
DMARD disease -modifying antirheumatic drug
ECG electrocardiogram
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
EQ-5D-5L European Quality of Life –5 Dimensions –5 Level
GCP good clinical practice
IB Investigator’s Brochure
IBD inflammatory bowel disease (eg,Crohn’s disease and ulcerative colitis)
ICF informed consent form
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT intent -to-treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence that 
patients allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS interactive web -
response sy stem
JSEQ Jenkins Sleep Evaluation Questionnaire
LOCF last observation carried forward
MASES Maastricht Ankylosing Spondylitis Enthesitis Score
I1F-MC-RHBW( d) Clinical Protocol Page 92
LY2439821Term Definition
mBOCF modified baseline observation carried forward
MMRM mixed-effects model of repeated measures
mNY modified New York crit eria
MRI magnetic resonance imaging
nonrad -axSpA nonradiographic axial spondyloarthritis:  a subset of axSpA in which there is no clear 
structural damage as defined by conventional imaging
NRI nonresponder imputation
NRS numeric rating scale
NSAID nonsteroidal anti -inflammatory drug
PK/PD pharmacokinetics/pharmacodynamics
PPS per-protocol set:  The set of data generated by the subset of patients who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
Q2W every 2 weeks
Q4W every 4 weeks
rad-axSpA radiographic axial spondyloarthritis:  a subset of axSpA in which there is evidence of 
disease features on radiographic imaging
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SF-36 MCS Short Form 36 mental component score
SF-36 PCS Short Form 36 physical component score
SIJ sacroiliac joints
SpA spondyloarthritis
SPARCC Spondyloarthritis Research Consortium of Canada
TEAE treatment -emergent adverse event:  Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to 
have a causal relationship with this treatment.
TNFi tumor necrosis factor inhibitor
I1F-MC-RHBW( d) Clinical Protocol Page 93
LY2439821Term Definition
ULN upper limit of normal
WPAI -SpA Work Productivity Activity Impairment –Spondyloarthritis
I1F-MC-RHBW( d) Clinical Protocol Page 94
LY2439821Appendix 2. Schedule of A ctivities
I1F-MC-RHBW( d) Clinical Protocol Page 95
LY2439821Schedule of Activities , Protocol I1F -MC -RHB W(Periods 1 -2)
Screening
(Period 1)Baseline 
RandomizationBlinded Treatment Dosing Period (Period 2) a
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7 V8
Weeks Since Randomization W0 W1 W2 W4 W8 W12 W16
Study Days Up to -42 d 0 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 4d 84 ± 4d 112 ± 4d
Informed consent X
Demographics b X
Physical examination c X X
Vital signs (BP and pulse) d X Xd X X X X X X d
Weight z X X X X X X
Height X
Habits e X
Body temperature X
Posterior anterior c hest x-rayf X
Inclusion/Exclusion criteria g X X
Evaluate presence of SpA features X X
Randomization X X
Concomitant medications X X X X X X X X
NSAID use X X X X X X X X
Preexisting conditions and medical history h X X X X X X X X
Adverse events X X X X X X X X
Eye symptom assessment iX X X X X X X X
Dispense IP X X X X X X
Administer IP on site jX X
IP compliance X X X X X
Dispense SDAL X X X X X X
Collect, review, and enter data from SDAL X X X X X X
I1F-MC-RHBW( d) Clinical Protocol Page 96
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW (Periods 1 -2)
Screening
(Period 1)Baseline 
RandomizationBlinded Treatment Dosing Period (Period 2) a
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7 V8
Weeks Since Randomization W0 W1 W2 W4 W8 W12 W16
Study Days Up to -42 d 0 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 4d 84 ± 4d 112 ± 4d
Clinical Efficacy/Health Outcomes
X-ray of the SIJ k X
X-ray of the spine l X
Linear BASMI X X X
Chest expansion X X X
Occiput to wall distance X X X
Enthesitis (MASES and SPARCC ) X X X
Assessment of TJC/SJC ( 46/44 ) X X X
Healthcare resource utilization X X X
Patient Global (Assessment of Disease 
Activity  NRS)X X X X X X X X
Spinal pain X X X X X X X X
BASFI X X X X X X X X
BASDAI X X X X X X X X
Fatigue NRS X X X X
SF-36 X X X X X
ASAS HI X X X X X
QIDS -SR16 X X X
C-SSRS m X X X X X X X
Self-Harm Supplement Form m X X X X X X X
EQ-5D-5L X X
WPAI -SpA X X
JSEQ X X X
I1F-MC-RHBW( d) Clinical Protocol Page 97
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW (Periods 1 -2)
Screening
(Period 1)Baseline 
RandomizationBlinded Treatment Dosing Period (Period 2) a
CRF Visit (V) Number V1 V2 V3 V4 V5 V6 V7 V8
Weeks Since Randomization W0 W1 W2 W4 W8 W12 W16
Study Days Up to -42 d 0 7 ± 2d 14 ± 2d 28 ± 2d 56 ± 4d 84 ± 4d 112 ± 4d
Laboratory Tests
HLA -B27 n X
CRP Xo X X X X X X X
Administer PPD/ Collect QuantiFERON® -
TB Gold/T -SPOT® pX
ECG X
FSHqX
HIV/HCV X
HBV Xr Xr Xr
Serum pregnancy test s X
Urine pregnancy test s X X
Serum chemistry X X X X X X
PTT, PT/INR X X
Lipid panel (fasting) t X X
Hematology X X X X X X
Urinaly sis X X
TSH and free T4 X
Non-pharmacogen etic biomarker 
exploratory storage samples (urine, serum, 
plasma, RNA, and whole blood) uX Xv Xv X X v Xv X
Pharmacogenetic exploratory sample
(DNA )u,aaX
Immunogenicity testing w X X X X X X X
PK sampling w,x X X X X X X X
I1F-MC-RHBW( d) Clinical Protocol Page 98
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW (Period 3)
Extended Treatment Period
(Period 3) aETV
CRF Visit (V) Number V9 V10 V11 V12 V13 V14 V15 ETV
Weeks Since Randomization W20 W24 W28 W32 W36 W44 W52
Study Days 140 ± 4d 168 ± 4d 196 ± 4d 224 ± 4d 252± 4d 308 ±7d 364 ± 7d
Physical examination c X X
Vital signs (BP and pulse) d X X X X X X X X
Weight z X X X X X X X X
Concomitant medications X X X X X X X X
NSAID use X X X X X X X X
Preexisting conditions and medical history h X X X X X X X X
Adverse events X X X X X X X X
Eye symptom assessment i X X X X X X X X
Dispense IP X X X X X X
IP compliance X X X X X X X X
Dispense SDAL X X X X X X
Collect, review, and enter data from SDAL X X X X X X X X
Clinical Efficacy/Health Outcomes
Linear BASMI X X X X
Chest expansion X X X X
Occiput to wall distance X X X X
Enthesitis (MASES and SPARCC) X X X X
Assessment of TJC/SJC (46/44) X X X X
Healthcare resource utilization X X X X
Patient Global (Assessment of Disease Activity NRS) X X X X X X X X
Spinal Pain X X X X X X X X
BASFI X X X X X X X X
BASDAI X X X X X X X X
Fatigue NRS X X X
I1F-MC-RHBW( d) Clinical Protocol Page 99
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW (Period 3)
Extended Treatment Period
(Period 3) aETV
CRF Visit (V) Number V9 V10 V11 V12 V13 V14 V15 ETV
Weeks Since Randomization W20 W24 W28 W32 W36 W44 W52
Study Days 140 ± 4d 168 ± 4d 196 ± 4d 224 ± 4d 252± 4d 308 ±7d 364 ± 7d
SF-36 X X X
ASAS HI X X X
QIDS -SR16 X X X
C-SSRS m X X X X X X X X
Self-Harm Supplement Form m X X X X X X X X
EQ-5D-5L X X
WPAI -SpA X X
JSEQ X X X
Laboratory Tests
CRP X X X X X X X X
HBV Xr Xr Xr Xr Xr
Urine pregnancy test s X X X X X
Serum chemistry X X X X X X X X
PTT, PT/INR X X X
Lipid panel (fasting) t X X X
Hematology X X X X X X X X
Urinaly sis X X X X
Non-pharmacogen etic biomarker exploratory storage 
samples (urine, serum, plasma, RNA ,and whole 
blood )uX X v Xv X
Immunogenicity testing w X X X X X
PK sampling w,x X X X X X
I1F-MC-RHBW( d) Clinical Protocol Page 100
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW (Period 4 )
Post-Treatment Follow -Upfor Patients Discontinuing Treatment at or AfterWeek 16
(Period 4) y
Required Follow -Up Visits As-N eeded Follow -Up Visits
CRF V (visit) number V801 V802 V803 and o nwards
Study Weeks LV + 4W LV + 12W LV + 24 W
Study Days ±14d ±14d ±14d
Concomitant medications X X X
Vital signs (BP and pulse) d X X X
Weigh tz X X X
Preexisting conditions and medical history h X X X
Adverse events X X X
C-SSRS m X X X
Self-Harm Supplement Form m X X X
HBV Xr
Serum chemistry X X X
Hematology X X X
Non-pharmacogen etic biomarker exploratory storage samples
(urine , serum, plasma, RNA ,and whole blood )uXv Xv
Immunogenicity testing w X X
PK sampling w,x X X
I1F-MC-RHBW( d) Clinical Protocol Page 101
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW (Period 4)
Patients who discontinue treatment prior to Week 16 are to use the timetable below to schedule activities for Post-Treatment Follow -Up visits .
Discontinued Week No. (Visit No.) Corresponding V801 
(LV + 4 weeks)Corresponding V802 Corresponding V803 
(LV + 24 weeks)
Week 1 (Visit 3) Week 5 Week 16 Week 25
Week 2 (Visit 4) Week 6 Week 16 Week 26
Week 4 (Visit 5) Week 8 Week 16 Week 28
Week 8 (Visit 6) Week 12 Week 16 Week 32
Week 12 (Visit 7) Week 16 Week 24 Week 36
Post-Treatment Follow -Up for Patients Discontinuing Treatment Prior to Week 16
(Period 4) y
Required Follow -Up Visits As-N eeded Follow -Up Visits
CRF (V) Visit Number V801 V802 V803 and o nwards
Study Days ±14d ±14d ±14d
Concomitant medications X X X
Vital signs (BP and pulse) d X X X
Weight z X X X
Preexisting conditions and medical history h X X X
Adverse events X X X
C-SSRS m X X X
Self-Harm Supplement Form m X X X
HBV Xr Xr
Serum chemistry X X X
Hematology X X X
Non-pharmacogen etic biomarker exploratory storage 
samples (urine, serum, plasma, RNA and whole blood )uXv Xv
Immunogenicity testing w X X
PK sampling w,x X X
Patient Global (Assessment of Disease Activity NRS) X X
Spinal pain X X
BASFI X X
BASDAI X X
CRP X X
I1F-MC-RHBW( d) Clinical Protocol Page 102
LY2439821Schedule of Activities , Protocol I1F -MC -RHBW
Abbreviations:   ASAS HI = ASAS Health Index; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis 
Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; BP = blood pressure; CRF = case report form; CRP = high sensitivity C -reac tive 
protein; C-SSRS = Columbia –Suicide Severity Rating Scale; d = days; DNA = deoxyribonucleic acid; ECG = electrocardiogram; EQ -5D-5L = European 
Quality  of Life –5 Dimensions –5Level; ETV = early termination visit; FSH = follicle stimulating hormone; HBcA b+ = positive for anti -hepatitis B core 
antibody; HBsAb = anti -hepatitis B surface antibody; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; HLA = 
human leukocyte antigen; INR = international normalized ratio; IP = inv estigational product; JSEQ = Jenkins Sleep Evaluation Questionnaire; LV = last visit; 
MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; NRS = numeric rating scale; NSAID = nonsteroidal anti -inflammatory drug; PK = 
pharmacokinetic; PPD = purified protein derivative; PT = prothrombin time; PTT = partial thromboplastin time; QIDS -SR16 = Quick Inventory of Depressive 
Symptomatology
–Self-Report (16 Items); rad-axSpA = radiographic axial spondyloarthritis; RNA = ribonucleic acid; SDAL = Study Drug Administration 
Log; SF-36 = Short Form 36; SIJ = sacroiliac joints; SJC = swollen joint count; SpA = spondyloarthritis; SPARCC = Spondyloarthritis Research Consortium 
of Canada; T4 = thyroxine; TB = tuberculosis; TJC = tender joint count; TSH = thyroid stimulat ing hormone; V = study visit; W = study week; W PAI-SpA = 
Work Productivity Activity Impairment Questionnaire –Spondyloarthritis.
aIf a patient who has received at least 1 dose of IPdiscontinues from study treatment early , the patient will complete the ETV and then enter the 
Post-Treatment Follow -Up Period (Period 4).  If a patient discontinues prior to Week 16, the patient will complete additional activities during Per iod4.
bDemographics includes recording of year of birth, gender, race,and ethnicity.
cOne complete physical examination (excluding pelvic, rectal examination) will be performed at screening.  All physical examin ations throughout the study 
must include a symptom -directed phy sical as well as examination of heart, lungs, abdomen, eyes ,and vi sual examination of the skin.
dBP and pulse will always be measured in sitting position and will be recorded before IP dosing at all visits; in addition, BP and pulse will be recorded 
approximately 1 hour post -dosing at baseline (Week 0) and Week 16 .  Ref er to Section 8.4.2 for more details.
eHabits include recording of caffeine, alcohol ,and tobacco consumption.
fAposterior anterior chest x-ray will be taken locally at screening unless one has been obtained within 6 months of screening (Visit 1) (provided the x -ray 
and/o r report are available for review).  Refer to Section 8.4.6 for more details.
gRefer to rescreening guidance as appropriate (Section 5.3).
hEvaluatio n includes historical event sand preexisting conditions.
iPatients need to be asked about presence of eye symptoms; if eye symptoms are present, then an eye examination is required.  Refer to Section 8.4.5 for 
specific instructions.
jRefer to Section 6.1.1 for specific IP administrat ion instructions.
kAn x-ray of the SIJ will be performed during the S creening Period (Period 1) unless an x -ray taken prio r to screening is available for central reading, is of 
good quality , and confirms diagnosis of rad -ax-Spa.  All x -rays require centra l reading ONLY, regardless of date taken.  Central reading will define eligibility 
using the modified New York (m NY) criteria .  If central reading of apreexisting x-ray is not consistent with rad -axSpA by central reading , a new x-ray of the 
SIJ may  be taken during Period 1 and sent in for central reading.
lCervical and lumbar spine only; serves :  1)as baseline for later assessments of structural changes and 2 ) to evaluate presence of total ankylosis at screening 
(refer to Section
 5.2, Exclusion Criterion [11] ).  X-ray of the spine does not need to be repeated if one is available that was taken ≤3 months prior to screening
and has passed quality assessment by central reading vendor . 
I1F-MC-RHBW( d) Clinical Protocol Page 103
LY2439821mASelf-Harm Follow -Up Form is to be completed for each discrete self-harm event identified on the C-SSRS and the Self -Harm Supplement Form.
nHLA -B27 test will be performed centrally .
oAppro val from the Lilly clinical research physician or clinical research scientist must be obtained before a CRP retest is permitted.   If the CRP lab is retested, 
the most recent value will be used for randomization.
pIn countries where the QuantiFERON® -TB Gold test or T -SPOT® is available, either test may be used instead of the PPD TB test.  The QuantiFERON®-TB 
Gold test may be performed locally or centrally; the T -SPOT® must be performed locally.  PPD tests must be re ad 2-3 days after Visit 1.   Refer to 
Section 8.4.6 for more details.
qFor female patients ≥40 and <60 years of age who have had a cessation of mens es for at least 12 months, an FSH test will be performed to confirm 
nonchildbearing potential (FSH ≥40 mIU/mL or ≥40IU/L ).  FSH test will be performed centrally.
rAll patients will be tested for HBV at screening.   Patients that are HBcAb+ at screening, r egardless of HBsAb status, will have a serum HBV DNA obtained 
by the central laboratory. Patients that are found to be HBV DNA positive (detectable) at screening will be excluded from the trial. Patients that are HBV 
DNA negative (undetectable) may be en rolled into the study with required HBV DNA monitoring ever y 3 months during treatment and 12 weeks after the last 
dose of ixekizumab.  If the result of the HBV DNA testing is positive, the patient is to be discontinued from the study and is to receive app ropriate follow -up 
medical care (refer to Section 8.4.10.2 for further information regarding the timing of discontinuation).
sOnly for females of childbearing potential.  Serum pregnancy test will be done at Visit 1 only and will be performed centrall y.  Patients determined to be 
pregnant will be discontinued from treatment and will no longer be administered IP(see Section 7.1).  Patients will undergo urine pregnancy testing at the 
clinic during scheduled visits through Week 52 .  Additional urine pregnancy testing can be pe rformed at the investigator’s discretion.  If required per local 
regulations, testing can occur at other intervals during the study treatment period and/or follow -up period.
tFor the fasting lipid profile ,patients are not to eat or drink anything except water for 12 hours prior to test.
uWhere collection is allowed by local regulations .
vOnly serum and plasma arecollected at this visit .
wImmunogenicity samples may also be analyzed for ixekizumab serum concentration to facilitate in the interpretation of immunogenicity data.  An additional 
blood sample will be collected, when possible, for any patient who experiences a potential systemic allergic/hypersensitivity reaction during the study as 
judged by the investigator.
xPK samples are to be collected before IPinjection.
yPatients receiving IPwho discontinue at any time prior to the end of the study or who complete the study (Week 52) and do not choose to enroll in Study 
RHBY , will have safety Follow -Up Visits 801 and 802 at 4 and 12 weeks ,respectiv ely,after the date of their last visit.  Visit 803 will occur if a patient’s 
neutrophil counts have not returned to the criteria defined in Section 8.4.10.1 .
zWeight is only captured on eCRF at V2, V8, V10, V15 ,and/or ETV.  Body weight collected at other visits is used only for calculation of creatinine 
clearance.
aaIf not completed at Visit 2, the sample should be collected as soon as possible at the next scheduled visit.
I1F-MC-RHBW( d) Clinical Protocol Page 104
LY2439821Appendix 3. Clinical Laboratory  Tests
Clinical Safety Laboratory Tests to be Performed by Sponsor -Designated Laboratory
Hematology a: Serum Chemistry a:
Hemoglobin    Sodium
Hematocrit    Potassium
Erythrocy te count (RBC)    Bicarbonate
Mean cell volume (MCV)    Chloride
Mean cell hemoglobin concentration (MCHC)    Phosphorus
Leukocytes (WBC)    Total bilirubin
Platelets    Direct bilirubin
Absolute counts of:    Alkaline phosphatase
Neutrophils, segmented    Alanine aminotransferase (ALT/SGPT)
Neutrophils, juvenile (bands)    Aspartate aminotransferase (AST/SGOT)
Lymphocy tes    Blood urea nitrogen (BUN)
Monocytes    Uric acid
Eosinophils    Creatinine
Basophils    Calcium
Urinalysis (dipstick) a:    Glucose
Color    Albumin
Specific gravity    Cholesterol (total)
pH    Total protein
Protein    Calculated creatinine clearance b
Glucose    Creatine phosphokinase (CPK)
Ketones    Trigly cerides
Bilirubin    Gamma -glutamyl transferase (GGT)
Urobilinogen
Blood Lipid Panel c:
Nitrite    Low density lipoprotein (LDL)
Urine creatinine    High density lipoprotein (HDL)
Leukocyte esterase    Very  low density lipoprotein (VLDL)
Other Tests :
Human immunodeficiency virus antibody (HIV) f Pregnancy test (serum) d
Hepatitis B surface antigen (HBsAg) f Follicle -stimulating hormone (FSH) e
Anti– hepatitis B surface antibody (HBsAb) f Thyroid-stimulating hormone (TSH) and free T4
Anti– hepatitis B core antibody (HBcAb) f Ixekizumab serum concentrat ion (pharmacokinetic [PK] )
Anti– hepatitis C antibody f,h Partial thromboplastin time (PTT)
HBV DNA g Prothrombin time/international normalized ratio (PT/INR)
High sensitivity C -reactive protein ( hsCRP) Explo ratory  storage samples ( urine, serum, plasma, RNA , 
and w hole blood ) Purified protein derivative (PPD) i
Urine pregnancy test d(assayed by clinical study site) Pharmacogenetic sample (DNA)
QuantiFERON® -TB Gold test i Immunogenicity testing (anti -ixekizumab Ab)
T-SPOT® i
HLA -B27
I1F-MC-RHBW( d) Clinical Protocol Page 105
LY2439821Clinical Safety Laboratory Tests
Abbreviations:  Ab = antibody; DNA = deoxyribonucleic acid; HBV = hepatitis B virus; RNA = ribonucleic acid; 
RBC = red blood cells; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic 
transaminase; T4 = thyroxine; WBC = white blood cells.
aUnscheduled blood chemistry, hematology, and urinalysis panels may be performed at the discretion of the 
investigator.  
bCockcroft -Gault calculation is used for the calculated creatinine clearance.
cFor the fasting lipid profile ,patients are not to eat or drink anything except water for 12 hours prior to test.  
Fasting is not required for the screening visit(Visit 1) .
dSerum pregnancy test for all women <60 years of age who are still of childbearing potential at V isit 1 only and 
will be performed centrally ; after Visit 1, urine pregnancy test p erformed locally for women of childbearing 
potential.
eWomen ≥40 and <60 years of age who have had a cessation of menses for ≥12 months will have an FSH test 
confirming nonc hildbearing potential ( ≥40 mIU/mL).
fTest required at Visit 1 to determine eligibility of patient for the study.  
gHBV DNA testing will be done in those patients who are HBcA b+ at screening.
hSee exclusion criteria ( Section 5.2) specific to Hepatitis C antibody.  A confirmatory test for HCV will be 
performed if the patient is positive for HCV antibody.
iIn countries wher e the QuantiFERON® -TB Go ld test or T-SPOT® is available, either test may be used instead 
of the PPD TB test .  The QuantiFERON® -TB Gold test may be performed locally or centrally; the T -SPOT® 
must be performed locally.
I1F-MC-RHBW( d) Clinical Protocol Page 106
LY2439821Appendix 4. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the clinical research physician from 
Lilly or i ts desi gnee .
Hepatic Monitoring Tests
Hepatic Hematol ogy a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Anti –smooth muscle antibody
Alkaline phosphatase isoenzymes a
CPK Anti -Actin a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I1F-MC-RHBW( d) Clinical Protocol Page 107
LY2439821Appendix 5. Spondy loarthritis Features
To be included in Study  RHBW , pati ents m ust have sacroiliit is defined radiographically 
according to the mNY criteria based on central reading
AND
at least one of the spondylo arthri tis features (fro m Box 4, ASAS cri teria for cl assificat ion of 
axSpA [to be applied in patients with chronic back pain ≥3 m onths and age at onset of back pain 
<45 y ears]) bulleted below:
Inflammatory back pain (IBP):   According to experts , 4out of 5of the fo llowing 
param eters present: (1) age at onset <40 years, (2) insidious onset, (3) improvement with 
exercise, (4) no improvement with rest, (5) pain at night (with improvement upon getting 
up).
Arthritis :Past or present active syno vitis diagnosed by a doctor .
Enthesitis (heel) :  Heel enthesit is:  past or present spontaneous pain or tenderness at 
examinat ion at the site of the insertion of the Achilles tendon or plantar fascia at the 
calcaneus .
Uveitis :Past or present uveit is anterior, confirmed by an ophthalmo logist.
Dactylitis :Past or present dactylit is diagnosed by a doctor .
Psoriasis :Past or present psoriasis diagnosed by a doctor.
Crohn’s/Colitis :Past or present Crohn ’sdisease or ul cerat ive co litis diagnosed by a 
doctor .
Good response to NSAIDs :At 24to 48 hours after a f ull dose of NSAID ,the back pain 
was not present anymore or much better.
Note: As patients enro lling into the study should have failed 2 NSAIDs or be intolerant 
to NSAID s, a doctor should assess whether patients had “good” prior response to 
NSAIDs .
Family history for SpA :Presence in first -degree or second- degree re latives of any o f 
the following: (a) AS, (b) psoriasis, (c) uveit is, (d) reactive arthrit is, (e) IBD.
Note: A doctor should confirm wi th his/her patient there was a clear diagnosis (not self-
diagnosis) for any  of these in first - or second- degree relat ives.
HLA- B27:Posit ive testing according to standard laboratory techniques .
Elevated CRP :CRP >5.00 m g/L in the presence of back pain, after exclusio n of other 
causes for elevated CRP concentration .
References: Rudwaleit et al . 2009; Sieper et al .
2009.
I1F-MC-RHBW( d) Clinical Protocol Page 108
LY2439821Appendix 6. Protocol A mendment I1F -MC-RHBW (d) 
Summary :  A Multicenter, Randomized, Double -Blind, 
Placebo- Controlled 16 -Week Study  Followed by  
Long- Term Evaluation of Efficacy  and Safety  of 
Ixekiz umab (LY2439821) in TNFi -Experienced Patients 
with Radiographic A xial Spondy loarthritis
Overview
Protocol I1F-MC-RHBW , A Mult icenter, Rando mized, Double -Blind, Pl acebo -Controlled 
16-Week Study  Followed by Long -Term  Evaluat ion of Efficacy and Safet y of Ixekizumab 
(LY2439821) in TNFi -Experienced Patients wi th Radi ographic Axial Spondyloarthrit is,has been 
amended.  The new protocol is indicated by  amendment ( d) and will be used to conduct the study 
in place of any preceding version of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
The addit ional Exclusio n Cri terion added to Protocol Amendment I1F -MC-RHBW(c) 
was numbered incorrectly.  Inclusio n/Exclusio n Criteri on [58] i s being used in a protocol  
addendum .  In Protocol  Amendment (d), the Exclusion Criterion has been correctly  
renumbered as [59].  Text referring to the new Exclusio n Cri terion numbering was also 
updated.
The ASDAS crpformula contained t ypographical errors.  These were corrected in Protocol  
Amendment (d) .
I1F-MC-RHBW( d) Clinical Protocol Page 109
LY2439821Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Addit ions have been identified by  the use of underscore .
Section 5.2. Exclusion Criteria
Patients will  be excluded from study  enro llment if they meet any o f the following cri teria at
screening or as specified:
[58] This criterion is applicable only to patients enrolled in the MRI subgroup and was 
assigned in a Protocol Addendum.
[59] Do not m eet the enrollment requirements for the open cohort once the other cohorts 
have closed (Section 6.2).
Section 5.3 .Screen Failures
Patients who do not qualify  at screening for the elevated CRP cohort and therefore do not qualify 
for the study  under Exclusion Criterion [58][59] may be rescreened once at least 4 weeks after 
the init ial screening.  If the CRP is elevated (>5.00 mg/L) dur ing rescreening, patients may be 
enrolled via the elevated CRP cohort, provided all other entry criteria are met.
Section 8.1.2.9. Ankylosing Spondylitis Disease A ctivity Score
The ASDAS crpis calculated with the fo llowing equati on:  0.121 6× total back pain + 0.110 6× 
patient gl obal + 0.073 6 × peripheral pain/swelling + 0.0586 × duration of morning st iffness + 
0.579 6× Ln(CRP+1) (Machado et al. 2015).   (Note:  CRP is in mg/liter, the range of other 
variables is fro m 0 to 10; Ln represents t he natural logarithm. )
PPDLeo Document ID = bfaa70a9-3abe-47ae-8e9d-83b7a54d1943
Approver: 
Approval Date & Time: 01-Jun-2017 22:33:33 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 02-Jun-2017 05:49:24 GMT
Signature meaning: ApprovedPPD